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This thesis describes the development of new metal-mediated chemical reactions 
which enable the rapid construction of stereocontrolled heterocycles. The reactions 
proceed by functionalizing olefins to form a ring, a carbon-heteroatom bond, a carbon-
carbon bond or carbon-hydrogen bond, and 1-2 stereocenters with high selectivity. This 
strategy is especially attractive for generating libraries of new compounds simply by 
exchanging the coupling partners. Three new methods are described below for the 
formation of guanidines, sulfamides, and tetrahydrofurans. 
Cyclic guanidines are prevalent motifs in a wide array of pharmaceuticals and 
natural products.  In addition, the synthetic community has exhibited a strong interest in 
utilizing silver as a catalyst for the formation of heterocycles.  For these reasons, a new 
method was developed which accomplishes the silver-catalyzed hydroamination reaction 
of tosyl-protected guanidines onto unactivated olefins. This intramolecular cyclization 
reaction proceeds using catalytic amounts of silver (15-20%) in the presence of 
atmospheric oxygen and one equivalent of strong base. The cyclic guanidines are 
constructed in high yields (up to 98%). Sterically congested quaternary centers can be 
formed by cyclization onto 1,1-disubstitued alkenes. Also, bicyclic guanidines are formed 




Sulfamides are present in a variety of biologically active compounds and often 
serve as isosteres for ureas in the medicinal chemist's toolbox. Due to their biological and 
synthetic importance, an asymmetric synthesis of cyclic sulfamides was developed 
showcasing the ability of the Pd-catalyzed carboamination reaction for rapidly generating 
a diverse set of compounds in high yield and enantioselectivity. The new asymmetric 
method utilized Pd2(dba)3 and the commercially available chiral ligand (S)-Siphos-PE for 
high enantio-induction. Transformations of electron-neutral or electron-rich aryl bromides 
provided the highest levels of asymmetric induction whereas use of electron-poor 
electrophiles resulted in lower selectivity. The presence of water in the reaction had a 
remarkable influence on yield, improving the yield by up to 45%. The possible influence 
of competing syn and anti aminopalladation pathways prompted a mechanistic study by 
deuterium labeling studies which showed that the predominant mechanistic pathway 
occurred by syn aminopalladation. This asymmetric reaction has also been applied to the 
synthesis of 6-membered cyclic sulfamides, although geminal substitution is required in 
the homoallyl backbone for effective cyclization. This carboamination reaction proceeds 
in good yields and high enantioselectivity (up to 94% yield, up to 96% ee). A Pd-catalyzed 
desymmetrization reaction which operates under anti aminopalladation conditions was 
also examined. Asymmetric induction is achieved using axially chiral ligands with 
electron-rich phosphines, and hopefully, further manipulation of the ligand will improve 
enantioselectivity. 
Tetrahydrofurans bearing substituents at the C2 position are prominent motifs 
present in many biologically active compounds. Early developments in the Wolfe group 




heterocyclic ring along with a C–O bond, a C–C bond, and 1-2 stereocenters with high 
diastereoselectivity. Conversely, a palladium-catalyzed enantioselective alkoxylation 
reaction remained elusive even though the racemic reaction was described in 2004. The 
realization of an enantioselective alkoxylation reaction employed a new chiral ligand with 
a TADDOL backbone. The asymmetric carboalkoxylation reaction proceeds in moderate 
to good yields (54%-85%) and moderate to good enantiomeric ratios (68:32 to 95:5). High 









Application and Synthesis of Cyclic Guanidines 
 
1.1 Background and Significance 
Cyclic guanidines are prominent motifs in a variety of natural products and 
pharmaceuticals as this functional group ultimately derives from the amino acid 
arginine. In most instances, cyclic guanidines are comprised of 5 or 6-membered rings. 
Figure 1.1 showcases a collection of natural products which contain cyclic guanidine 
motifs.1 The remarkable feature of cyclic guanidine containing natural products arises 
from the variety of possible structures derived from different connectivities with the 
guanidine subunit. For example, batzelladine A2 bears three differentially functionalized 
guanidines: a guanidine at the terminus of an aliphatic chain, a guanidine which 
occupies the periphery of a bicycle, and a third guanidine embedded centrally within a 
tricyclic core.  





Due to the unique structural elements in cyclic guanidine natural products and 
due to the challenge associated with synthesizing these highly polar compounds, the 
synthetic community has sought the total synthesis of and methods towards many of the 
natural products outlined in Figure 1.1.1 Besides efforts in total synthesis towards the 
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synthesis of cyclic guanidine-containing natural products, cyclic guanidines have found 
utility in their own right primarily within the realm of organocatalysis.3  
 
Figure 1.2 Chiral Cyclic Guanidines as Organocatalysts 
 
 
Examining the biosynthetic pathway for the guadinomines, which has recently 
been elucidated, can help understand better how molecular complexity develops 
towards the formation of cyclic guanidines. This work lends some insight into how 
Nature accomplishes the formation of cyclic guanidines.4 Guanidinoacetate is formed by 
transfer of an amidino group of arginine to the acceptor molecule, the amino acid 
glycine. Through a series of biochemical reactions, guanidinoacetate is transformed into 
an α,β-unsaturated diketide that can undergo cyclization with the nucleophilic guanidine 
to form the heterocycle. The activated electrophile permits ready cyclization of the 
guanidine. The remarkable ease with which this biosynthetic pathway accomplishes 
formation of a cyclic guanidine seems to render synthetic efforts towards cyclic 
guanidines puerile. But, because chemists in general do not have the luxury of enzymes 
and enzymatic pathways for catalysis, more efficient, sophisticated, and novel methods 
for C-N bond closure are required which do not always rely on attack of the guanidine 




Figure 1.3 Biosynthetic Pathway for Guadinomines 
 
1.2 Formation of Cyclic Guanidines by Nucleophilic Attack of Acyclic Guanidine 
Nucleophiles 
The chemical synthesis of cyclic guanidines has been explored in a wide variety 
of ways. Natural products containing cyclic guanidine units have garnered the attention 
of the synthetic community because of the challenge associated with devising 
syntheses and handling of these compounds. Many cyclic guanidine-containing natural 
products have been successfully synthesized, and a few highlighted syntheses are 
described below so that the significance of developing new reactions for generating 
cyclic guanidines is elucidated. The formation of cyclic guanidines is accomplished by 
several different strategies depending on the retrosynthetic disconnections associated 
with the heterocycle (Is the guanidine pre-formed prior to cyclization? Is the guanidine 
formed in the same instant as the heterocycle? Is the guanidine formed after formation 
of the hetercycle?).  
For the purposes of highlighting the need for the new reaction described in 
Chapter 2 of this thesis, only reactions which undergo an intramolecular ring-forming 
event accomplished by a guandine nucleophile for formation of a heterocycle will be 
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described. In terms of complete synthetic routes mentioned below, please direct your 
attention to the citation, as each total synthesis is NOT fully described; rather the key 
step that forms the cyclic guanidine is discussed. By examining the different methods 
and the different applications of such methods for the formation of cyclic guanidines, the 
importance of continued development in this area will be highlighted. Also, it is the hope 
of the author that discussing the methods below will expose the limitations in current 
existing technology.  
One popular guanidine-containing target for synthetic chemists is saxitoxin (STX) 
which is a paralytic shellfish toxin utilized as an ion channel probe.5 STX is comprised of 
two cyclic guanidines, one of which occupies the boundaries of a bicycle.6 Numerous 
groups including Kishi,7 Jacobi,8 and Du Bois9 have developed well-designed synthetic 
routes towards this natural product, but this body of work will not be described. Instead, 
this discussion will focus on the work of Nagasawa and Looper which utilize acyclic 
guanidines as nucleophiles during ring closure events. 
  





The Nagasawa group capitalized on several unique transformations for realizing 
the total synthesis of (+)-saxitoxin.10 In this synthesis, the two cyclic guanidine units 
were constructed via intramolecular substitution reactions as shown in Scheme 1.1. In 
the first cyclization shown in Scheme 1.1, a secondary alcohol is converted into a good 
leaving group, and subsequent stereospecific SN2 attack ensues, providing the bicyclic 
guanidine in great yield (98%). Later in the synthesis, the second cyclic guanidine is 
formed by interception of an intermediate iminium ion which is formed in the presence of 
the boron reagent. Further transformations lead to (+)-saxitoxin. 
 




Bhonde and Looper demonstrated a concise stereoselective synthesis of (+)-
saxitoxin by implementing a silver(I)-initiated hydroamination cascade which develops 
the bicyclic guanidinium core.11 The synthesis was completed in 14 steps from N-Boc-L-
serine methyl ester. As shown in Scheme 1.2, the key tricyclic scaffold was synthesized 
in one pot by an intramolecular silver-mediated cascade reaction. During this cascade, 
silver acetate facilitates the hydroamination of the tethered alkyne. Then, iodine 
undergoes electrophilic addition to the new olefin forming a halonium ion which is 
subsequently ring-opened by the other guanidine. Formation of the oxazolidi-2-one, the 
third and last ring, occurs when the mixture is subjected to acetic acid which facilitates 
the decomposition of the boc group to a carboxylate which displaces the neighboring 
iodine atom by an SN2 reaction. Overall, the reaction accomplishes the construction of a 




Scheme 1.3 Formation of Bicyclic Guanidine towards Araiosamine C 
 
 
Recent work from the Baran group outlined an expeditious total synthesis of 
araiosamine C which utilized a sequential ring closure strategy for the synthesis of 
bicycle 1-10 (Scheme 1.3).12 This natural product contains a unique densely 
functionalized topology bearing two cyclic guanidine units and three pendant 
bromoindole heterocycles (Figure 1.1). The Baran group set out to synthesize this 
unique structure despite it having no significant bioactivity. En route to the natural 
product, a novel guanylating reagent 1-8 was developed which chemoselectively 
guanylates the amino-alcohol at the primary amine. Then, the cyclic guanidine was 
formed by DDQ oxidation under “Yonemitsu-type” conditions13 affording a crude 
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reaction mixture which was further reduced with DIBALH to form the hemiaminal in 
bicyclic guanidine 1-10. From here, the natural product was formed in four subsequent 
steps (not shown). 
 
Scheme 1.4 Pd-Catalyzed Synthesis of Cyclic Guanidines 
 
 
The Pd-catalyzed functionalization of olefins tethered to heteroatoms offers 
another potential strategy for synthesizing cyclic guanidines. This strategy has several 
advantages over existing methods for the formation of heterocycles including simple 
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protocols (catalysts can be weighed in air), opportunity for high stereoselectivity through 
well-defined transition states, and rapid generation of compound libraries by exchange 
of electrophilic coupling partners.14 Because of these advantages, developing new 
methods for generating cyclic guanidines by Pd-catalyzed cyclization onto units of 
unsaturation is attractive.  
Recently, Wolfe and coworkers demonstrated that guanidines protected with 
PMP groups can undergo Pd-catalyzed carboamination reactions, providing new cyclic 
guanidines in good yields (up to 99%) and moderate to good dr (2:1 dr up to 20: 1 dr) 
(Scheme 1.4).15 The reaction exploits a catalyst derived from Pd2(dba)3 and the ligand 
Xantphos for achieving reactivity. Presumably, the reaction proceeds by initial oxidation 
addition to a Pd(0) complex which is followed by formation of an intermediate Pd-amido 
complex which engages migratory insertion and subsequent reductive elimination for 
formation of the heterocycle.16 Efforts to render the reaction enantioselective were 
largely unsuccessful; the best enantiomeric ratio was generated by use of (S)-
Phanephos (92% yield, 61:39 er). 
 






Additionally, Wolfe and coworkers have developed a new Pd-mediated protocol 
for the synthesis of 2-aminoimidazoles (Scheme 1.4). The formation of several new 2-
aminoimidazoles (up to 97% yield) is achieved utilizing a catalyst derived from Pd(OAc)2 
and the ligand RuPhos.17 This reaction proceeds by cyclization of a Ts-protected 
guanidine onto an alkyne under an anti-type mechanism in which the Pd preferentially 
coordinates to the alkyne facilitating backside attack of the electron deficient guanidine. 
This alkyl-Pd complex undergoes reductive elimination to afford a product which rapidly 
undergoes isomerization to generate the 2-aminoimidazole. The power of this method is 
further highlighted by the synthesis of three natural products from the same starting 
material simply by exchanging the electrophilic coupling partner. The synthesis of 
preclathridine A is shown above.  The synthesis is completed after the Pd-mediated 
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cyclization by acidic removal of the TMS group followed by cleavage of the Ts group 
under reductive conditions.  
 




1.3 Hydroamination Protocols for the Synthesis of Cyclic Guanidines 
The hydroamination of alkynes in the presence of transition metals is useful for 
the formation of cyclic guanidines because nucleophilic attack is facilitated by π-
activation of the alkyne. This strategy has been elegantly utilized by Gin, Van der 
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Eckyen, and Looper for synthesizing different 5- and 6-membered cyclic guanidines as 
described below. 
 
Scheme 1.5 Gin Total Synthesis of Crambidine 
 
 
The sophisticated synthesis of crambidine by the Gin group18 which utilizes an 
innovative [4+2] thioimidate-vinyl carbodiimide annulation strategy for formation of 1-16 
also showcases a late stage Au-mediated cyclization of a guanidine onto an alkyne to 
close the tricyclic core (Scheme 1.5). The synthesis of 1-15 occurs in 5 steps from (S)-
2-(tert-butylsilyloxy)butyraldehyde staging the penultimate cyclization of the tricyclic 
core. It should be noted that many strategies that accomplish the total synthesis of 
these types of tricyclic guanidines utilize a retrosynthesis which proceeds through this 
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common bicyclic intermediate.19 Here, the key step is accomplished with AuCl3 serving 
as a Lewis acid to activate the alkyne for nucleophilic attack of the guanidine, thus 
closing the third ring of the tricylic core in 78% yield. Further transformations lead to the 
natural product Crambidine. 
 




In a second example, the Van der Eckyen group20 demonstrated the utility of 
silver nitrate for facilitating a one-pot guanylation/cyclization sequence for generating 
cyclic guanidines bearing exocyclic alkenes. The silver nitrate serves two purposes in 
this reaction: facilitating the guanylation by assisting the leaving group ability of –SMe, 
and secondly, by activating the alkyne for nucleophilic attack. The reaction is competent 
for bis-protected guanidines bearing either Boc or Cbz protecting groups. Moreover, the 
reaction is highly successful proceeding in up to 100% yield. The utility of this 
transformation was showcased by the total synthesis of 6 different 2-aminoimidazole 




Scheme 1.7 Regioselective Hydroamination of bis-Boc Protected Guanidines 
 
 
In addition to applications toward the synthesis of STX described above, the 
Looper group devised a regioselective method for performing hydroamination reactions 
of guanidines bearing tethered alkynes (Scheme 1.7).21 This method accomplishes a 5-
exo-dig cyclization utilizing AgOAc as a Lewis acid. The regioselectivity is altered by 
utilizing [Rh2(oct)4] as a catalyst providing the product derived from the 6-endo-dig 
cyclization.  
 
1.4. Hydroamination Reactions of Unactivated Alkenes for the Synthesis of Other 
Heterocycles 
While the methods developed by the Gin, Van der Eckyen and Looper groups 
showcased successful hydroamination reactions of guanidines onto alkynes, no 
examples have been proffered for the direct cyclization of guanidines onto alkenes, 
even though metal-mediated hydroamination protocols have found widespread use in 
the literature for many other functional groups.  
For instance, Widenhoefer and coworkers described the hydroamination of 
ethylene using a Pt catalyst as early as 2004.22 In addition, the Widenhoefer group 
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accomplished the hydroamination of ureas across unactivated olefins using a catalytic 
amount of Au[P(tBu)2(o-biphenyl)]Cl and AgOTf (5 mol%).23 This reaction proceeds in 
great yield (up to 100% yield) and moderate dr (up to 5.5:1 dr) to form pyrrolidines and 
piperidine scaffolds. The reaction also tolerates 1,1-disubstituted alkenes in 92% yield. 
 
Table 1.1. Aminoauration Reaction with Urea Substrates  
 
 
In a similar work, Toste and co-workers developed conditions for aminoauration 
reactions between ureas and unactivated olefins to form alkylgold(I) complexes with 
attached pyrrolidines (Table 1.1).24 These complexes can undergo protodemetallation 
to afford the hydroamination products. The reaction proceeds in 2-14 h using 40 mol% 
[(Ph3PAu)3O]BF4 in the presence of NEt3 and CDCl3. The substrate scope reveals some 
interesting aspects of this reaction. In terms of alkene substitution, 1,1-disubstituted 
alkenes were competent under the reaction conditions (Entry 2) to form tertiary amines, 
but 1,2-disubstituted were unable to engage the aminoauration reaction with either 
methyl or phenyl substitution at the 2 position (Entry 3 shows trace product for R3 = Ph). 
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Moreover, forcing conditions (1 equiv of [(Ph3PAu)3O]BF4 and 48 h reaction time) were 
able to generate 30% yield of the alkylgold(I) complex with a piperidine ring attached. All 
in all, this work provides a basis for Lewis acid-mediated hydroamination protocols, and 
moreover this work suggests which alkene substitutions will be fit for other Lewis acid-
mediated cyclizations onto unactivated alkenes. 
 
1.5 Conclusion 
In this chapter, the current technologies available for creating cyclic guanidines 
are discussed by reviewing the current literature. The next chapter will outline the 
discovery and development of the first example of a metal-mediated hydroamination 
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Chapter 2  
Synthesis of Cyclic Guanidines via Silver-Catalyzed Intramolecular Alkene 
Hydroamination Reactions of N-Allylguanidines 
 
2.1 Introduction and Background 
Inspiration for developing new methods for the synthesis of cyclic guanidines 
derives from interests in synthesizing the batzelladine alkaloids. The batzelladine 
alkaloids are defined by a guanidine functionality embedded within a tricyclic core that is 
decorated along the periphery by multiple stereocenters. Due to interest in these 
complex alkaloids, several groups have devoted efforts towards completing the 
synthesis of these natural products.1  
 
Figure 2.1 Batzelladine Natural Products 
 
 
Specifically, two strategies from the Wolfe group have been exploited towards 
the synthesis of two members of this family of natural products, merobatzelladine B and 
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batzelladine K (Figure 2.1).2 Both methods rely on sequential Pd-catalyzed 
carboamination reactions, the second of which is a cyclization of a urea which forms the 
key bicyclic retron. The Pd carboamination reaction is attractive for the synthesis of 
these compounds because these reactions proceed with high stereoselectivity. While 
these methods have been successful in targeting these natural products, a more direct 
strategy which implements guanidines as nucleophilic components rather than ureas 
could shorten step-count and improve the overall efficiency of the reaction. As such, the 
Wolfe group has sought the development of Pd-catalyzed carboamination reactions by 
which utilize protected guanidines as nucleophiles. 
As described in Chapter 1, two methods have been developed so far for the 
formation of cyclic guanidines by the Pd-catalyzed carboamination reaction. One 
method achieves formation of 2-aminoimidazoles by Pd-mediated cyclization of Ts-
protected guanidines onto alkynes via an anti-type mechanism.3 The other method 
produces saturated cyclic guanidines by cyclization of a bis PMP-protected guanidine 
onto a tethered alkene.4 While this last method demonstrated great success in 
accomplishing the Pd-catalyzed carboamination reaction, the utility of this reaction 
suffered due to protecting group removability. Despite efforts to cleave the protecting 
groups, the best result only produced 37% of product 2-4 with one PMP group still 
appended (see Scheme 2.1). Due to this limitation, further studies on the competence 
of different cleavable protecting groups has been underway.  
 





2.2 Discovery and Optimization  
The discovery of the hydroamination reaction of Ts-protected guanidines onto 
tethered alkenes occurred while investigating the influence of silver salts on the 
development of cationic palladium complexes for the Pd-catalyzed carboamination 
reaction. Cationic palladium complexes were under investigation because the 
mechanism of the palladium carboamination reaction for the formation of cyclic 
sulfamides showed that judicious choice of reaction conditions like solvent, ligand, and 
base could divert mechanistic pathways by formation of such a cationic Pd complex.5 In 
this regard, a syn-aminopalladation mechanism is operative for the carboamination 
reaction when aryl halides, non-polar solvents, and bidentate ligands like DPEPhos are 
used. Conversely, an anti-aminopalladation mechanism is operative when aryl triflates, 
polar solvents, and electron-rich Buchwald ligands are used. Discovering new avenues 
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by which the cationic palladium complex might be modified to promote anti-
aminopalladation pathways could extend the synthetic utility of this divergent reactivity, 
and thus silver salts were under investigation. The literature suggested that the 
implementation of silver salts might generate a cationic Pd complex by abstraction of 
halides from the metal center.6 
While studying the competence of tosyl-protecting groups for the Pd-catalyzed 
carboamination reaction in tandem with the use of silver salts for promoting cationic Pd 
complexes, a new hydroamination side product was isolated in 20% yield (along with 
about 50% Heck products and 13% starting material). Control reactions demonstrated 
that the palladium was unnecessary for the transformation to occur, but the presence of 
silver acetate (1 equiv) and base were required for high conversion.  
 





A rigorous optimization proceeded to obtain synthetically useful yields for this 
transformation as shown in Table 2.1. First, attempts to render the reaction catalytic in 
silver were made by lowering the loading of AgOAc to 10 mol %, but this prevented the 
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formation of desired product. Switching to AgOTf7 as catalyst improved the yield to 
14%, and an increase in temperature to 138 °C (with solvent switch to xylenes) 
improved the yield further to 40% (Table 2.1, entry 2 and entry 3). At this point, the 
reaction was conducted without ligand, and the change in yield was negligible (45%) 
(Table 2.1, entry 4). Several other metal sources were tested but did not improve the 
yield (Table 2.1, entry 5 through entry 8). As a consequence, further improvements to 
the overall yield were impeded until the influence of oxygen on the reaction was 
considered.  
It was hypothesized that adventitious oxygen might be promoting the reaction, so 
the reaction was conducted under a balloon of oxygen. This improved the yield to 70% 
(Table 2.1, entry 9). From here, the temperature and solvent were optimized with the 
best yields being obtained at 80 °C in 0.1 M PhCl. The reaction could also proceed 
under ambient atmosphere through exposing the reaction with a needle pierced into the 
septum, but these reactions were not reproducible and were likely sensitive to humidity 
(Table 2.1, entry 13 and entry 14).  
Two final control experiments were conducted to investigate the role of oxygen in 
the reaction. First, the reaction was conducted under an atmosphere of nitrogen in 
rigorously degassed and dried chlorobenzene proceeding to generate 60% of desired 
product which suggested that oxygen was unnecessary for catalyst turnover (Table 2.1, 
entry 16). Lastly, the reaction was conducted with a full equivalent of silver nitrate under 





2.3 Substrate Scope and Limitations 
The substrates for the hydroamination reaction are readily made by a two-step 
protocol beginning with the desired allylamine (Scheme 2.2). First, methyl 
tosylcarbonochloridoimidothioate is reacted with an allylic amine to produce the 
intermediate carbimidothioate. This is reacted further with ammonia in the presence of 
mercury oxide in order to produce the desired guanidine.  
 
Scheme 2.2. Substrate Synthesis 
 
 
 The substrate scope was first examined by exploring other suitable protecting 
groups (Scheme 2.3). The 4-methoxylphenylsulfonyl variant of the Ts group worked 
well under the optimized reaction conditions producing the desired product 2-8 in 96% 
yield. Unfortunately, substrate 2-9 failed to achieve desired reactivity leading to 
decomposition of starting material. This was disappointing because the boc group is 
readily cleaved to generate the free guanidine. 
 





 The substrate scope of the silver-catalyzed hydroamination reaction of tosyl-
protected guanidines was evaluated by synthesizing several differentially substituted N-
allyl guanidines and subjecting the substrates to the optimized reaction conditions 
(Scheme 2.4). Substrates bearing substitutions at the non-cyclizing nitrogen with a wide 
array of alkyl groups including methyl, benzyl, allyl, and p-methoxyphenyl were 
transformed with great yields (up to 99%). Hemiacetals and silyl protected ethers were 
also tolerated, although the latter afforded the desilylated product in 20% yield. The 
desilylated product was verified by subjecting 2-16 to TBAF deprotection. Quaternary 
centers were also generated by the cyclization of 1,1-disubstituted alkenes in high 
yields, although slightly more catalyst was required when reactions were conducted at 




Scheme 2.4 Substrate Scope 
 
 
Substrates bearing 1,2-disubstituted alkenes did not cyclize efficiently under the 
hydroamination conditions as shown in Scheme 2.5. When the olefin was embedded 
within a ring system, the hydroamination reaction was still unsuccessful. Some 
moderate success was achieved when a cinnamyl group was tested, but the substrate 
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could not be separated from the starting material, and the reaction suffered from 
irreproducibility. Also, attempts to make larger rings failed when a homoallyl group was 
used rather than an allyl group. Attempts to perform the hydroamination reaction with 2-
21 (which limits degrees of freedom due to the pyrrolidine backbone) were also made. 
While crude NMR data unveiled encouraging results, the starting material and product 
were once again inseparable. Attempts to increase the temperature or use more 
catalyst failed to improve this reaction.  
 
Scheme 2.5 Substrates Bearing Limited or No Reactivity 
 
 
The limited reactivity of substituted alkenes, while disappointing, is not too 
surprising. First, studies have shown that formation constants for complexation of silver 
triflate decrease in the order: monosubstituted alkene > 1,1-disubstituted alkene > 1,2-
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disubstituted alkene.8 This limitation was also evidenced in the work of Toste and 
coworkers9  for the aminoauration to form cyclic ureas which was described in Chapter 
1. As a consequence, the failure of the silver-catalyzed hydroamination reaction to 
undergo intramolecular cyclization with 1,2-disubstituted olefins follows the precedent 
established in the literature. 
In order to explore the diastereoselectivity of this reaction, several attempts were 
made to construct substrates bearing an aliphatic alkene with allylic substitution 
(Scheme 2.6). The synthesis of N-allyl tosyl protected guanidine substrates with either 
a methyl group (2-25) or phenyl group (2-26) in the allylic position was attempted using 
normal conditions for synthesizing the substrates (guanylation of NH3 in EtOH mediated 
by HgO) but failed to provide the desired compound, presumably due to steric 
congestion. Attempts to reverse the coupling partners by making methyl-N'-
tosylcarbamimidothioate or N'-tosyl-1H-pyrazole-1-carboximidamide and coupling N-
benzylbut-3-en-2-amine in the presence of HgO and trimethylamine were also met with 
failure. 
 
Scheme 2.6 Unsuccessful Attempts to Synthesize  





Therefore, the diastereoselectivity of the reaction was examined for the 
hydroamination reaction to form bicylic guanidines. Successful hydroamination of 
guanidine 2-30 afforded the bicyclic guanidine 2-31 with modest diastereoselectivity (3:1 
dr) but good yield (89%). The major diastereomer likely arises from the more favored 
chair-like transition state which positions the alkene in an equatorial position rather than 
axial position. Successful hydroamination of 2-32 bearing an exocyclic guandine was 
also successfully achieved with high dr (>20:1 dr) and high yield (99%).  
 





2.4 Protecting Group Removal 
The deprotection of the tosyl-protected cyclic guanidines was also briefly 
examined to demonstrate potential synthetic utility of the methodology. Previous work in 
the Wolfe group showed that the tosyl group is readily cleaved in the presence of lithium 
and napthalene to afford 2-aminoimidazoles.3 This deprotection methodolgy was 
applied to the cyclic guanidines, but it ultimately proved impractical and unusable.  The 
best results using this reductive strategy required additional Boc protection and removal 
to retrieve the products from the aqueous layer and verify their identities. In addition, the 
overall reaction led to overdeprotection by de-benzylation, producing mixtures of 
products that were difficult to separate by column chromatography.  
 





Instead, a more electron rich 4-methoxyphenyl sulfonyl protecting group was 
considered as a suitable substitute for accessing the free guanidine through 
deprotection. This variant of the Ts group exhibited high reactivity (96% as shown for 2-
8 in Scheme 2.3) and likely performs similarly for all the substrates described in 
Scheme 2.4. Successful cleavage of the 4-methoxyphenyl sulfonyl protecting group 
was achieved using a method described by Du Bois and coworkers.10 Reacting cyclic 
guanidine 2-8 with MeSO3H, in the presence of thioanisole and TFA at room 
temperature afforded the deprotected guanidinium salt 2-36 in 60% yield.  
 
2.5 Reaction Mechanism 
The mechanism for this reaction is not currently well understood. At this point, 
the evidence suggests that the mechanism for this reaction proceeds via classical Lewis 
acid-mediated π activation as shown in Figure 2.2. This mechanistic manifold is also 
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proposed by Van Der Eckyen and coworkers in the similar Ag-mediated hydroamination 
of alkynes.11 The proposed mechanism proceeds by coordination of Ag to the olefin. 
Then, deprotonation followed by nucleophilic attack of the alkene gives the alkyl-Ag  
complex which undergoes protonlysis to afford the cyclic guanidine and regenerate the 
catalyst.  
Figure 2.2 Proposed Mechanism for Silver-Catalyzed  
Formation of Cyclic Guanidines 
 
 
The role of oxygen is also not entirely clear. The oxygen most likely inhibits 
catalyst decomposition to Ag0. It is known that 2AgNO3(l) decomposes under heating to 
2Ag(s) + O2(g) + 2NO2(g). It is plausible that oxygen simply slows this decomposition 
pathway by Le Chatelier’s Principle. Experiments conducted during the optimization 
suggest that oxygen is not required for catalyst turnover. For instance, when the 
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reaction was conducted in rigorously dried and degassed chlorobenzene, the reaction 
proceeded to 60% conversion to product (6 turnovers) (See Table 2.1, entry 16). In 
addition, the reaction proceeded to completion under an atmosphere of N2(g) with 1 
equiv of AgNO3. Further studies would be needed to fully elucidate the role of oxygen in 
this reaction. In addition, using persulfate oxidants or inorganic nitrate salts might also 
serve the same purpose as oxygen gas, and if this reaction were to be constructed on a 
large scale, these methods might be preferred to the use of oxygen.  
 
2.6 Conclusion 
This chapter describes the first metal-catalyzed intramolecular alkene hydroamination 
reactions of guanidine nucleophiles. These transformations proceed in high yield 
generating a variety of five-membered cyclic guanidines containing a methyl substituent 
adjacent to the ring nitrogen atom.  
 Future directions for this project may include the following. First, the exact role of 
oxygen is not clear, so distinct mechanistic studies should be conducted to elucidate the 
role of oxygen. While a Lewis acid-mediated model in which oxygen simply slows the 
decomposition of silver is favored, a radical mechanism could still be operative. As 
such, re-visiting some of the early experiments conducted during optimization may 
provide insight. Oxygen could slow down the rate of decomposition for silver nitrate, but 
what is the influence of oxygen on silver triflate? Also, synthesizing a substrate which 
bears a cyclopropyl protecting group on the guanidine may unveil whether a radical is 
formed at the guanidine center. In addition, further explorations of viable protecting 
groups will expand the substrate scope of the reaction and perhaps improve the 
37 
 
synthetic utility of the reaction. Finally, devising a method for the synthesis of acyclic 
substrates which bear allylic substitution would provide much desired information 
regarding the diastereoselectivity of the reaction. Lastly, while all literature precedent for 
hydroamination reactions indicate that 1,2-disubstituted alkenes fail to undergo this type 
of reaction, the successful cyclization of a nucleophile onto a 1,2-disubstituted alkene 
would be a significant achievement. 
 
A portion of this work was adapted with permission from Garlets, Z.J.; Silvi, M.; Wolfe, 
J.P. Org. Lett. 2016, 18, 2331. Copyright 2016 American Chemical Society. 
 
2.7 Experimental Section 
 
General Considerations: All reactions were carried out under a nitrogen atmosphere 
using flame-dried or oven dried glassware unless otherwise noted. Silver nitrate was 
purchased from Sigma Aldrich. Toluene, THF, dichloromethane, ether and triethylamine 
were purified using a GlassContour solvent purification system. Chlorobenzene was 
purchased from Fisher Scientific and used as received. Ratios of diastereomers were 
determined by 1H NMR analysis of the crude material. Dimethyl 
tosylcarbonimidodithioate12 and N1-Allyl-N2,N3-Bis(tert-butoxycarbonyl)-N1-
methylguanidine13 were prepared according to published procedures. Yields refer to 
isolated compounds that are estimated to be >95% pure as judged by 1H NMR. The 
yields reported in 2.7 Experimental Section describe the result of a single experiment, 
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whereas yields reported in Table 2.1, Scheme 2.4, and Scheme 2.7 are average yields 
of two or more experiments.  
 
Experimental Procedures and Characterization Data for Substrates 
Synthesis of Substrates: 
 
Methyl tosylcarbonochloridoimidothioate:14 The title compound was prepared using 
a procedure developed by DuBois and coworkers.9 A 250 mL flame dried flask 
equipped with a stirbar was purged with nitrogen and charged with dimethyl 
tosylcarbonimidodithioate (18 mmol, 5.0 g) and dichloromethane (60 mL). While stirring, 
sulfuryl chloride (36.5 mmol, 3 mL) was added dropwise to the mixture. The resulting 
mixture was heated to reflux for 3 h, and then cooled to rt. The solvent was removed 
under reduced pressure and the crude product was purified by flash chromatography on 
silica gel using ethyl acetate/hexanes as eluant to afford 4.0 g (85%) of the title 
compound as a white solid. 1H NMR (CDCl3, 500 MHz):  7.88 (d, J = 8.1 Hz, 2 H), 7.36 
(d, J = 8.3 Hz, 2 H), 2.47 (s, 3 H), 2.44 (s, 3 H).  
 
 
Methyl N-allyl-N-methyl-N'-tosylcarbamimidothioate: A 15 mL thick-walled glass 
pressure tube equipped with a Teflon screwcap was flame dried, cooled under a stream 
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of nitrogen and charged with N-methylprop-2-en-1-ylamine (8.0 mmol, 770 L), dimethyl 
tosylcarbonimidodithioate (7.3 mmol, 2.0 g), and toluene (5 mL). The mixture was 
heated to 100 °C with stirring for 3 h, then was cooled to rt and the methanethiol 
byproduct was removed by purging the flask with nitrogen. The solvent was removed 
under reduced pressure, and the crude product was purified by flash chromatography 
on silica gel using ethyl acetate/hexanes as eluant to afford 2.17 g (91%) of the title 
compound as a yellow oil. 1H NMR (CDCl3, 500 MHz):  7.73 (d, J = 7.8 Hz, 2 H), 7.17 
(d, J = 7.8 Hz, 2 H), 5.61–5.70 (m, 1 H), 5.16 (dd, J = 10.3, 1.2 Hz, 1 H), 5.09 (dd, J = 
17.1, 1.2 Hz, 1 H), 4.08 (d, J = 5.6 Hz, 2 H), 3.07 (s, 3 H), 2.45 (s, 3 H), 2.31 (s, 3 H); 
13C NMR (175 MHz, CDCl3)  167.4, 142.0, 141.6, 130.8, 129.0, 125.8, 118.9, 55.8, 
38.9, 21.4, 17.7. 
 
General Procedure 1 for Preparation of carbamimidothioates.  
 
A flame dried flask equipped with a stirbar was cooled under a stream of nitrogen and 
charged with methyl tosylcarbonochloridoimidothioate (or derivative) and anhydrous 
acetonitrile (0.15 M). The mixture was cooled to 0 °C then triethylamine (1.2 equiv.) was 
added dropwise. The appropriate secondary amine (1.1 equiv.) was then added 
dropwise as a solution in acetonitrile (1.5 mL/mmol of amine). The reaction mixture was 
then warmed to rt and stirred overnight (18 h). The solvent was removed under reduced 
pressure, and the crude product was purified by flash chromatography on silica gel 




Methyl N-allyl-N-benzyl-N'-tosylcarbamimidothioate: General procedure 1 was used 
to acylate N-benzylprop-2-en-1-ylamine15 (3.6 mmol, 530 mg) with methyl 
tosylcarbonochloridoimidothioate (1.5 mmol, 396 mg). This procedure afforded 434 mg 
(77%) of the title compound as a viscous oil. 1H NMR (CDCl3, 400 MHz):  7.78 (d, J = 
8.3 Hz, 2 H), 7.24–7.32 (m, 3 H), 7.19 (d, J = 8.3 Hz, 2 H), 7.13 (d, J = 6.4 Hz, 2 H), 
5.69 (ddt, J = 16.8, 10.5, 5.8 Hz, 1 H), 5.19 (d, J = 10.0 Hz, 1 H), 5.08 (d, J = 17.1 Hz, 1 
H), 4.69 (s, 2 H), 4.06 (d, J = 5.6 Hz, 2 H), 2.72 (s, 3 H), 2.35 (s, 3 H); 13C NMR (175 
MHz, CDCl3)  167.5, 141.8, 135.3, 131.1, 129.2, 128.9, 128.0, 127.7, 126.0, 119.2, 
53.3, 52.8, 21.5, 18.6, (one peak is missing due to incidental equivalence). 
 
 
Methyl N-allyl-N-(4-methoxyphenyl)-N'-tosylcarbamimidothioate: General 
procedure 1 was used to acylate N-allyl-4-methoxyaniline16 (5.0 mmol, 820 mg) with 
methyl tosylcarbonochloridoimidothioate (4.5 mmol, 1.2 g). This procedure afforded 
1.70 g (97%) of the title compound as a viscous oil. 1H NMR (500 MHz, CDCl3)  7.83 
(d, J = 8.3 Hz, 2 H), 7.23 (d, J = 8.1 Hz, 2 H), 7.02–7.10 (m, 2 H), 6.83–6.90 (m, 2 H), 
5.69–5.79 (m, 1 H), 5.03 (dd, J = 10.1, 0.9 Hz, 1 H), 4.88 (dd, J = 17.1, 1.2 Hz, 1 H), 
4.30 (d, J = 6.4 Hz, 2 H), 3.78 (s, 3 H), 2.37 (s, 3 H), 2.38 (s, 3 H); 13C NMR (175 MHz, 
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CDCl3)  167.4, 159.5, 141.9, 141.6, 134.6, 131.4, 129.2, 129.1, 126.2, 119.5, 114.7, 
57.9, 55.5, 21.5, 18.3. 
 
 
Methyl N,N-diallyl-N'-tosylcarbamimidothioate: General procedure 1 was used to 
acylate diallylamine (6.0 mmol, 580.0 mg) with methyl tosylcarbonochloridoimidothioate 
(5.5 mmol, 1.44 g). This procedure afforded 1.65 g (93%) of the title compound as a 
viscous oil. 1H NMR (500 MHz, CDCl3)  7.77–7.82 (m, 2 H), 7.19–7.25 (m, 2 H), 5.66–
5.76 (m, 2 H), 5.19 (dd, J = 10.1, 1.1 Hz, 2 H), 5.11 (dd, J = 17.1, 1.2 Hz, 2 H), 4.08 (d, 
J = 5.6 Hz, 4 H), 2.68 (t, J = 1.7 Hz, 3 H), 2.38 (s, 3 H); 13C NMR (175 MHz, CDCl3)  
167.2, 142.0, 141.9, 131.4, 129.2, 126.1, 119.1, 53.0, 21.6, 18.5. 
 
 
Methyl N-benzyl-N-(2-methylallyl)-N'-tosylcarbamimidothioate: General procedure 1 
was used to acylate N-benzyl-2-methylprop-2-en-1-amine17 (3.75 mmol, 605 mg) with 
methyl tosylcarbonochloridoimidothioate (3.4 mmol, 900 mg). This procedure afforded 
1.33 g (91%) of the title compound as a viscous oil. 1H NMR (500 MHz, CDCl3)  7.76 
(d, J = 8.3 Hz, 2 H), 7.21–7.32 (m, 3 H), 7.17 (d, J = 8.1 Hz, 2 H), 7.09–7.13 (m, 2 H), 
4.90 (s, 1 H), 4.68 (d, J = 18.1 Hz, 3 H), 4.01 (s, 2 H), 2.70 (s, 3 H), 2.33 (s, 3 H), 1.60 
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(s, 3 H); 13C NMR (175 MHz, CDCl3)  168.0, 141.7, 141.7, 138.7, 135.3, 129.1, 128.8, 
127.9, 127.7, 126.0, 113.2, 55.3, 53.1, 21.4, 20.0, 18.6. 
 
 
Methyl N-ethyl-N-(2-methylallyl)-N'-tosylcarbamimidothioate: General procedure 1 
was used to acylate N-ethyl-2-methylprop-2-en-1-ylamine (6.27 mmol, 622 mg) with 
methyl tosylcarbonochloridoimidothioate (5.7 mmol, 1.5 g). This procedure afforded 1.7 
g (90%) of the title compound as a viscous oil. 1H NMR (500 MHz, CDCl3)  7.71 (d, J = 
8.3 Hz, 2 H), 7.14 (d, J = 8.3 Hz, 2 H), 4.78 (s, 1 H), 4.62 (s, 1 H), 3.96 (s, 2 H), 3.40 (q, 
J = 7.1 Hz, 2 H), 2.61 (s, 3 H), 2.29 (s, 3 H), 1.51 (s, 3 H), 1.01 (t, J = 7.2 Hz, 3 H); 13C 
NMR (175 MHz, CDCl3)  166.8, 142.0, 141.4, 139.0, 128.9, 125.7, 112.7, 55.7, 45.7, 
21.3, 19.8, 18.3, 12.5.  
 
 
Methyl-N-allyl-N-phenethyl-N'-tosylcarbamimidothioate: A flame-dried flask was 
cooled under a stream of nitrogen and charged with allylamine (150 mmol, 11.3 mL) 
and potassium carbonate (90 mmol, 12.5 g). Neat (2-bromoethyl)benzene was added 
dropwise via syringe pump to the vigorously stirring mixture over 45 minutes and the 
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resulting mixture was stirred at rt overnight. The mixture was then filtered through celite, 
the celite was washed with dichloromethane (3 x 30 mL), and then the solvent was 
removed under reduced pressure. The crude secondary amine was purified by flash 
chromatography on silica gel using hexanes/ethyl acetate as eluant to afford N-
phenethylprop-2-en-1-amine (3.95 g, 82%) as an orange oil. 1H NMR (500 MHz, 
CDCl3): 7.29–7.34 (m, 2 H), 7.18–7.25 (m, 3 H), 5.90 (ddt, J = 16.9, 10.5, 6.1 Hz, 1 H), 
5.16 (dq, J = 17.2, 1.6 Hz, 1 H), 5.09 (dq, J = 10.3, 1.4 Hz, 1 H), 3.28 (dt, J = 5.9, 1.4 
Hz, 2 H), 2.87–2.93 (m, 2 H), 2.81–2.85 (m, 2 H), 1.32 (s, br, 1 H).  
General procedure 1 was used to acylate N-phenethylprop-2-en-1-amine (7.7 
mmol, 1.24 g) with methyl tosylcarbonochloridoimidothioate (7 mmol, 1.85 g). This 
procedure afforded 2.67 g (98%) of the title compound as a viscous oil. 1H NMR (700 
MHz, CDCl3)  7.85 (d, J = 8.3 Hz, 2 H), 7.16–7.28 (m, 5 H), 6.96 (s, br, 2 H), 5.66–5.73 
(m, 1 H), 5.19 (d, J = 10.2 Hz, 1 H), 5.11 (d, J = 17.2 Hz, 1 H), 4.06 (d, J = 5.1 Hz, 2 H), 
3.58 (s, br, 2 H), 2.77–2.83 (m, 2 H), 2.75 (s, 3 H), 2.40 (s, 3 H); 13C NMR (175 MHz, 
CDCl3)  166.6, 142.1, 141.9, 137.9, 131.6, 129.3, 128.8, 128.7, 126.8, 126.2, 118.9, 




dried flask was cooled under a stream of nitrogen and charged with allylamine (200 
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mmol, 15.0 mL) and potassium carbonate (120 mmol, 17.0 g). Neat 2-(2-bromoethyl)-
1,3-dioxane (40 mmol, 5.5 mL) was added dropwise via syringe pump to the vigorously 
stirring mixture over 60 minutes and the resulting mixture was stirred at rt overnight. The 
mixture was then filtered through celite, the celite was washed with dichloromethane (3 
x 30 mL), and then the solvent was removed under reduced pressure. The crude 
secondary amine was purified by flash chromatography on silica gel using 
hexanes/ethyl acetate as eluant to afford 3.32 g (48%) of N-[2-(1,3-dioxan-2-
yl)ethyl]prop-2-en-1-amine as a yellow oil. 1H NMR (400 MHz, CDCl3)  5.88 (ddt, J = 
17.2, 10.3, 6.0 Hz, 1 H), 5.15 (dq, J = 17.2, 1.6 Hz, 1 H), 5.06 (dq, J = 10.3, 1.4 Hz, 1 
H), 4.62 (t, J = 5.0 Hz, 1 H), 4.05–4.10 (m, 2 H), 3.65–3.81 (m, 2 H), 3.22 (dt, J = 6.0, 
1.4 Hz, 2 H), 2.70 (t, J = 6.8 Hz, 2 H), 1.96–2.15 (m, 1 H), 1.79 (td, J = 6.8, 5.1 Hz, 2 H), 
1.43 (s, br, 1 H), 1.32 (dtt, J = 13.4, 2.6, 1.3 Hz, 1 H) 
General procedure 1 was used to acylate N-(2-(1,3-dioxan-2-yl)ethyl)prop-2-en-
1-amine (7.7 mmol, 1.32 g) with methyl tosylcarbonochloridoimidothioate (7.0 mmol, 
1.32 g). This procedure afforded 2.77 g (99%) of the title compound as a viscous oil. 1H 
NMR (700 MHz, CDCl3)  7.81 (d, J = 8.3 Hz, 2 H), 7.19–7.24 (m, 2 H), 5.65–5.72 (m, 1 
H), 5.16 (d, J = 10.2 Hz, 1 H), 5.10 (d, J = 17.0 Hz, 1 H), 4.45 (s, br, 1 H), 4.09 (d, J = 
3.2 Hz, 2 H), 4.04 (dd, J = 11.1, 4.9 Hz, 2 H), 3.68 (td, J = 12.3, 2.0 Hz, 2 H), 3.55 (t, J = 
6.8 Hz, 2 H), 2.71 (s, 3 H), 2.38 (s, 3 H), 1.97–2.06 (m, 1 H), 1.80–1.85 (m, 2 H), 1.31 
(d, J = 13.5 Hz, 1 H); 13C NMR (175 MHz, CDCl3)  166.8, 142.2, 141.7, 131.6, 129.2, 






tosylcarbamimidothioate: A flame-dried flask was cooled under a stream of nitrogen 
and charged with allylamine (150 mmol, 11.3 mL) and potassium carbonate (90 mmol, 
12.5 g). Neat (3-bromopropoxy)(tert-butyl)dimethylsilane18 (30 mmol, 7.6 mL) was 
added dropwise via syringe pump to the vigorously stirring mixture over 50 minutes and 
the resulting mixture was stirred at rt overnight. The mixture was then filtered through 
celite, the celite was washed with dichloromethane (3 x 30 mL), and then the solvent 
was removed under reduced pressure. The crude secondary amine was purified by 
flash chromatography on silica gel using hexanes/ethyl acetate as eluant to afford 4.45 
g (65%) of N-{3-[(tert-butyldimethylsilyl)oxy]propyl}prop-2-en-1-amine as a yellow oil. 1H 
NMR (400 MHz, CDCl3) 5.81–5.97 (m, 1 H), 5.15 (dd, J = 17.2, 1.7 Hz, 1 H), 5.06 (dd, 
J = 10.3, 1.4 Hz, 1 H), 3.67 (t, J = 6.1 Hz, 2 H), 3.23 (dt, J = 6.0, 1.4 Hz, 2 H), 2.68 (t, J 
= 6.9 Hz, 2 H), 1.69 (t, J = 6.5 Hz, 2 H), 1.34 (s, br, 1 H), 0.86 (s, 9 H), 0.03 (s, 6 H). 
General procedure 1 was used to acylate N-{3-[(tert-
butyldimethylsilyl)oxy]propyl}prop-2-en-1-amine (7.7 mmol, 1.77 g) with methyl 
tosylcarbonochloridoimidothioate (7.0 mmol, 1.85 g). This procedure afforded 3.2 g 
(99%) of the title compound as a viscous oil. 1H NMR (500 MHz, CDCl3)  7.80 (d, J = 
8.3 Hz, 2 H), 7.22 (d, J = 8.1 Hz, 2 H), 5.66–5.75 (m, 1 H), 5.17 (d, J = 10.0 Hz, 1 H), 
5.11 (dd, J = 17.1, 1.0 Hz, 1 H), 4.11 (d, J = 5.4 Hz, 2 H), 3.48–3.55 (m, 4 H), 2.71 (s, 3 
H), 2.38 (s, 3 H), 1.69–1.76 (m, 2 H), 0.86 (s, 9 H), 0.0 (m, 6 H); 13C NMR (126 MHz, 
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CDCl3)  166.9, 142.3, 141.7, 131.7, 129.2, 126.1, 118.9, 60.2, 54.2, 48.4, 30.9, 26.0, 
21.6, 18.6, 18.4, -5.3. 
 
 
Methyl-N-allyl-N-(2-phenoxyethyl)-N'-tosylcarbamimidothioate: A flame-dried flask 
was cooled under a stream of nitrogen and charged with allylamine (150 mmol, 11.3 
mL) and potassium carbonate (90, 12.5 g). A solution of (2-bromoethoxy)benzene (30 
mmol, 6.0 g) was added dropwise as a solution in anhydrous DMF (6 mL) via syringe 
pump to the vigorously stirring mixture over 70 minutes and the resulting mixture was 
stirred at rt overnight. The mixture was then filtered through celite, the celite was 
washed with dichloromethane (3 x 30 mL), and then the solvent was removed under 
reduced pressure. The dichloromethane solution was then transferred to a separatory 
funnel and washed with 5% lithium chloride solution (60 mL) and brine (60 mL). The 
organic layer was dried with sodium sulfate, and then the solvent was removed under 
reduced pressure. The crude secondary amine was purified by flash chromatography on 
silica gel using hexanes/ethyl acetate as eluant to afford 4.92 g (92%) of N-(2-
phenoxyethyl)prop-2-en-1-amine as a yellow oil. 1H NMR (500 MHz, CDCl3)  7.26–7.32 
(m, 2 H), 6.90–6.99 (m, 3 H), 5.90–5.99 (m, 1 H), 5.23 (dq, J = 17.1, 1.7 Hz, 1 H), 5.13 
(dq, J = 10.3, 1.4 Hz, 1 H), 4.08–4.12 (t, J = 5.0 Hz, 2 H), 3.35 (dt, J = 6.0, 1.4 Hz, 2 H), 
3.01–3.05 (t, J = 5.0 Hz, 2 H), 1.70 (s, 1 H). 
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General procedure 1 was used to acylate N-(2-phenoxyethyl)prop-2-en-1-amine 
(7.7 mmol, 1.36 g) with methyl tosylcarbonochloridoimidothioate (7.0 mmol, 1.85 g). 
This procedure afforded 2.6 g (92%) of the title compound as a viscous oil. 1H NMR 
(500 MHz, CDCl3)  7.80 (d, J = 8.1 Hz, 2 H), 7.19–7.29 (m, 4 H), 6.96 (t, J = 7.3 Hz, 1 
H), 6.77 (d, J = 8.3 Hz, 2 H), 5.71–5.81 (m, 1 H), 5.22 (d, J = 10.3 Hz, 1 H), 5.15 (d, J = 
17.1 Hz, 1 H), 4.31 (d, J = 5.1 Hz, 2 H), 4.01 (t, J = 5.4 Hz, 2 H), 3.83 (t, J = 5.3 Hz, 2 
H), 2.73 (s, 3 H), 2.37 (s, 3 H); 13C NMR (CDCl3, 126 MHz)  167.2, 158.2, 142.0, 141.9, 




General procedure 1 was used to acylate N-benzylprop-2-en-1-amine15 (4.2 mmol, 620 
mg) with methyl [(4-methoxyphenyl)sulfonyl]carbonochloridoimidothioate10 (3.8 mmol, 
1.05 g). This procedure afforded 1.44 g (97%) of the title compound as a viscous oil. 1H 
NMR (500 MHz, CDCl3) 7.79–7.84 (m, 4 H), 7.23–7.31 (m, 7 H), 7.10–7.15 (m, 4 H), 
6.83–6.89 (m, 5 H), 5.64–5.73 (m, 2 H), 5.18 (dd, J = 10.3, 1.0 Hz, 2 H), 5.07 (dd, J = 
17.2, 0.9 Hz, 2 H), 4.69 (s, 5 H), 4.06 (d, J = 5.9 Hz, 5 H), 3.79 (s, 7 H), 2.71 (s, 7 H); 
13C NMR (175 MHz, CDCl3)  167.2, 161.8, 136.7, 135.3, 131.2, 128.9, 128.0, 127.9, 





Methyl N-tosyl-2-vinylpiperidine-1-carbimidothioate: A round bottom flask equipped 
with a stirbar was charged with tert-butyl 2-vinylpiperidine-1-carboxylate19 (6 mmol, 1.27 
g) dichloromethane (30 mL) and trifluoracetic acid (6.0 mL). The reaction was stirred at 
rt until the boc group had been completely cleaved as judged by 1H NMR analysis. The 
solvent was removed under reduced pressure, to afford 2-vinylpiperidinium 
trifluroacetate, which was used without further purification. 
The crude 2-vinylpiperidinium trifluroacetate was converted to the title compound 
using a slight modification of general procedure 1 by addition to a stirring solution of 
methyl tosylcarbonochloridoimidothioate (5.5 mmol, 1.5 g) and triethylamine (13.2 
mmol, 1.8 mL, 2.4 equiv.) in acetonitrile (0.15 M). This procedure afforded 1.4 g (75% 
over two steps) of the title compound as a viscous oil. 1H NMR (500 MHz, CDCl3)  7.75 
(d, J = 8.1 Hz, 2 H), 7.18 (d, J = 8.1 Hz, 2 H), 5.68 (ddd, J = 17.4, 10.6, 4.0 Hz, 1 H), 
5.19–5.25 (m, 1 H), 5.19 (s, br, 1 H), 5.01–5.11 (m, 1 H), 4.30 (d, J = 13.7 Hz, 1 H), 3.10 
(td, J = 13.1, 2.9 Hz, 1 H), 2.43 (s, 3 H), 2.33 (s, 3 H), 1.76–1.84 (m, 1 H), 1.40–1.74 (m, 
5 H); 13C NMR (175 MHz, CDCl3)  167.4, 141.9, 141.6, 134.7, 129.1, 126.0, 117.8, 





Methyl N-benzyl-N-(2-methylenecyclohexyl)-N'-tosylcarbamimidothioate: A round 
bottom flask equipped with a stirbar was cooled under a stream of nitrogen and charged 
with 2-(benzylamino)cyclohexan-1-ol20 (11.7 mmol, 2.4 g), potassium carbonate (12.9 
mmol, 1.78 g) and THF (15 mL). The mixture was cooled to 0 °C and di-tert-butyl 
dicarbonate (12.9 mmol, 2.8 g) was added in one portion. The reaction mixture was 
warmed to rt and stirred until the starting material had been completely consumed as 
judged by TLC analysis. The mixture was then filtered through celite, the celite was 
rinsed with ether (2 x 50 mL), and the solvent was removed under reduced pressure. 
The crude product was purified by flash chromatography on silica gel using 
hexanes/ethyl acetate as eluant to afford 3.2 g (89 %) of tert-butyl benzyl(2-
hydroxycyclohexyl)carbamate. 1H NMR (400 MHz, CDCl3) 7.27–7.37 (m, 4 H), 7.21–
7.25 (m, 1 H), 4.41 (s, br, 2 H), 3.87 (s, br, 1 H), 3.52 (s, br, 1 H), 2.04 (s, 1 H), 1.68 (s, 
br, 4 H), 1.44 (s, 9 H), 1.11–1.31 (m, 4 H). 
A round bottom flask was flame dried, cooled under a stream of nitrogen, and 
charged with tert-butyl benzyl(2-hydroxycyclohexyl)carbamate (10.0 mmol, 3.0 g) and 
DMSO (20 mL). The mixture was stirred at rt and triethylamine (142 mmol, 20.0 mL) 
was added followed by a solution of sulfur trioxide pyridine complex (48 mmol, 7.6 g) in 
DMSO (30 mL). The mixture was stirred at rt until the starting material had been 
completely consumed as judged by TLC analysis, then water (50 mL) and ether (50 mL) 
were added. The mixture was transferred to a separatory funnel, the layers were 
separated, and the aqueous layer was extracted with ether (3 x 50 mL). The organic 
layers were combined and washed with water (3 x 50 mL) and brine (1 x 50 mL). The 
organic layers was then dried with sodium sulfate, filtered, and the solvent was removed 
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under reduced pressure. The crude product was purified by flash chromatography on 
silica gel using hexanes/ethyl acetate as eluant to afford 2.9 g (95 %) of tert-butyl 
benzyl(2-oxocyclohexyl)carbamate. NMR analysis indicated the presence of impurities 
in the product. However, this material was carried on without further purification. The 
material was found to exist as a ca 2:1 mixture of rotamers based on 1H NMR analysis.  
1H NMR (400 MHz, CDCl3) 7.17–7.38 (m, 5 H), 4.58–4.83 (m, 1.5 H), 4.28–4.41 (m, 
0.5 H), 4.04 (d, J = 17.8 Hz, 0.5 H), 3.83–3.95 (m, 0.5 H) 1.50–2.37 (m, 8 H), 1.35 (s, br, 
9 H).  
A flame dried round bottom flask equipped with a stirbar was charged with 
potassium tert butoxide (20.0 mmol, 2.2 g) and ether (70 mL). Solid 
methyltriphenylphosphonium bromide (20.0 mmol, 7.1 g) was added and the color of the 
solution became orange. The reaction mixture was stirred at rt for1 h, and then a 
solution of tert-butyl benzyl(2-oxocyclohexyl)carbamate (10 mmol, 3.03 g) in ether (20 
mL) was added. The mixture was stirred at rt until the starting material had been 
completely consumed as judged by TLC analysis. Water (50 mL) was added, the 
mixture was transferred to a separatory funnel, and the layers separated. The aqueous 
layer was extracted with ether (1 x 50 mL) and hexanes (4 x 50 mL). The organic layers 
were combined, dried over anhydrous sodium sulfated, filtered, and the solvent was 
removed under reduced pressure. The crude product was purified by flash 
chromatography on silica gel using hexanes/ethyl acetate as eluant to afford 2.53 g of 
tert-butyl benzyl(2-methylenecyclohexyl)carbamate (84% yield over two steps). 
1H NMR (400 MHz, CDCl3) 7.26–7.33 (m, 2 H), 7.17–7.25 (m, 3 H), 4.78 (s, 1 H), 4.56 
(s, br, 2 H), 4.07–4.16 (m, 1 H), 2.43 (d, J = 12.9 Hz, 1 H), 2.00–2.16 (m, 1 H), 1.74 (s, 
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br, 3 H), 1.40 (s, br, 11 H), 1.12–1.28 (m, 2 H). 
A round bottom flask equipped with a stirbar was charged with tert-butyl 
benzyl(2-methylenecyclohexyl)carbamate (7.3 mmol, 2.2 g), dichloromethane (37 mL), 
and trifluoracetic acid (7.3 mL). The resulting solution was stirred at rt until the starting 
material had been completely consumed as judged by 1H NMR analysis. The solvent 
was then removed under reduced pressure, and the crude N-benzyl-2-
methylenecyclohexylammonium trifluoroacetate product was dissolved in acetonitrile (8 
mL), and then was converted to the title compound using a slight modification of general 
procedure 1 by addition of this solution to a separate stirring solution of methyl 
tosylcarbonochloridoimidothioate (6.2 mmol, 1.6 g) and triethylamine (22.0 mmol, 3.1 
mL, 2.4 equiv.) in acetonitrile (40 mL) at 0 °C. This procedure afforded 2.2 g (70% over 
two steps) of the title compound as a viscous oil. The product appears to exist as a 
mixture of conformers, and contains some impurities. This material was used without 
further purification. Due to the complexity of the carbon NMR spectrum, all visible peaks 
are reported: 1H NMR (500 MHz, CDCl3)  7.61 (s, br, 2 H), 7.16–7.32 (m, 4 H), 7.07 (d, 
J = 6.3 Hz, 3 H), 5.12 (d, J = 16.8 Hz, 1 H), 5.02 (d, J = 10.0 Hz, 1 H), 4.74–4.82 (m, 1 
H), 4.44 (s, 1 H), 4.30 (d, J = 12.9 Hz, 1 H), 2.74 (s, 3 H), 2.27–2.43 (m, 4 H), 1.77–2.04 
(m, 1 H), 1.62–1.74 (m, 3 H), 1.04–1.42 (m, 3 H); 13C NMR (175 MHz, CDCl3)  145.4, 
141.8, 141.6, 137.1, 129.0, 128.9, 128.6, 128.3, 127.9, 127.1, 126.1, 126.0, 110.1, 






(2Z)-Methyl N-benzyl-N-(-3-cyclopropylallyl)-N'-tosylcarbamimidothioate: A flame 
dried round bottom flask was charged with potassium tert-butoxide (7.5 mmol, 840 mg) 
and ether (30 mL). Solid (cyclopropylmethyl)triphenylphosphonium bromide21 (7.5 
mmol, 3.0 g) was added and the color of the solution became orange. This mixture was 
stirred at rt for 1 h, and then tert-butyl benzyl(2-oxoethyl)carbamate22 (5 mmol, 1.2 g) 
was added in a solution in ether (10 mL). The resulting mixture was stirred at rt until the 
starting material had been completely as judged by TLC analysis. Then, water (30 mL) 
was added, the mixture was transferred to a separatory funnel, and the layers were 
separated. The organic layers were combined, dried over anhydrous sodium sulfated, 
filtered, and the solvent was removed under reduced pressure. The crude product was 
purified by flash chromatography on silica gel using hexanes/ethyl acetate as eluant to 
afford 1.44 g (99%) of (Z)-tert-butyl benzyl(3-cyclopropylallyl)carbamate. 
A round bottom flask equipped with a stirbar was charged with (Z)-tert-butyl 
benzyl(3-cyclopropylallyl)carbamate (4.2 mmol, 1.20 g), dichloromethane (20 mL), and 
trifluoracetic acid (4.2 mL). The resulting solution was stirred at rt until the starting 
material had been completely consumed as judged by 1H NMR analysis. The solvent 
was then removed under reduced pressure, and the crude (Z)-N-benzyl-3-
cyclopropylprop-2-en-1-aminium 2,2,2-trifluoroacetate was dissolved in acetonitrile (5 
mL), and then was converted to the title compound using a slight modification of general 
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procedure 1 by addition of this solution to a separate stirring solution of 
tosylcarbonochloridoimidothioate (4.2 mmol, 1.1 g) and triethylamine (9.1 mmol, 1.3 mL, 
2.4 equiv.) in acetonitrile (20 mL). This procedure afforded 1.2 g (70%) over two steps 
of the title compound as a viscous oil. The compound was isolated as an 1:3 mixture of 
E:Z alkene diastereomers as judged by 1H NMR analysis. Data are for the major isomer: 
1H NMR (400 MHz, CDCl3)  7.78 (d, J = 8.2 Hz, 2 H), 7.22–7.32 (m, 3 H), 7.13–7.21 
(m, 4 H), 5.22 (dt, J = 10.6, 7.1 Hz, 1 H), 4.92 (t, J = 10.4 Hz, 1 H), 4.73 (s, 2 H), 4.21 
(d, J = 7.0 Hz, 2 H),2.71 (s, 3 H), 2.35 (s, 3 H), 1.17–1.28 (m, 1 H), 0.63–0.73 (m, 2 H), 
0.26–0.36  (m, 2 H); 13C NMR (175 MHz, CDCl3)  167.4, 141.9, 141.6, 134.7, 129.1, 
126.0, 117.8, 58.2, 45.8, 29.1, 25.7, 21.4, 19.3, 17.7. 
 
 
(E)-Methyl N-benzyl-N-(-but-2-en-1-yl)-N'-tosylcarbamimidothioate: A round bottom 
flask equipped with a stirbar was charged with benzylamine (96 mmol, 10.5 mL) and 
potassium carbonate (24 mmol, 3.3 g). The mixture was stirred at rt and neat crotyl 
bromide (20 mmol, 2.0 mL, 85:15 E:Z) was added slowly dropwise. The resulting 
mixture was heated to 70 °C with stirring for 14 h. The mixture was then cooled to rt, 
filtered through celite, and the celite was washed with ethyl acetate (50 mL). The 
solvent was removed under reduced pressure, and then the crude product was purified 
by flash chromatography on silica gel using hexanes/ethyl acetate as eluant to afford 
2.56 g (79%) of (E)-N-benzylbut-2-en-1-ylamine as a yellow oil.  
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General procedure 1 was used to acylate (E)-N-benzylbut-2-en-1-ylamine (6.05 
mmol, 980 mg) with methyl tosylcarbonochloridoimidothioate (5.5 mmol, 1.4 g). This 
procedure afforded 2.04 g (85%) of the title compound as a viscous oil. The compound 
was isolated as an 85:15 mixture of E:Z alkene diastereomers as determined by 1H 
NMR analysis. 1H NMR data are for the major isomer. 13C NMR data are listed as 
observed, as it was not possible to rigorously assign some peaks to one isomer vs. the 
other: 1H NMR (CDCl3, 400 MHz):  7.77 (d, J = 8.2 Hz, 2 H), 7.31–7.21 (m, 3 H), 7.18 
(d, J = 8.0 Hz, 2 H), 7.11 (d, J = 6.1 Hz, 2 H), 5.54–5.43 (m, 1 H), 5.36–5.24 (m, 1 H), 
4.66 (s, 2 H), 3.97 (d, J = 6.1 Hz, 2 H), 2.71 (s, 3 H), 2.34 (s, 3 H), 1.63 (d, J = 6.3 Hz, 3 
H); 13C NMR (175 MHz, CDCl3)  167.4, 142.0, 141.8, 135.5, 131.2, 129.5, 129.2, 
128.9, 128.0, 127.9, 127.7, 126.1, 126.0, 124.0, 123.7, 53.5, 53.1, 52.4, 47.2, 21.5, 
18.6, 18.6, 17.8, 13.1.  
 
 
Methyl-N-benzyl-N-(but-3-en-1-yl)-N'-tosylcarbamimidothioate: General procedure 1 
was used to acylate N-benzylbut-3-en-1-amine23 (10 mmol, 1.6 g) with methyl 
tosylcarbonochloridoimidothioate (5 mmol, 1.3 g). This procedure afforded 1.74 g (90%) 
of the title compound as a viscous oil. 1H NMR (700 MHz, CDCl3):  7.79 (d, J = 8.2 Hz, 
2 H), 7.26–7.32 (m, 3 H), 7.20 (d, J = 8.2 Hz, 2 H), 7.13 (d, J = 7.0 Hz, 2 H), 5.53–5.62 
(m, 1 H), 4.99 (d, J = 10.2 Hz, 1 H), 4.95 (d, = 17.0 J Hz, 1 H), 4.73 (s, br, 2 H), 3.47 (t, 
J = 7.3 Hz, 2 H), 2.76 (s, 3 H), 2.36 (s, 3 H), 2.23 (q, J = 7.1 Hz, 2 H); 13C NMR (CDCl3, 
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175 MHz)  167.3, 141.9, 141.8, 135.5, 134.0, 129.2, 129.0, 128.1, 127.6, 126.1, 117.8, 
54.5, 50.3, 32.0, 21.6, 18.8. 
 
General Procedure 2 for preparation of N-allylguanidine substrates: 
 
A flame-dried round bottom flask equipped with a stir bar was cooled under a stream of 
N2 and charged with the appropriate carbamimidothioate (1 equiv), mercuric oxide (1.5 
equiv), and triethylamine (4.5 equiv), followed by a 2 M solution of NH3 in ethanol (20-40 
equiv NH3). The flask was capped with a greased glass stopper and the mixture was 
stirred at rt for 3 days. The solution was then filtered through celite, and the solvent was 
removed under reduced pressure. The crude product was purified by flash 




procedure 2 was used for the conversion of methyl N-allyl-N-methyl-N'-
tosylcarbamimidothioate (7.2 mmol, 2.14 g) to the title compound using mercuric oxide 
(10.8 mmol, 2.3 g), triethylamine (18.9 mmol, 4.6 mL), and NH3 (75 mL, 2 M solution in 
ethanol). This procedure afforded 1.5 g (78%) of the title compound as a colorless solid, 
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mp 121–125 °C: 1H NMR (500 MHz, CDCl3)  7.75 (d, J = 8.3 Hz, 2 H), 7.21 (d, J = 8.1 
Hz, 2 H), 6.17 (s, br, 2 H), 5.64–5.76 (m, 1 H), 5.19 (d, J = 10.3 Hz, 1 H), 5.11 (dd, J = 
17.2, 1.1 Hz, 1 H), 3.97 (d, J = 4.2 Hz, 2 H), 2.94 (s, 3 H), 2.39 (s, 3 H); 13C NMR (126 
MHz, CDCl3)  156.2, 141.9, 141.3, 132.0, 129.3, 126.1, 117.7, 52.3, 21.6, one peak is 
missing due to incidental equivalence; IR (neat) 3407.0, 1629.8, 1557.6, 1481.7, 1252.3 




procedure 2 was used for the conversion of methyl N-allyl-N-benzyl-N'-
tosylcarbamimidothioate (2.9 mmol, 1.1 g) to the title compound using mercuric oxide 
(4.4 mmol, 962 mg), triethylamine (13.3 mmol, 1.9 mL), and NH3 (60 mL, 2 M solution in 
ethanol). This procedure afforded 800 mg (79%) of the title compound as a colorless 
solid, mp 118–121 °C: 1H NMR (500 MHz, CDCl3)  7.74 (d, J = 8.1 Hz, 2 H), 7.23–7.29 
(m, 3 H), 7.21 (d, J = 8.1 Hz, 2 H), 7.08–7.15 (m, 2 H), 6.26 (s, br, 2 H), 5.63–5.73 (m, 1 
H), 5.19 (d, J = 10.3 Hz, 1 H), 5.13 (d, J = 17.1 Hz, 1 H), 4.57 (s, 2 H), 3.90 (s, br, 2 H), 
2.39 (s, 3 H); 13C NMR (175 MHz, CDCl3)  156.4, 141.9, 141.2, 136.2, 131.9, 129.2, 
128.9, 127.9, 127.5, 126.1, 118.1, 51.3, 50.4, 21.6. IR (neat) 3414.0, 3319.8, 1624.2, 






procedure 2 was used for the conversion of methyl N,N-diallyl-N'-
tosylcarbamimidothioate (3.8 mmol, 1.22 g) to the title compound using mercuric oxide 
(5.6 mmol, 1.2 g), triethylamine (17.1 mmol, 2.4 mL), and NH3 (60 mL, 2 M solution in 
ethanol). This procedure afforded 1.05 g (95%) of the title compound as a colorless 
solid, mp 114–118 °C: 1H NMR (500 MHz, CDCl3)  7.75 (d, J = 8.3 Hz, 2 H), 7.22 (d, J 
= 8.3 Hz, 2 H), 6.19 (s, br, 2 H), 5.73 (ddt, J = 17.3, 10.5, 5.3 Hz, 2 H), 5.19 (d, J = 10.3 
Hz, 2 H), 5.13 (d, J = 17.2, 2 H), 3.93 (s, br, 4 H), 2.38 (s, 3 H); 13C NMR (175 MHz, 
CDCl3)  156.3, 141.9, 141.3, 132.3, 129.2, 126.1, 118.1, 50.5, 21.6; IR (neat) 3414.6, 
3316.6, 1616.7, 1540.7, 1490.8 cm-1; MS (ESI+) 294.1274 (294.1271 calcd for 




methylbenzenesulfonamide: General procedure 2 was used for the conversion of 
methyl N-allyl-N-(4-methoxyphenyl)-N'-tosylcarbamimidothioate (3.1 mmol, 1.22 g) to 
the title compound using mercuric oxide (4.7 mmol, 1.0 g), triethylamine (14.0 mmol, 2.0 
mL), and NH3 (60 mL, 2 M solution in ethanol). This procedure afforded 900 mg (81%) 
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of the title compound as a colorless solid. mp 105–109 °C: 1H NMR (500 MHz, CDCl3)  
7.82 (d, J = 8.3 Hz, 2 H), 7.22–7.28 (m, 2 H), 7.07–7.11 (m, 2 H), 6.89–6.95 (m, 2 H), 
5.74–5.84 (m, 1 H), 5.04 (dd, J = 10.0, 1.2 Hz, 1 H), 4.97 (dd, J = 17.1, 1.5 Hz, 1 H), 
4.29 (d, J = 6.4 Hz, 2 H), 3.81 (s, 3 H), 2.40 (s, 3 H); 13C NMR (175 MHz, CDCl3)  
159.9, 155.5, 142.0, 141.2, 133.1, 131.9, 129.7, 129.3, 126.2, 118.5, 115.6, 55.7, 53.9, 
21.6  IR (neat) 3446.3, 3330.1, 1607.5, 1506.2 cm-1; MS (ESI+) 360.1380 (360.1376 




General procedure 2 was used for the conversion of methyl N-benzyl-N-(2-methylallyl)-
N'-tosylcarbamimidothioate (2.57 mmol, 998 mg) to the title compound using mercuric 
oxide (3.85 mmol, 834 mg), triethylamine (11.6 mmol, 1.6 mL), and NH3 (60 mL, 2 M 
solution in ethanol). This procedure afforded 577 mg (63%) of the title compound as a 
colorless solid, mp 98–102 °C: 1H NMR (500 MHz, CDCl3)  7.75 (d, J = 8.1 Hz, 2 H), 
7.23–7.29 (m, 3 H), 7.21 (d, J = 7.8 Hz, 2 H), 7.09–7.14 (m, 2 H), 6.25 (s, br, 2 H), 4.93 
(s, 1 H), 4.80 (s, 1 H), 4.59 (s, br, 2 H), 3.79 (s, br, 2 H), 2.40 (s, 3 H), 1.63 (s, 3 H); 13C 
NMR (175 MHz, CDCl3)  156.8, 141.9, 141.3, 139.5, 136.2, 129.2, 129.0, 128.0, 127.7, 
126.1, 112.9, 53.4, 51.4, 21.6, 19.9; IR (neat) 3414.2, 3320.8, 1616.8, 1534.0, 1490.7 






General procedure 2 was used for the conversion of methyl N-ethyl-N-(2-methylallyl)-N'-
tosylcarbamimidothioate (4.6 mmol, 1.50 g) to the title compound using mercuric oxide 
(6.9 mmol, 1.5 g), triethylamine (20.7 mmol, 2.9 mL), and NH3 (80 mL, 2 M solution in 
ethanol). This procedure afforded 600 mg (44%) of the title compound as a colorless 
solid, mp 109–113 °C: 1H NMR (500 MHz, CDCl3)  7.76 (d, J = 8.3 Hz, 2 H), 7.21 (d, J 
= 8.1 Hz, 2 H), 6.17 (s, br, 2 H), 4.89 (s, 1 H), 4.76 (s, 1 H), 3.80 (s, br, 2 H), 3.38 (d, J = 
5.6 Hz, 2 H), 2.38 (s, 3 H), 1.65 (s, 3 H), 1.10 (t, J = 7.1 Hz, 3 H); 13C NMR (175 MHz, 
CDCl3)  156.1, 141.8, 141.4, 139.9, 129.2, 126.0, 112.5, 53.3, 43.6, 21.6, 19.9, 12.9; 
IR (neat) 3424.3, 3337.1, 1633.8, 1557.3, 1489.9 cm-1; MS (ESI+) 296.1430 (296.1427 





General procedure 2 was used for the conversion of methyl-N-allyl-N-phenethyl-N'-
tosylcarbamimidothioate (5.0 mmol, 1.96 g) to the title compound using mercuric oxide 
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(7.6 mmol, 1.7 g), triethylamine (22.7 mmol, 3.2 mL), and NH3 (75 mL, 2 M solution in 
ethanol). This procedure afforded 1.5 g (82%) of the title compound as a colorless solid, 
mp 89–91 °C: 1H NMR (700 MHz, CDCl3)  7.79 (d, J = 8.2 Hz, 2 H), 7.23–7.26 (m, 4 
H), 7.19–7.22 (m, 1 H), 7.07 (d, J = 7.2 Hz, 2 H), 6.05 (s, br, 2 H), 5.60–5.67 (m, 1 H), 
5.18 (d, J = 10.4 Hz, 1 H), 5.11 (d, J = 17.2 Hz, 1 H), 3.74 (s, br, 2 H), 3.55 (s, br, 2 H), 
2.81 (t, J = 7.2 Hz, 2 H), 2.40 (s, 3 H); 13C NMR (175 MHz, CDCl3)  156.0, 141.9, 
141.4, 138.5, 132.2, 129.3, 128.9, 126.9, 126.1, 117.9, 51.5, 50.1, 34.6, 21.6, one peak 
is missing due to incidental equivalence; IR (neat) 3415.3, 3337.3, 1634.4, 1540.6, 




methylbenzenesulfonamide: General procedure 2 was used for the conversion of 
methyl-N-[2-(1,3-dioxan-2-yl)ethyl]-N-allyl-N'-tosylcarbamimidothioate (5.27 mmol, 2.1 
g) to the title compound using mercuric oxide (7.9 mmol, 1.7 g), triethylamine (23.7 
mmol, 3.3 mL), and NH3 (80 mL, 2 M solution in ethanol). This procedure afforded 1.77 
g (92%) of the title compound as a viscous oil: 1H NMR (700 MHz, CDCl3)  7.74–7.77 
(m, 2 H), 7.19–7.22 (m, 2 H), 6.39–6.77 (s, br, 2 H), 5.66–5.74 (m, 1 H), 5.12 (d, J = 9.9 
Hz, 1 H), 5.08 (d, J = 17.2 Hz, 1 H), 4.53 (t, J = 4.8 Hz, 1 H), 4.01–4.06 (m, 2 H), 3.97 
(s, br, 2 H), 3.68 (td, J = 12.3, 2.4 Hz, 2 H), 3.33 (s, br, 2 H), 2.37 (s, 3 H), 1.97–2.05 (m, 
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1 H), 1.81 (td, J = 6.7, 4.9 Hz, 2 H), 1.33 (d, J = 13.6 Hz, 1 H); 13C NMR (175 MHz, 
CDCl3)  156.1, 141.7, 141.5, 132.9, 129.2, 126.1, 117.9, 99.5, 66.9, 50.7, 41.6, 33.3, 
25.6, 21.6; IR (neat) 3417.9, 3337.1, 2959.8, 1630.8, 1544.6, 1487.8, 1259.0 cm-1; MS 




methylbenzenesulfonamide: General procedure 2 was used for the conversion of 
methyl-N-allyl-N-{3-[(tert-butyldimethylsilyl)oxy]propyl}-N'-tosylcarbamimidothioate (5.2 
mmol, 2.4 g) to the title compound using mercuric oxide (7.8 mmol, 1.7 g), triethylamine 
(23.4 mmol, 3.3 mL), and NH3 (75 mL, 2 M solution in ethanol). This procedure afforded 
1.2 g (54%) of the title compound as a colorless solid, mp 89–92 °C: 1H NMR (500 MHz, 
CDCl3)  7.77 (d, J = 8.1 Hz, 2 H), 7.21 (d, J = 8.3 Hz, 2 H), 6.78 (s, br, 2 H), 5.68–5.77 
(m, 1 H), 5.04–5.15 (m, 2 H), 3.97 (d, J = 5.6 Hz, 2 H), 3.59 (t, J = 5.5 Hz, 2 H), 3.33 (t, 
J = 5.9 Hz, 2 H), 2.38 (s, 3 H), 1.64–1.73 (m, 2 H), 0.88 (s, 9 H), 0.06 (s, 6 H), one peak 
is missing due to incidental equivalence; 13C NMR (126 MHz, CDCl3)  156.9, 141.7, 
141.6, 133.2, 129.2, 126.1, 117.8, 59.1, 50.7, 30.5, 26.0, 21.6, 18.4, -5.2; IR (neat) 
3421.2, 3339.8, 2927.4, 1630.3, 1543.0, 1487.7, 1256.8 cm-1; MS (ESI+) 426.2241 






General procedure 2 was used for the conversion of methyl-N-allyl-N-(2-phenoxyethyl)-
N'-tosylcarbamimidothioate (5.0 mmol, 2.0 g) to the title compound using mercuric oxide 
(7.5 mmol, 1.6 g), triethylamine (22.5 mmol, 3.2 mL), and NH3 (75 mL, 2 M solution in 
ethanol). This procedure afforded 1.1 g (59%) of the title compound as a colorless solid, 
mp 100–105 °C: 1H NMR (500 MHz, CDCl3)  7.77 (d, J = 8.3 Hz, 2 H), 7.24–7.30 (m, 2 
H), 7.21 (d, J = 8.1 Hz, 2 H), 6.98 (t, J = 7.3 Hz, 1 H), 6.79 (d, J = 7.8 Hz, 2 H), 6.51 (s, 
br, 2 H), 5.75–5.85 (m, 1 H), 5.12–5.24 (m, 2 H), 4.01–4.12 (m, 4 H), 3.73 (s, br, 2 H), 
2.38 (s, 3 H); 13C NMR (175 MHz, CDCl3)  158.0, 157.0 142.0, 141.3, 132.7, 129.8, 
129.3, 126.1, 121.7, 118.1, 114.5, 67.1, 52.3, 48.6, 21.6; IR (neat) 3416.0, 3327.7, 
1626.6, 1544.5, 1489.5, 1259.9 cm-1; MS (ESI+) 375.1532 (375.1533 calcd for 






General procedure 2 was used for the conversion of methyl N-allyl-N-benzyl-N'-[(4-
methoxyphenyl)sulfonyl]carbamimidothioate (2.74 mmol, 1.07 g) to the title compound 
using mercuric oxide (4.1 mmol, 890 mg), triethylamine (12.0 mmol, 1.7 mL), and NH3 
(60 mL, 2 M solution in ethanol). This procedure afforded 890 mg (90%) of the title 
compound as a colorless solid, mp 108–111 °C: 1H NMR (500 MHz, CDCl3)  7.77–7.82 
(m, 2 H), 7.23–7.29 (m, 3 H), 7.09–7.14 (m, 2 H), 6.87–6.91 (m, 2 H), 6.25 (s, br, 2 H), 
5.63–5.74 (m, 1 H), 5.19 (dd, J = 10.3, 0.7 Hz, 1 H), 5.10–5.16 (m, 1 H), 4.57 (s, 2 H), 
3.90 (s, br, 2 H), 3.84 (s, 3 H); 13C NMR (175 MHz, CDCl3)  162.0, 156.4, 136.2, 132.0, 
129.0, 128.1, 128.0, 127.5, 118.1, 113.8, 55.7, 51.3, 50.4, one peak is missing due to 
incidental equivalence; IR (neat) 3417.5, 3320.8, 1613.4, 1541.0, 1488.0, 1249.5 cm-1; 




methylbenzenesulfonamide: General procedure 2 was used for the conversion of 
(2Z)-Methyl N-benzyl-N-(-3-cyclopropylallyl)-N'-tosylcarbamimidothioate (2.4 mmol, 1.0 
g) to the title compound using mercuric oxide (3.6 mmol, 780 mg), triethylamine (10.8 
mmol, 1.5 mL), and NH3 (50 mL, 2 M solution in ethanol). This procedure afforded 702 
mg (76%) of the title compound as a colorless solid. The compound was isolated as a 
1:3 mixture of E:Z alkene stereoisomers as determined by 1H NMR analysis, mp 85–88 
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°C, 1H NMR data are for the major isomer. 13C NMR data are for the mixture of isomers: 
1H NMR (500 MHz, CDCl3)  7.70–7.77 (m, 2 H), 7.21–7.27 (m, 3 H), 7.19 (d, J = 8.0 
Hz, 2 H), 7.11 (dd, J = 6.3, 2.7 Hz, 2 H), 6.17–6.35 (m, 2 H), 5.14 (dt, J = 10.6, 6.6 Hz, 1 
H), 4.91 (t, J = 10.5 Hz, 1 H), 4.60 (s, 1 H), 4.02 (d, J = 4.7 Hz, 2 H), 2.38 (s, 3 H), 1.34–
1.45 (m, 1 H), 0.69–0.77 (m, 2 H), 0.30–0.37 (m, 2 H); 13C NMR (175 MHz, CDCl3)  
156.4, 141.8, 141.3, 139.1, 138.7, 129.2, 129.2, 128.9, 127.9, 127.6, 126.1, 121.5, 51.5, 
45.4, 21.6, 13.5, 9.6, 7.4, 7.0; IR (neat) 3403.5, 3322.3, 1632.9, 1540.2, 1481.7, 1262.6 




methylbenzenesulfonamide: General procedure 2 was used for the conversion of (E)-
Methyl N-benzyl-N-(-but-2-en-1-yl)-N'-tosylcarbamimidothioate (2.5 mmol, 990 mg) to 
the title compound using mercuric oxide (3.8 mmol, 810 mg), triethylamine (11.3 mmol, 
1.6 mL), and NH3 (50 mL, 2 M solution in ethanol). This procedure afforded 760 mg 
(85%) of the title compound as a colorless solid. The compound was isolated as an 
85:15 mixture of E:Z alkene stereoisomers as determined by 1H NMR analysis,  mp 61–
68 °C; 1H NMR data are for the major isomer. 13C NMR data are for the mixture of 
isomers: 1H NMR (500 MHz, CDCl3)  7.73 (d, J = 8.0 Hz, 2 H), 7.14–7.28 (m, 5 H), 
7.03–7.12 (m, 2 H), 6.22 (s, br, 2 H), 5.49–5.61 (m, 1 H), 5.21–5.34 (m, 1 H), 4.55 (s, 2 
H), 3.80 (s, br, 2 H), 2.38 (s, 3 H), 1.64 (d, J = 6.3 Hz, 5 H); 13C NMR (175 MHz, CDCl3) 
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 156.4, 156.4, 141.9, 141.8, 141.3, 141.3, 129.9, 129.2, 129.2, 129.2, 128.9, 128.9, 
127.9, 127.9, 127.5, 126.1, 124.8, 124.7, 51.2, 49.9, 44.9, 21.6, 17.8, 13.1; IR (neat) 
3428.1, 3336.7, 1625.9, 1537.3, 1486.5, 1251.5 cm-1; MS (ESI+) 358.1587 (358.1584 




General procedure 2 was used for the conversion of methyl-N-benzyl-N-(but-3-en-1-yl)-
N'-tosylcarbamimidothioate (3.3 mmol, 1.28 g) to the title compound using mercuric 
oxide (4.9 mmol, 1.0 g), triethylamine (14.9 mmol, 2.0 mL), and NH3 (60 mL, 2 M 
solution in ethanol). This procedure afforded 840 mg (71%) of the title compound as a 
colorless solid, mp 121–123 °C: 1H NMR (700 MHz, CDCl3)  7.74 (d, J = 8.2 Hz, 2 H), 
7.26–7.30 (m, 3 H), 7.21 (d, J = 8.0 Hz, 2 H), 7.09–7.12 (m, 2 H), 6.22 (s, br, 2 H), 5.69 
(ddt, J = 17.1, 10.2, 7.0 Hz, 1 H), 4.98–5.04 (m, 2 H), 4.54 (s, br, 2 H), 3.41 (s, br, 2 H), 
2.40 (s, 3 H), 2.27 (q, J = 7.2 Hz, 2 H); 13C NMR (175 MHz, CDCl3)  156.1, 141.9, 
141.3, 135.9, 134.5, 129.2, 129.1, 128.1, 127.0, 126.1, 117.9, 51.6, 48.2, 32.3, 21.6; IR 
(neat) 3413.1, 3317.9, 1618.3, 1541.7, 1489.5, 1247.0 cm-1; MS (ESI+) 358.1585 





N'-Tosyl-2-vinylpiperidine-1-carboximidamide (2-30): General procedure 2 was used 
for the conversion of methyl N-tosyl-2-vinylpiperidine-1-carbimidothioate (3.2 mmol, 
1.08 g) to the title compound using mercuric oxide (4.8 mmol, 1.0 g), triethylamine (14.4 
mmol, 2.0 mL), and NH3 (60 mL, 2 M solution in ethanol). This procedure afforded 630 
mg (64%) of the title compound as a colorless solid. mp 115–119 °C: 1H NMR (500 
MHz, CDCl3)  7.74 (d, J = 7.8 Hz, 2 H), 7.20 (d, J = 7.8 Hz, 2 H), 6.27 (s, br, 2 H), 5.67 
(ddd, J = 17.4, 10.6, 4.0 Hz, 1 H), 5.16 (dd, J = 10.6, 1.6 Hz, 1 H), 4.89–4.95 (m, 1 H), 
4.84 (s, br, 1 H), 3.95 (d, J = 13.2 Hz, 1 H), 2.93 (td, J = 12.8, 3.3 Hz, 1 H), 2.38 (s, 3 
H), 1.56–1.82 (m, 4 H), 1.39–1.54 (m, 2 H); 13C NMR (175 MHz, CDCl3)  156.0, 141.8, 
141.3, 135.6, 129.2, 126.1, 116.9, 53.7, 40.7, 29.0, 25.0, 21.6, 19.0; IR (neat) 3417.0, 
3337.1, 1634.2, 1520.6, 1480.7, 1256.1 cm-1; MS (ESI+) 308.1430 (308.1427 calcd for 




methylbenzenesulfonamide (2-32): General procedure 2 was used for the conversion 
of methyl N-benzyl-N-(2-methylenecyclohexyl)-N'-tosylcarbamimidothioate (3.0 mmol, 
1.3 g) to the title compound using mercuric oxide (4.8 mmol, 1.0 g), triethylamine (13.5 
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mmol, 1.9 mL), and NH3 (60 mL, 2 M solution in ethanol). This procedure afforded 320 
mg (27%) of the title compound as a colorless solid: mp 76–80 °C. The product was 
determined to exist as a mixture of conformers as judged by 1H NMR analysis. 1H NMR 
data are for the major conformer, whereas 13C NMR data are for the mixture: 1H NMR 
(500 MHz, CDCl3)  7.70 (d, J = 8.2 Hz, 2 H), 7.08–7.29 (m, 7 H), 6.15 (s, br, 2 H), 4.77 
(s, br, 2 H), 4.34–4.47 (m, 2 H), 2.32–2.47 (m, 4 H), 2.07 (t, J = 12.5 Hz, 1 H), 1.75 (s, 
br, 3 H), 1.41 (s, br, 2 H), 1.08–1.28 (m, 2 H); 13C NMR (175 MHz, CDCl3)  157.1, 
145.4, 141.8, 141.2, 129.1, 128.9, 127.6, 126.5, 126.2, 107.1, 60.5, 48.9, 35.0, 31.9, 
26.9, 25.7, 22.8, 21.6; IR (neat) 3427.0, 3328.2, 2933.9, 1625.0, 1516.7, 1487.8 cm-1; 




methylbenzenesulfonamide (2-23): General procedure 2 was used for the conversion 
of methyl-N-benzyl-N-(cyclopent-2-en-1-yl)-N'-tosylcarbamimidothioate (2.82 mmol, 
1.13 g) to the title compound using mercuric oxide (4.2 mmol, 910 mg), triethylamine 
(12.7 mmol, 1.8 mL), and NH3 (60 mL, 2 M solution in ethanol). This procedure afforded 
620 mg (60%) of the title compound as a colorless solid: 1H NMR (700 MHz, CDCl3)  
7.76 (d, J = 8.0 Hz, 2 H), 7.24–7.31 (m, 3 H), 7.22 (d, J = 7.9 Hz, 2 H), 7.12 (d, J = 7.3 
Hz, 2H), 6.12 (br. s, 2 H), 5.95–5.99 (m, 1 H), 5.56–5.61 (m, 1 H), 4.33–4.51 (m, 2 H), 





methylbenzenesulfonamide: General procedure 2 was used for the conversion of 
methyl-N-benzyl-N-(3-methylbut-2-en-1-yl)-N'-tosylcarbamimidothioate (2.8 mmol, 1.13 
g) to the title compound using mercuric oxide (4.2 mmol, 900 mg), triethylamine (12.6 
mmol, 1.8 mL), and NH3 (50 mL, 2 M solution in ethanol). This procedure afforded 1.0 g 
(96%) of the title compound as a colorless solid: 1H NMR (400 MHz, CDCl3)  7.77 (d, J 
= 8.0 Hz, 2 H), 7.31–7.20 (m, 5H), 7.13 (dd, J = 6.6, 2.9 Hz, 2H), 6.15 (s, 2H), 5.06 (t, J 
= 7.0 Hz, 1 H), 4.57 (s, 2 H), 3.87 (d, J = 6.6 Hz, 2 H), 2.40 (s, 3 H), 1.70 (s, 3 H), 1.60 
(s, 3 H). 
 
2-Allyl-N'-tosylpyrrolidine-1-carboximidamide (2-21): General procedure 2 was used 
for the conversion of methyl-2-allyl-N-tosylpyrrolidine-1-carbimidothioate (3.4 mmol, 
1.16 g) to the title compound using mercuric oxide (5.1 mmol, 1.1 g), triethylamine (15.3 
mmol, 2.13 mL), and NH3 (70 mL, 2 M solution in ethanol). This procedure afforded 750 
mg (72%) of the title compound as a colorless solid: 1H NMR (500 MHz, CDCl3)  7.79 
(d, J = 7.8 Hz, 2 H), 7.23 (d, J = 7.8 Hz, 2 H), 6.02 (s, br, 2 H), 5.62–5.70 (m, 1 H), 
4.95–5.99 (m, 2 H), 4.14 (br. s, 1 H), 2.39–2.44 (br. s, 2 H), 2.05–2.11 (m, 1 H), 1.89–






General procedure 2 was used for the conversion of methyl-N-benzyl-N-cinnamyl-N'-
tosylcarbamimidothioate (2.9 mmol, 1.08 g) to the title compound using mercuric oxide 
(4.4 mmol, 942 mg), triethylamine (12.8 mmol, 1.8 mL), and NH3 (40 mL, 2 M solution in 
ethanol). This procedure afforded 620 mg (62%) of the title compound as a colorless 
solid: 1H NMR (400 MHz, CDCl3)  7.80 (d, J = 8.1 Hz, 2 H), 7.27–7.36 (m, 4 H), 7.21 
(d, J = 8.0 Hz, 2 H), 6.40 (d, J = 15.9 Hz, 1 H), 6.18 (s, 2 H), 6.06 (dt, J = 15.9, 5.9 Hz, 1 
H), 4.15 (d, J = 6.0 Hz, 2 H), 2.98 (s, 3 H), 2.38 (s, 3 H). 
 
General Procedure 3 for intramolecular Ag-catalyzed guanidine hydroamination 
reactions: 
An oven-dried test tube was charged with the appropriate guanidine substrate (1.0 
equiv), sodium tert-butoxide (1.0 equiv), and 15-40 mol% silver nitrate. The tube was 
capped with a septum and purged with oxygen. Chlorobenzene (0.1 M) was added, and 
a balloon of oxygen was affixed to the septum with a needle connection. The mixture 
was stirred vigorously at room temperature for 10 min, and then transferred to a 
hotplate and heated to (80–100 °C) with vigorous stirring until the starting material had 
been completely consumed (16–24 h). The mixture was then cooled to rt and the 
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reaction was quenched with saturated ammonium chloride (8 mL/mmol). The mixture 
was transferred to a separatory funnel and the aqueous layer was extracted with ethyl 
acetate (3 x 8 mL/mmol). The combined organic layers were filtered through a plug of 
celite, and solvent was removed under reduced pressure. The crude product was 





General procedure 3 was used for the hydroamination of N-
{[Allyl(methyl)amino](amino)methylene}-4-methylbenzenesulfonamide (0.25 mmol, 67 
mg) with AgNO3 (0.038 mmol, 6.4 mg), and sodium tert-butoxide (0.25 mmol, 24.0 mg) 
for 16 h at 80°C. This procedure afforded 63 mg (94%) of the title compound as a 
colorless solid, mp 175–177 °C: 1H NMR (500 MHz, CDCl3)  7.78 (d, J = 8.2 Hz, 2 H), 
7.22 (d, J = 8.0 Hz, 2 H), 6.95 (s, br, 1 H), 3.89–4.00 (m, 1 H), 3.53 (t, J = 9.1 Hz, 1 H), 
2.98 (dd, J = 9.2, 7.2 Hz, 1 H), 2.82 (s, 3 H), 2.37 (s, 3 H), 1.25 (d, J = 6.3 Hz, 3 H); 13C 
NMR (175 MHz, CDCl3)  158.5, 141.9, 141.1, 129.2, 126.2, 54.9, 48.7, 31.4, 21.6, 
21.2; IR (neat) 3375.2, 2917.5, 1586.1, 1531.5, 1256.5 cm-1; MS (ESI+) 268.1120 






General procedure 3 was used for the hydroamination of N-
{[Allyl(benzyl)amino](amino)methylene}-4-methylbenzenesulfonamide (0.25 mmol, 90 
mg) with AgNO3 (0.038 mmol, 6.4 mg), and sodium tert-butoxide (0.25 mmol, 24.0 mg) 
for 16 h at 80°C. This procedure afforded 89 mg (90%) of the title compound as a 
colorless solid, mp 104–105 °C: 1H NMR (500 MHz, CDCl3)  7.82 (d, J = 8.2 Hz, 2 H), 
7.23–7.28 (m, 5 H), 7.12 (dd, J = 6.6, 2.8 Hz, 2 H), 7.07 (s, br, 1 H), 4.39–4.49 (m, 2 H), 
3.88–3.99 (m, 1 H), 3.41 (t, J = 9.2 Hz, 1 H), 2.86 (dd, J = 9.2, 7.0 Hz, 1 H), 2.41 (s, 3 
H), 1.22 (d, J = 6.1 Hz, 3 H); 13C NMR (175 MHz, CDCl3)  158.1, 142.0, 141.1, 135.8, 
129.2, 128.8, 128.2, 127.9, 126.2, 51.8, 48.8, 48.0, 21.6, 21.2 ; IR (neat) 3381.9, 





General procedure 3 was used for the hydroamination of N-
[Amino(diallylamino)methylene]-4-methylbenzenesulfonamide (0.25 mmol, 74 mg) with 
AgNO3 (0.038 mmol, 6.4 mg), and sodium tert-butoxide (0.25 mmol, 24.0 mg) for 18 h at 
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80°C. This procedure afforded 69 mg (94%) of the title compound as a colorless solid, 
mp 99–103 °C: 1H NMR (700 MHz, CDCl3)  7.76 (d, J = 7.8 Hz, 2 H), 7.21 (d, J = 7.8 
Hz, 2 H), 6.99 (s, br, 1 H), 5.64 (ddt, J = 16.9, 10.4, 6.1 Hz, 1 H), 5.15 (dd, J = 10.2, 1.2 
Hz, 1 H), 5.10–5.13 (m, 1 H), 3.91–3.97 (m, 1 H), 3.80–3.89 (m, 2 H), 3.49 (t, J = 9.2 
Hz, 1 H), 2.94 (dd, J = 9.4, 7.2 Hz, 1 H), 2.37 (s, 3 H), 1.25 (d, J = 6.1 Hz, 3 H); 13C 
NMR (175 MHz, CDCl3)  158.0, 142.0, 141.0, 132.1, 129.2, 126.2, 118.7, 52.0, 48.8, 
46.9, 21.6, 21.2; IR (neat) 3347.3, 2915.7, 1576.2, 1514.2, 1264.2 cm-1; MS (ESI+) 




methylbenzenesulfonamide (2-12): General procedure 3 was used for the 
hydroamination of N-{[Allyl(4-methoxyphenyl)amino](amino)methylene}-4-
methylbenzenesulfonamide (0.25 mmol, 90 mg) with AgNO3 (0.038 mmol, 6.4 mg), and 
sodium tert-butoxide (0.25 mmol, 24.0 mg) for 16 h at 80°C. This procedure afforded 89 
mg (99%) of the title compound as a colorless solid, mp 111–113 °C: 1H NMR (500 
MHz, CDCl3)  7.78 (d, J = 8.2 Hz, 2 H), 7.35 (s, 1 H), 7.27–7.32 (m, 2 H), 7.23 (d, J = 
8.0 Hz, 2 H), 6.79–6.85 (m, 2 H), 4.02–4.12 (m, 1 H), 3.92–3.99 (m, 1 H), 3.77 (s, 3 H), 
3.44 (dd, J = 9.0, 7.0 Hz, 1 H), 2.38 (s, 3 H), 1.34 (d, J = 6.1 Hz, 3 H); 13C NMR (175 
MHz, CDCl3)  157.0, 156.2, 142.1, 140.8, 131.6, 129.3, 126.2, 123.4, 114.2, 55.6, 
54.6, 48.4, 21.6, 21.2; IR (neat) 3370.0, 1569.0, 1512.4, 1246.7 cm-1; MS (ESI+) 
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13): General procedure 3 was used for the hydroamination of N-{Amino[benzyl(2-
methylallyl)amino]methylene}-4-methylbenzenesulfonamide (0.25 mmol, 90 mg) with 
AgNO3 (0.05 mmol, 8.5 mg), and sodium tert-butoxide (0.25 mmol, 24.0 mg) for 18 h at 
100°C. This procedure afforded 85 mg (94%) of the title compound as a colorless solid, 
mp 130–133 °C: 1H NMR (500 MHz, CDCl3)  7.80 (d, J = 8.3 Hz, 2 H), 7.22–7.27 (m, 5 
H), 7.08–7.13 (m, 2 H), 6.98 (s, 1 H), 4.44 (s, 2 H), 3.03 (s, 2 H), 2.41 (s, 3 H), 1.28 (s, 6 
H); 13C NMR (175 MHz, CDCl3)  157.2, 142.0, 141.2, 135.9, 129.3, 128.8, 128.2, 
127.9, 126.2, 57.5, 56.1, 48.0, 28.3, 21.6; IR (neat) 3343.8, 1579.0, 1508.2, 1266.8 cm-




14): General procedure 3 was used for the hydroamination of N-{Amino[ethyl(2-
methylallyl)amino]methylene}-4-methylbenzenesulfonamide (0.25 mmol, 90 mg) with 
AgNO3 (0.05 mmol, 8.5 mg), and sodium tert-butoxide (0.25 mmol, 24.0 mg) for 18 h at 
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100°C. This procedure afforded 71 mg (96%) of the title compound as a colorless solid, 
mp 168–173 °C: 1H NMR (500 MHz, CDCl3)  7.73–7.77 (m, 2 H), 7.18–7.22 (m, 2 H), 
6.89 (s, br, 1 H), 3.29 (q, J = 7.1 Hz, 2 H), 3.14 (s, 2 H), 2.36 (s, 3 H), 1.28 (s, 6 H), 1.03 
(t, J = 7.2 Hz, 3 H); 13C NMR (175 MHz, CDCl3)  157.0, 141.8, 141.3, 129.2, 126.0, 
57.5, 55.9, 38.7, 28.1, 21.5, 12.4; IR (neat) 3342.1, 2920.0, 1581.7, 1514.8, 1259.9 cm-




15): General procedure 3 was used for the hydroamination of N-
{[Allyl(phenethyl)amino](amino)methylene}-4-methylbenzenesulfonamide (0.25 mmol, 
89 mg) with AgNO3 (0.038 mmol, 6.4 mg), and sodium tert-butoxide (0.25 mmol, 24.0 
mg) for 18 h at 80°C. This procedure afforded 87 mg (98%) of the title compound as a 
colorless solid, mp 114–118 °C: 1H NMR (700 MHz, CDCl3)  7.76–7.79 (m, 2 H), 7.20–
7.25 (m, 4 H), 7.16–7.20 (m, 1 H), 7.07–7.10 (m, 2 H), 6.92 (s, 1 H), 3.81–3.87 (m, 1 H), 
3.50–3.53 (m, 2 H), 3.35 (t, J = 9.2 Hz, 1 H), 2.75–2.83 (m, 3 H), 2.40 (s, 3 H), 1.14 (d, J 
= 6.3 Hz, 3 H); 13C NMR (175 MHz, CDCl3)  158.0, 142.0, 141.2, 138.6, 129.3, 128.9, 
128.7, 126.7, 126.2, 53.1, 48.8, 45.4, 34.0, 21.6, 21.2; IR (neat) 3349.6, 2925.8, 1576.3, 







methylbenzenesulfonamide (2-16): General procedure 3 was used for the 
hydroamination of N-[(allyl{3-[(tert-
butyldimethylsilyl)oxy]propyl}amino)(amino)methylene]-4-methylbenzenesulfonamide 
(0.25 mmol, 106 mg) with AgNO3 (0.038 mmol, 6.4 mg), and sodium tert-butoxide (0.25 
mmol, 24.0 mg) for 18 h at 80°C. This procedure afforded 74 mg (70%) of the title 
compound as a colorless solid, mp 84–87 °C: 1H NMR (500 MHz, CDCl3)  7.76 (d, J = 
8.3 Hz, 2 H), 7.21 (d, J = 8.1 Hz, 2 H), 6.94 (s, br, 1 H), 3.90–3.98 (m, 1 H), 3.54–3.59 
(m, 3 H), 3.25–3.38 (m, 2 H), 3.01 (dd, J = 9.0, 7.1 Hz, 1 H), 2.37 (s, 3 H), 1.63–1.71 (m, 
2 H), 1.24 (d, J = 6.1 Hz, 3 H), 0.85 (s, 9 H), 0.00 (s, 6 H); 13C NMR (175 MHz, CDCl3)  
158.2, 141.8, 141.2, 129.2, 126.1, 60.5, 52.9, 48.8, 41.4, 30.6, 26.0, 21.6, 21.2, 18.4, -
5.3; IR (neat) 3353.0, 2926.4, 2856.6, 1581.7, 1515.8, 1262.4, 1084.3 cm-1; MS (ESI+) 




methylbenzenesulfonamide: The hydroamination of substrate 2-16 generated 
approximately 20% of de-silylated cyclic guanidine N-[1-(3-Hydroxypropyl)-4-
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methylimidazolidin-2-ylidene]-4-methylbenzenesulfonamide. The identity of N-[1-(3-
Hydroxypropyl)-4-methylimidazolidin-2-ylidene]-4-methylbenzenesulfonamide was 
verified by TBAF deprotection of 2-16. A flame-dried round bottom flask was cooled 
under a stream of nitrogen and charged with 2-16 (104 mg, 0.25 mmol) and THF (2.5 
mL). The mixture was cooled to 0 °C then a solution of TBAF (300 μL, 1 M solution in 
THF) was then added dropwise. The resulting mixture was stirred at rt for 80 minutes, 
then a solution of saturated ammonium chloride (2 mL) was added, the mixture was 
transferred to a separatory funnel and the aqueous layer was extracted with ethyl 
acetate (3 x 2 mL). The combined organic layers were filtered through a plug of celite, 
and the solvent was removed under reduced pressure. The crude product was purified 
by flash chromatography on silica gel using dichloromethane/methanol as eluant. This 
afforded 39 mg (50 %) of the title compound as a colorless solid, mp 114–117 °C: 1H 
NMR (500 MHz, CDCl3)  7.77 (J = 7.8 Hz, 2 H), 7.24 (d, J = 7.8 Hz, 2 H), 6.97 (s, 1 H), 
3.95–4.04 (m, 1 H), 3.58 (t, J = 9.3 Hz, 1 H), 3.43–3.52 (m, 2 H), 3.33–3.43 (m, 2 H), 
3.05 (dd, J = 9.4, 7.0 Hz, 1 H), 2.98 (s, br, 1 H), 2.38 (s, 3 H), 1.60–1.68 (m, 2 H), 1.28 
(d, J = 6.1 Hz, 3 H); 13C NMR (126 MHz, CDCl3)  158.49, 142.36, 140.53, 129.38, 
126.23, 58.20, 52.74, 49.05, 40.39, 29.75, 21.33; IR (neat) 3374.6, 2943.3, 1585.0, 






methylbenzenesulfonamide (2-17): General procedure 3 was used for the 
hydroamination of N-({[2-(1,3-Dioxan-2-yl)ethyl](allyl)amino}(amino)methylene)-4-
methylbenzenesulfonamide (0.25 mmol, 92 mg) with AgNO3 (0.038 mmol, 6.4 mg), and 
sodium tert-butoxide (0.25 mmol, 24.0 mg) for 18 h at 80°C. This procedure afforded 81 
mg (88%) of the title compound as a colorless solid, mp 108–110 °C: 1H NMR (700 
MHz, CDCl3)  7.78 (d, J = 8.2 Hz, 2 H), 7.22 (d, J = 8.2 Hz, 2 H), 6.91 (s, 1 H), 4.52 (t, 
J = 5.0 Hz, 1 H), 3.97–4.03 (m, 2 H), 3.90–3.96 (m, 1 H), 3.62 (dtd, J = 18.2, 12.0, 2.6 
Hz, 2 H), 3.55 (t, J = 9.2 Hz, 1 H), 3.38 (t, J = 7.1 Hz, 2 H), 3.02 (dd, J = 9.2, 7.0 Hz, 1 
H), 2.38 (s, 3 H), 1.96–2.04 (m, 1 H), 1.71–1.80 (m, 2 H), 1.23–1.29 (m, 4 H); 13C NMR 
(175 MHz, CDCl3)  158.2, 141.9, 141.3, 129.2, 126.2, 100.5, 66.9, 66.9, 52.5, 48.9, 
39.7, 32.9, 25.8, 21.6, 21.3; IR (neat) 3350.6, 1575.8, 1262.4, 1127.8 cm-1; MS (ESI+) 




ylidene]benzenesulfonamide (2-18): General procedure 3 was used for the 
hydroamination of N-{[allyl(2-phenoxyethyl)amino](amino)methylene}-4-
methylbenzenesulfonamide (0.25 mmol, 93 mg) with AgNO3 (0.038 mmol, 6.4 mg), and 
sodium tert-butoxide (0.25 mmol, 24.0 mg) for 18 h at 80°C. This procedure afforded 84 
mg (90%) of the title compound as a colorless solid, mp 127–129 °C: 1H NMR (500 
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MHz, CDCl3)  7.78 (d, J = 8.1 Hz, 2 H), 7.18–7.31 (m, 4 H), 6.90–7.02 (m, 2 H), 6.79 
(d, J = 7.8 Hz, 2 H), 3.99–4.13 (m, 2 H), 3.89–3.99 (m, 1 H), 3.78 (t, J = 9.2 Hz, 1 H), 
3.65–3.72 (m, 1 H), 3.58–3.65 (m, 1 H), 3.22 (dd, J = 9.2, 7.2 Hz, 1 H), 2.38 (s, 3 H), 
1.24 (d, J = 6.1 Hz, 3 H); 13C NMR (175 MHz, CDCl3)  158.4, 158.2, 142.0, 141.1, 
129.7, 129.3, 126.2, 121.3, 114.5, 66.8, 54.3, 49.1, 44.0, 21.6, 21.2; IR (neat) 3360.0, 





General procedure 3 was used for the hydroamination of 2-7 (0.25 mmol, 90 mg) with 
AgNO3 (0.038 mmol, 6.4 mg), and sodium tert-butoxide (0.25 mmol, 24.0 mg). The 
reaction was conducted for 18 h at 80°C. This procedure afforded 85 mg (94%) of the 
title compound as a colorless solid. mp 118–122 °C: 1H NMR (500 MHz, CDCl3)  7.82–
7.87 (m, 2 H), 7.21–7.25 (m, 3 H), 7.10 (dt, J = 3.8, 2.8 Hz, 2 H), 7.05 (s, 1 H), 6.89–
6.94 (m, 2 H), 4.38–4.46 (m, 2 H), 3.87–3.96 (m, 1 H), 3.83 (s, 3 H), 3.40 (t, J = 9.2 Hz, 
1 H), 2.84 (dd, J = 9.3, 7.1 Hz, 1 H), 1.20 (d, J = 6.1 Hz, 3 H); 13C NMR (175 MHz, 
CDCl3)  162.1, 158.0, 136.0, 135.8, 128.8, 128.2, 128.1, 127.9, 113.8, 55.6, 51.7, 48.8, 
48.0, 21.2; IR (neat) 3370.1, 2916.0, 1565.8, 1517.0, 1500.6, 1252.8 cm-1; MS (ESI+) 






ylidene)benzenesulfonamide (2-31): General procedure 3 was used for the 
hydroamination of 2-30 (0.25 mmol, 77 mg) with AgNO3 (0.1 mmol, 17.0 mg), and 
sodium tert-butoxide (0.25 mmol, 24.0 mg) for 24 h at 100°C. This procedure afforded 
65 mg (84%) of the title compound as an colorless solid, mp 76–79 °C. This material 
was determined to be a 3:1 mixture of diastereomers as judged by 1H NMR analysis. 
Data are for the major diastereomer: 1H NMR (500 MHz, CDCl3)  7.76 (d, J = 7.8 Hz, 2 
H), 7.20 (d, J = 7.8 Hz, 2 H), 6.94 (s, br, 1 H), 3.88–4.02 (m, 1 H), 3.40–3.51 (m, 1 H), 
2.95–3.02 (m, 1 H), 2.56–2.69 (m, 1 H), 2.36 (s, 3 H), 1.76–1.91 (m, 2 H), 1.52–1.64 (m, 
2 H), 1.30–1.37 (m, 2 H), 1.23 (d, J = 6.3 Hz, 3 H); 13C NMR (175 MHz, CDCl3)  156.9, 
141.9, 141.2, 129.2, 126.2, 63.2, 55.9, 41.6, 29.9, 24.6, 23.2, 21.6, 19.7; IR (neat) 
3375.5, 2934.7, 1567.3, 1494.7, 1254.8 cm-1; MS (ESI+) 308.1435 (308.1427 calcd for 




methylbenzenesulfonamide (2-33): General procedure 3 was used for the 
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hydroamination of 2-32 (0.25 mmol, 99 mg) with AgNO3 (0.1 mmol, 17.0 mg), and 
sodium tert-butoxide (0.25 mmol, 24.0 mg) for 24 h at 100°C. This procedure afforded 
98 mg (99%) of the title compound as a colorless solid. mp 153–156 °C: 1H NMR (500 
MHz, CDCl3)  7.81 (d, J = 8.1 Hz, 2 H), 7.24 (d, J = 8.1 Hz, 2 H), 7.16–7.22 (m, 3 H), 
7.07 (d, J = 6.4 Hz, 2 H), 7.03 (s, 1 H), 4.93 (d, J = 15.4 Hz, 1 H), 3.97 (d, J = 15.2 Hz, 1 
H), 3.01 (t, J = 4.3 Hz, 1 H), 2.41 (s, 3 H), 1.68–1.77 (m, 1 H), 1.56–1.61 (m, 2 H), 1.45–
1.55 (m, 2 H), 1.30–1.38 (m, 1 H), 1.22–1.29 (m, 2 H), 1.21  (s, 3 H); 13C NMR (175 
MHz CDCl3)  158.5, 141.9, 141.2, 136.0, 129.2, 128.7, 128.2, 127.7, 126.2, 60.3, 58.0, 
45.4, 35.0, 25.1, 23.3, 21.6, 20.6, 19.5 ; IR (neat) 3316.1, 2936.6, 1574.3, 1254.6 cm-1; 




(Scheme 2.5, entry 4): General procedure 3 was used for the hydroamination of N-
(amino(cinnamyl(methyl)amino)methylene)-4-methylbenzenesulfonamide (0.25 mmol, 
86 mg) with AgNO3 (0.05 mmol, 8.5 mg), and sodium tert-butoxide (0.25 mmol, 24.0 
mg) in PhCl (0.1 M) for 19 h at 100°C. This procedure afforded a 3:2 mixture of sm and 
desired product based on analysis of the crude reaction mixture. The assignment of the 
desired product was made on the basis of the following signals in the crude reaction 
mixture (Note: not all of the signals are outlined following as the starting material and 
the product were inseparable by conventional chromatography): 1H NMR (400 MHz, 
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ylidene)benzenesulfonamide (2-22): General procedure 3 was used for the 
hydroamination of 2-allyl-N'-tosylpyrrolidine-1-carboximidamide (0.25 mmol, 77 mg) with 
AgNO3 (0.25 mmol, 43.0 mg), and sodium tert-butoxide (0.25 mmol, 24.0 mg) in PhCl 
(0.1 M) for 22 h at 100°C. This procedure afforded a 1:0.83 mixture of sm and desired 
product based on analysis of the crude reaction mixture. The dr was judged to be 3:1 
based on analysis of the ratio of the doublet signals corresponding to the new methyl 
group at 1.26 ppm and 1.21 ppm. 
 
Deprotection of Hydroamination Product 2-8 
 
 
1-Benzyl-4-methylimidazolidin-2-iminium 2,2,2-trifluoroacetate (2-36):  
Hydroamination product 2-8 was deprotected using a procedure reported by Du Bois.10 
A round bottom flask was charged with hydroamination product 2-8 (55 mg, 0.15 mmol) 
and trifluoroacetic acid (9 mL). Neat methanesulfonic acid (0.45 mL, 7 mmol, 46 equiv) 
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was added, followed by thioanisole (110 μL, 0.92 mmol, 6 equiv). The resulting mixture 
was stirred at rt for 28 h and then the solvent was removed under reduced pressure. 
The crude product was purified by flash chromatography on silica gel using 
dichloromethane/methanol as eluant. This procedure afforded 27 mg (60%) of the title 
compound as a colorless solid, mp 190–195 °C: 1H NMR (700 MHz, CD3OD)  7.42 (t, J 
= 7.5 Hz, 2H), 7.36 (t, J = 7.4 Hz, 1H), 7.31 (d, J = 7.2 Hz, 2H), 4.53 (s, 2H), 4.09–4.01 
(m, 1H), 3.70 (t, J = 9.4 Hz, 1H), 3.13 (dd, J = 9.7, 6.7 Hz, 1H), 1.26 (d, J = 6.2 Hz, 3H).; 
13C NMR (175 MHz, CD3OD)  159.4, 135.8, 130.2, 129.4, 128.9, 55.3, 50.5, 20.8, one 
peak is missing due to incidental equivalence; IR (neat) 3162.8, 3041.6, 1667.7, 1560.2 
cm-1; MS (ESI+) 190.1340 (190.1339 calcd for C11H15N3, M + H+). 
 
Assignment of Configuration 
The configuration of 2-31 was assigned based on NOESY analysis as shown below.  
 
 







(1)  For total syntheses of batzelladine alkaloids, see: (a) Snider, B.B.; Chen, J. 
Tetrahedron Lett. 1998, 39, 5697; (b) Cohen, F.; Overman, L.E.; Sakata, S.K.L. 
Org. Lett. 1999, 1, 2169; (c) Cohen, F.; Overman, L.E. J. Am. Chem. Soc. 2006, 
128, 2604; (d) Shimokawa, J.; Shirai, K.; Tanatani, A.; Hashimoto, Y.; Nagasawa, 
K. Angew. Chem. 2004, 116, 1585; Angew. Chem. Int. Ed. 2004, 43, 1559; (e) 
Arnold, M.A.; Day, K.A.; Durón, S.D.; Gin, D.Y. J. Am. Chem. Soc. 2006, 128, 
13255; (f) Evans, P.A.; Qin, J.; Robinson, J.E.; Bazin, B. Angew. Chem. 2007, 
119, 7561; Angew. Chem. Int. Ed. 2007, 46, 7417; (g) Parr, B.T.; Economou, C.; 
Herzon, S.B. Nature, 2015, 525, 507. 
(2)  (a) Babij, N. R.; Wolfe, J.P. Angew. Chem. 2012, 124, 4204; Angew. Chem. Int. 
Ed. 2012, 51, 4128; (b) Babij, N. R.; Wolfe, J.P. Angew. Chem. 2013, 125, 9417; 
Angew. Chem. Int. Ed. 2013, 52, 9247. 
(3) Zavesky, B.P.; Babij, N.R.; Wolfe, J.P. Org. Lett. 2014, 16, 4952. 





(5) (a) Fornwald, R.M.; Fritz, J.A.; Wolfe, J.P. Chem. Eur. J. 2014, 20, 8782; (b) 
Babij, N.R.; McKenna, G.M.; Fornwald, R.M.; Wolfe, J.P. Org. Lett. 2014, 16, 
3412. 
(6) Karabelas, K.; Westerlund, C.; Hallberg, A. J. Org. Chem. 1985, 50, 3896. 
(7) Silver Triflate has also been used in AgOTf-catalyzed 
Isomerization/Hydroalkoxylation Sequence for the synthesis of lactones. See  
Gooβen, L.J.; Ohlmann, D.M.; Dierker, M. GreenChem. 2010, 12, 197. 
(8)  For two different studies which demonstrate this, see: (a)  Muhs, M.A.; Weiss, 
F.T. J. Am. Chem. Soc. 1962, 84, 4697; (b) Vardhan, H.B.; Bach, R.D. J. Org. 
Chem. 1985, 50, 3896. 
(9)  LaLonde, R.L. Brenzovich, Jr., W.E.; Tkatchouk, E.; Kelley, K.; Goddard, III, 
W.A.;  Toste, F.D. Chem Sci. 2010, 1, 226. 
(10) Fleming, J.J.; McReynolds, M.D.; Du Bois, J. J. Am. Chem. Soc. 2007, 129, 
9964. 
(11)  Ermolat’ev, D.S.; Bariwal, J.B.; Steenackers, H.P.L.; De Keersmaecker, S.C.J.; 
Van der Eycken, E.V. Angew. Chem. Int. Ed. 2010, 49, 9465. 
(12)  van Loevezijn, A.; Venhorst, J.; Iwema Bakker, W. I.; de Korte, C. G.; de Looff, 
W.; S. Verhoog, van Wees, J.-W.; van Hoeve, M.; van de Woestijne, R. P.; van 
der Neut, M. A. W.; Borst, A. J. M.; van Dongen, M. J. P.; de Bruin, N. M. W. J; 
Keizer, H. G.; Kruse, C. G. J. Med. Chem. 2011, 54, 7030. 





(14)  Bosin, T. R.; Hanson, R. N.; Rodricks, J. V.; Simpson, R. A.; Rapoport, H. J. Org. 
Chem. 1973, 38, 1591. 
(15)  Mukherjee, S.; List, B. J. Am. Chem. Soc. 2007, 129, 11336. 
(16)  Betou, M.; Male, L.; Steed, J. W.; Grainger, R. S. Chem. Eur. J. 2014, 20, 6505. 
(17) Marhold, M; Stillig, C.; Fröhlich, R.; Haufe, G. Eur. J. Org. Chem. 2014, 26, 5777. 
(18)  Trapella, C.; Fischetti, C.; Pela’, M.; Lazzari, I.; Guerrini, R.; Calo’, G.; Rizzi, A.; 
Camarda, V.; Lambert, D.G.; McDonald, J.; Regoli, D.; Salvadori, S. Bioorg. Med. 
Chem., 2009, 17, 5080. 
(19)  Molander, G. A.; Nichols, P. J. J. Org. Chem., 1996, 61, 6040. 
(20)  Shivani; Pujala, B.; Chakraborti, A. K. J. Org. Chem. 2007, 72, 3713. 
(21)  Schuch, D.; Fries, P.; Dönges, M.; Menéndez Pérez, B.; Hartung, J. J. Am. 
Chem. Soc., 2009, 131, 12918. 
(22)  Lutz, C.; Lutz, V.; Knochel, P. Tetrahedron, 1998, 54, 6385. 







Applications and Synthesis of Cyclic Sulfamides 
 
3.1 Background and Significance 
Cyclic sulfamides are widely present in a number of biologically active 
compounds including natural products and pharmaceuticals.1 In addition, the cyclic 
sulfamide motif has also been utilized as a chiral auxiliary in aldol reactions.2 The 
sulfamide is a versatile functional group which can be readily cleaved3 to produce 
important 1,2- and 1,3-diamines.4 Examples of cyclic sulfamides are shown in Figure 
3.1 along with their specific function or use. 
 





Due to the prevalence of this moiety, several groups have devoted synthetic 
efforts towards its expedient construction. In particular, the use of transition metal 
catalysis has demonstrated utility in constructing the requisite carbon-nitrogen bonds for 
formation of cyclic sulfamides. Highlighted in this chapter are efforts from several 
groups which achieve the synthesis of cyclic sulfamides by functionalization of an olefin 
using transition metal catalysis (other important transition metal-catalyzed methods for 
the synthesis of cyclic sulfamides are also discussed where deemed relevant). 
Mechanism is discussed where appropriate in order to frame the asymmetric synthesis 
of cyclic sulfamides by Pd-catalyzed carboamination reaction described in Chapter 4.  
 
3.2 Developments in Transition Metal Catalyzed Synthesis of Cyclic Sulfamides 
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Chemler and coworkers demonstrated a highly diastereoselective synthesis of a 
variety of cyclic sulfamides using copper catalysis.5 The reaction proceeds using 
stoichiometric amounts of copper(II) neodecanoate [Cu(ND)]2 and potassium carbonate 
as base, and it achieves diastereomeric ratios up to >20:1 dr. The reaction achieves 
high diastereoselectivity by syn aminocupration as shown in Scheme 3.1. Investigation 
of a substrate with a deuterium-substituted olefin generated a product in which the 
diastereomeric ratio was 1:1. The scrambling of the stereocenter likely arises upon 
homolytic cleavage of the copper generating a primary radical which combines with 
another equivalent of Cu(ND)2 in order to generate a Cu(III) species. This species 
facilitates the formation of the second C-N bond generating the bicyclic sulfamide.  
 





The generation of cyclic sulfamides by a palladium-catalyzed oxidative protocol 
was demonstrated by Stahl and coworkers (Scheme 3.2).6 This process utilizes 
catalytic amounts of Pd(TFA)2 in the presence of oxygen, catalytic DMSO, and catalytic 
NaOBz to generate cyclic sulfamides in excellent yields (73% to 99%). The reaction 
proceeds in moderate (11:1 dr) to excellent (>30:1 dr) diastereoselecivity as the steric 
bulk of the allylic substituent increases.  
Two possible reaction mechanisms are proposed for this oxidative cyclization. 
The first mechanism proceeds by aminopalladation followed by β-hydride elimination, 
and the second mechanism proceeds by allylic C-H activation followed by C-N coupling. 
The authors suggests that the failure of a substrate bearing a homoallyl chain to 
undergo the cyclization indicates that the allylic C-H activation mechanism is not 
operative. In addition, the reaction can be conducted on gram scale, and the cyclic 
sulfamide 3-11 can be further elaborated to the chiral diamine 3-12 by reduction in the 
presence of LiAlH4 in 89% yield. 
 





Bicyclic sulfamides were generated using an intramolecular diamination of 
acrylates as reported by Muñiz and coworkers.7 The acrylate substrates were 
synthesized by a cross metathesis procedure beginning from the fully substituted 
sulfamide bearing a terminal olefin. The reaction proceeds using catalytic amounts of 
Pd(OAc)2 along with 2 equiv of CuBr2 as stoichiometric oxidant. The reaction proceeds 
with 10:1 dr as shown for 3-15 and 3-16. The catalytic cycle presumably proceeds 
through a Pd(IV) species mediated by Cu which facilitates the second cyclization. The 




Scheme 3.3 Pd-Catalyzed Intramolecular Diamination of Acrylates to  
Form Bicyclic Sulfamides 
 
The Du Bois group achieved the synthesis of 1,3-diamines utilizing an 
intramolecular Rh-catalyzed C-H insertion strategy.8 This reaction proceeds using 2.5 
mol% Rh2(esp)2 and 1.1 equiv PhI(OAc)2 as oxidant in the presence of MgO and 
iPrOAc. The reaction constructs 6-membered cyclic sulfamides which contain a variety 
of substitution patterns in good yields. In addition, high diastereoselectivity can be 
obtained for certain products like 3-21 and 3-22. Different functional groups like esters 
as shown for the generation of 3-24 are additionally compatible with this reaction. The 
high diastereoselectivity is achieved by a transition state which minimizes A1,3-strain 
between the boc protecting group on the sulfamide and substitution α to the substituted 
nitrogen. Finally, 1,3-diamines are readily accessed by heating the cyclic sulfamides 




Scheme 3.4 Rh-Catalyzed C-H Insertion for Generating 6-Membered Cyclic Sulfamides 
 
 
Scheme 3.5 Facile Ring-Opening to Afford 1,3-Diamines 
 
 
More recent developments from the Du Bois group exhibit a method for the 
synthesis of cyclic sulfamides by a tandem Rh-catalyzed aziridination/NaI-promoted 
rearrangement sequence.9 The development of this method sought an efficient means 
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for aziridination, and initial investigations unveiled N-carbamoyl sulfamides as 
competent substrates for the aziridination when 2 mol% of Rh2(esp)2 was used. It was 
hypothesized that a one-flask protocol for synthesizing cyclic sulfamides could be 
achieved by the addition of NaI and DMF once the aziridination reaction was complete. 
This tandem sequence works well for a variety of substrates as shown in Scheme 3.6. 
Reactions proceed in good yields and at times high diastereoselectivity (3-34 was 
formed as a single stereoisomer).  
 
Scheme 3.6 Tandem Rh-catalyzed Aziridination-NaI Promoted  
Rearrangement for the Synthesis of Cyclic Sulfamides 
 
The utility of this reaction is demonstrated in two ways. First, the cyclic 
sulfamides can be readily transformed to chiral 1,2-diamines in the same manner as 
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described above by reaction with pyridine/water at 80 °C (Scheme 3.5). Additionally, 
the total synthesis of (±)-enduracididine was achieved in only three steps (1. Chiral 
resolution; 2. Desulfonylation/guanylation; 3. Deprotection) from 3-37 as shown in 
Scheme 3.7.  This natural product is an amino component of the macrocyclic 
polypeptide antibiotic enduracidin.  
 
Scheme 3.7 Short Total Synthesis of (±)-Enduracididine 
 
 
Wolfe and coworkers recently demonstrated a diastereodivergent strategy for 
accessing 5-membered cyclic sulfamides (Table 3.1).10 This reaction expands the 
scope of the Pd-catalyzed carboamination reaction which has been widely investigated 
by the Wolfe group.11 Interestingly, the increased acidity of sulfamides permits control of 
diastereoselectivity by diverting mechanistic pathways based on careful selection of 
electrophile, ligand, base, and solvent.12 In general, the anti-aminopalladation pathway 
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is favored by the use of aryl triflates, electron-rich Buchwald ligands, lithium tert-
butoxide, and polar solvents like PhCF3. Conversely, syn-aminopalladation pathways 
are favored by the use of aryl halides, XPhos as ligand, sodium tert-butoxide, and non-
polar solvents like dioxanes or toluene. For example, deuterated substrate 3-41 is 
transformed with high diastereoselectivity (>20:1) to 3-42 by use of RuPhos or CPhos 
as ligand and PhCF3 as solvent (Table 3.8, entry 1 and 12). In contrast, the use of 
XPhos in dioxane solvent or toluene solvent generate 3-43 with decent 
diastereoselectivity (Table 3.8, 1:10 dr for entry 4, 1:4 dr for entry 6). All in all, Table 3.8 
demonstrates that subtle changes to reaction conditions can drastically influence 
stereoselectivity in this Pd-catalyzed reaction. 
 





 This diastereo-divergent method was further applied in the synthesis of bicyclic 
sulfamides by Wolfe and coworkers (Scheme 3.8).13 Earlier work in the Wolfe group 
demonstrated that 1,3-bicyclic ureas were important retrons for the synthesis of 
batzelladine alkaloids.14 Unfortunately, the carboamination reaction of ureas towards the 
stereoselective syntheses of this family of natural products is limited because these 
reactions proceed by a syn-aminopalladation mechanism; only merobatzelladine A and 
B contain the appropriate configuration that this mechanistic pathway can access.  
Therefore, Wolfe and coworkers considered the viability of utilizing sulfamides as 
nucleophiles which can undergo anti-aminopalladation pathways thereby accessing the 
configuration more widely present in the batzelladine alkaloids (Scheme 3.8). To this 
end, the generation of bicyclic sulfamides was achieved using catalytic Pd(OAc)2 and 
CPhos as ligand. Fewer side products derived from β-hydride elimination were 
generated when tBuOH was employed as the solvent. The reaction proceeds for a 
variety of aryl and alkenyl triflates with diastereoselectivity up to >20:1 dr. 
 The mechanistic pathway is shown in Scheme 3.8. Since the anti-
aminopalladation pathway proceeds by pre-coordination of the olefin to the Pd catalyst, 
the attacking nitrogen of the sulfamide must attack from the backside. Two possible 
transitions states can occur under this system, and ultimately the major product 3-48 
derives from a transition state which avoids steric interactions between the olefin and 
the hydrogen on the pyrrolidine ring. 
  
Scheme 3.8 Synthesis of Bicyclic Sulfamides by Pd-Catalyzed 






3.3 Developments in Asymmetric Synthesis of Cyclic Sulfamides 
Despite the extensive amount of effort directed at the synthesis of cyclic 
sulfamides, little work has targeted efficient methods for producing cyclic sulfamides 
asymmetrically. In most instances, enantiomerically enriched cyclic sulfamides are 
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prepared by multistep routes from the corresponding amino acids. For example, 
Scheme 3.9 shows the synthesis of cyclic sulfamides beginning with amino acid methyl 
esters.15 The synthetic sequence proceeds by sulfonylation with ClSO2NHBoc which is 
followed by reduction of the methyl ester to the alcohol 3-53. From here, a one-step 
Mitsunobu ring closure can provide cyclic sulfamide 3-55 or a two-step sequence 
consisting of Appel reaction/nucleophilic addition under basic conditions can also 
provide 3-55. 
 
Scheme 3.9 Synthesis of Cyclic Sulfamides from Amino Acid Chiral Pool 
 
 
Even though amino acids provide cyclic sulfamides in high enantiopurity, relying 
on this chiral pool restricts the chemical space which can be accessed. Therefore, new 
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methods which develop asymmetric catalysts, especially by implementation of transition 
metals, for generating cyclic sulfamides are highly desirable.  
 
Scheme 3.10 Asymmetric Synthesis of Cyclic Sulfamides from Conjugated Dienes 
 
 
Only one group has provided enantioselective access to cyclic sulfamides using 
a transition metal catalyst. The Shi group has shown that cyclic sulfamides can be 
formed asymmetrically by reacting conjugated dienes with N,N’-di-tert-
butylthiadiaziridine 1,1-dioxide in the presence of Pd(0) and a chiral phosphoramidite 
ligand.16 Initial screening demonstrated that chiral phosphoramidite ligands were 
competent for inducing asymmetry and although several backbones were examined, the 
ligand that provided the best results derived from BINOL as shown in Scheme 3.10. 
These reactions afford a variety of cyclic sulfamides in high yields (up to 98%) and high 
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enantiopurity (96.5:93.5 er). Importantly, the reaction can selectively form the cyclic 
sulfamide in the presence of alkenes and protected alcohols.  
The catalytic cycle proceeds by insertion of the chiral Pd(0) complex into the N-N 
bond of N,N’-di-tert-butylthiadiaziridine 1,1-dioxide (Figure 3.2). The Pd(II) complex 3-
63 coordinates to the diene and undergoes migratory insertion to generate the -allyl Pd 
complex 3-65. Reductive elimination supplies the product and regenerates the chiral 
Pd(0) catalyst. 
 
Figure 3.2 Catalytic Cycle for Asymmetric Synthesis of Cyclic Sulfamides from 
Conjugated Dienes 
 
Although this reaction showcases a pragmatic disconnection for accessing 
enantioenriched cyclic sulfamides, it suffers from some limitations. First, N,N’-di-tert-
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butylthiadiaziridine 1,1-dioxide is not commercially available. Second, the reaction 
requires acyclic conjugated dienes as coupling partners. These limitations highlight the 
need for efforts towards the developments of new chiral catalysts with broader scope. 
Chapter 4 will describe work toward developing a chiral catalyst for the generation of 
new cyclic sulfamides. 
 
3.4 Conclusion 
 Cyclic sulfamides are widely present functional groups in natural products and 
pharmaceuticals rendering their expedient synthesis an important challenge for organic 
chemistry. Several groups have utilized transition metal catalysis for the synthesis of 
cyclic sulfamides, and many of these methods exploit olefins as a functional group 
handle for forging the required C-N bonds of the cyclic sulfamides. Despite the 
abundance of methods devised for generating cyclic sulfamides, little work has unveiled 
chiral catalysts for developing the asymmetric analogues of the racemic reactions. Only 
one example which utilized a Pd catalyst with a chiral phosphoramidite has achieved 
enantioselective synthesis of cyclic sulfamides. The shortage of asymmetric methods 
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Chapter 4  
Asymmetric Synthesis of Cyclic Sulfamides 
 
4.1 Background and Reaction Design 
 The development of a method for the asymmetric synthesis of cyclic sulfamides 
is rooted in the prior developments and knowledge gained from devising methods in the 
Wolfe group for the enantioselective synthesis of pyrrolidines,1 ureas,2 and benzofused 
heterocycles3 as shown in Scheme 4.1. In all of the asymmetric reactions that have 
been developed monophosphorus ligands have been utilized.4 Specifically, the chiral 
phosphoramidites (R)-Siphos-PE and (S)-Siphos-PE (which are actually diastereomers) 
have been the most effective ligands in asymmetric Pd-catalyzed carboamination 
reactions.  
Besides the chiral environment induced by the ligand, the structure and 
electronics of the substrates affect the enantioselectivity. For example, the asymmetric 
synthesis of pyrrolidines relied on geminal substitution in the backbone of the boc-
protected allylamine in order to achieve greater than 95:5 er. Also, consider the variety 
of different protecting groups on the cyclizing nitrogen in each of these reactions. Each 
protecting group is different, and this is due to each reaction operating slightly 
differently. In the case of the desymmetrization of meso-2,5-diallyl ureas, p-NO2 
substitution on the protecting group actually achieved higher levels of enantioselectivity 
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in similar fashion to the asymmetric synthesis of imidazolidin-2-ones, but the chemical 
yield was not satisfactory. The optimal protecting group which balanced good yield, dr, 
and er was p-Cl-phenyl. Informed by the important influence of substrate structure and 
electronics, corollary asymmetric reactions can be achieved.  
With the insight garnered from these previous developments, an asymmetric 
synthesis of cyclic sulfamides seemed feasible. Cyclic sulfamides are isosteres of ureas 
so utilizing conditions that were successful for generating enantiopure imidazole-2-ones 
would be a good starting point. In addition, protecting groups on the sulfamide nitrogens 
could influence the enantioselectivity favorably. As this asymmetric reaction of 
sulfamides was considered, the competing anti/syn aminopalladation mechanistic 
dichotomy5 was at the forefront of the reaction design. It was hoped that using 
conditions that were successful for the ureas, which operated under conditions that 
promote syn aminopalladation conditions, would also bias the mechanistic pathway so 
that this competition would not be ruinous to the development of enantiopure 
compounds. Also, finding a chiral ligand which enables successful carboamination 
reaction under anti aminopalladation conditions could provide a enantioselective 
diastereodivergent method for the synthesis of cyclic sulfamides. Efforts towards 
method development under both mechanistic frameworks is described below.    
 





4.2 Substrate Synthesis 
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 The sulfamide substrates are readily formed in one step by a sulfonylation 
protocol (Scheme 4.2).6 The desired secondary amine is reacted with a desired 
oxazolidine in order to produce the material. The desired oxazolidines can be made in 
one step for a variety of different amines.   
Scheme 4.2 Substrate Synthesis 
 
 
4.3 Reaction Optimization for Synthesis of 5-Membered Cyclic Sulfamides 
 Investigations into the asymmetric synthesis of 5-membered cyclic sulfamides 
were initiated by exploring the role of different protecting groups on the sulfamide. 
Protecting groups that could be readily cleaved were targeted. In addition, the catalyst 
that was successfully employed for the synthesis of cyclic ureas was also used during 
this study. As shown in Table 4.1, entry 1-4, substrates bearing several different 
protecting groups failed to undergo successful cyclization. However, when a tert-butyl 
substituent was utilized as the protecting group, 70% of the desired product was formed 
with great enantioselectivity (93:7 er). At this point, other cleavable protecting groups on 
the cyclizing nitrogen were examined, but no other group improved the 
enantioselectivity beyond that attained in entry 5. Therefore, the electrophile scope was 
examined with a sulfamide bearing a tert-butyl group on the non-cyclizing nitrogen and 




Table 4.1 Optimization by Protecting Group Investigation 
 
 
4.4 Reaction Scope for Asymmetric Synthesis of 5-Membered Cyclic Sulfamides 
The reaction is effective for a variety of electrophiles. In general, electrophiles 
bearing electron-rich substituents like those shown for 4-15, entry 5 and 4-15, entry 6 
achieved higher levels of enantioselectivity whereas electrophiles bearing electron-
deficient groups like those shown for 4-15, entry 9 and 4-15, entry 10 are transformed 
with lower selectivity. The use of alkenyl electrophiles produced cyclic sulfamides in 
high enantioselectivity (up to 95:5 er), but these reactions suffered from low chemical 
yield due to competing Heck arylation reactions. Steric bulk on the electrophile is not 
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tolerated well as demonstrated for entry 15 and entry 16 where the highest levels of 
enantioselectivity were 74:26. Finally, transformations which utilized electrophiles 
derived from heterocycles (see Table 4.2, entry 11 and 12) proceeded in 92:8 er. 
The addition of water exhibited a remarkable influence on the asymmetric 
reaction. In the asymmetric Pd-catalyzed carboamination reaction for the synthesis of 
imidazolidin-2-ones, the addition of 2 equiv of water improved the enantioselectivity for 
electron poor electrophiles. Interestingly, the addition of 2 equiv of water to the Pd-
catalyzed reaction for the synthesis of cyclic sulfamides does not have a remarkable 
influence on enantioselectivity; instead, the yields were improved by the addition of 
water by up to 45%. While the role of water is not entirely clear, it may play a role in 
suppressing competing decomposition of the substrate which occurs over the course of 
long reaction times. 
 






 While this method is effective for a variety of electrophiles, other sulfamide 
substrates failed to achieve desirable reactivity. For example, different substitution 
patterns around the olefin failed to generate the cyclic sulfamides. First, 1,1-
disubstituted alkenes, where R = Me or Ph as shown in Scheme 4.3, were unsuccessful 
under the optimized reaction conditions. The reactions afford starting material or the 
starting material undergoes decomposition.  
 
Scheme 4.3 Limitations for Generating 5-Membered Cyclic Sulfamides 
 
Additionally, attempts were made to synthesize sulfamide substrates bearing 
symmetric geminal substitution in the allylic position like 4-13 in Scheme 4.4 in order to 
extend substrate scope. Unfortunately, the synthesis of these substrates was 
unsuccessful, presumably due to excess steric bulk around the amine inhibiting the 
required sulfonylation. 
 





4.5 Mechanistic Investigations: Syn or Anti Aminopalladation Mechanism? 
Since anti aminopalladation and syn aminopalladation mechanistic pathways are 
competitive for the carboamination reaction of sulfamides, deuterated substrate 4-16 
was synthesized in two steps to evaluate the primary mode of reactivity. First, 
commercially available tert-butyl allylamine was deuterated under basic conditions 
followed by the requisite sulfonylation reaction. The desired deuterated substrate was 
formed in 27% yield over 2 steps with >95% deuterium incorporation.  
 
Scheme 4.5 Synthesis of Deuterated Substrate 4-21 
 
 
The carboamination reaction was conducted with a variety of electrophiles to 
examine if electronics influenced the diastereoselectivity. As shown in Table 4.3, all the 
electrophiles demonstrated that the syn aminopalladation pathway was the dominant 
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pathway. Interestingly, both the diastereoselectivity and enantioselectivity when 4-
bromobenzotrifluoride was used as the electrophile (entry 4) was lower than when 4-
tBu-C6H4Br was used as the electrophile (entry 1).  
 
Table 4.3 Synthesis of Deuterated Products Derived from 4-21a 
 
 
This correlation between lower enantioselectivity and lower diastereoselectivity 
may indicate that the use of electron deficient electrophiles increases anti-
aminopalladation pathways which lowers enantioselectivity. While this correlation is 
interesting, more mechanistic analysis is required to determine if anti aminopalladation 
pathways actually are interwoven with enantioselectivity.  
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It should be noted that the data outlined in Table 4.3 does not take into account 
that 4 potential compounds can be formed in the reaction as shown in Figure 4.1. The 
data obtained consists of mixtures of 4 compounds. The diastereoselectivity was 
determined by H1 NMR analysis of the mixture of the four compounds while the 
enantioselectivity was determined by chiral HPLC analysis of the four compounds.  
 
 
Figure 4.1 Possible Formation of Four Compounds from Deuterated Substrate 4-21 
 
 
To properly determine the ratios of the four compounds, a third set of data is 
needed: an H1 NMR analysis of one set of the HPLC peaks which could be isolated by 
preparative chiral HPLC analysis. This type of mechanistic analysis was performed by 
Weinstein and Stahl for studying the nucleopalladation pathways of Wacker-type 
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cyclizations.7 In order to fully determine the relationship between anti and syn 
aminopalladation pathways and enantioselectivity, this third data set is a necessity. 
Without this piece of data, the only conclusion that can be made is that the dominant 
mechanistic pathway is syn aminopalladtion; any conjecture regarding the relationship 
between enantioselectivity and the mechanistic pathway is only speculative. This will be 
the subject of future studies by the Wolfe group for unraveling the influence of 
electronics of the aryl halide on the mechanistic outcome. 
 
4.6 Methods for Deprotection  
 To demonstrate the synthetic utility of the method, deprotection strategies were 
evaluated as shown in Scheme 4.6. First, the tert-butyl protecting group could be 
selectively cleaved in the presence of trifluoroacetic acid which produced the free cyclic 
sulfamide 4-25 in 98% yield while maintaining the enantiopurity (94:6 er). Second, the 
sulfur dioxide component of the cyclic sulfamide in tandem with the tert-butyl protecting 
group could be removed by reaction with hydrobromic acid in the presence of phenol at 
elevated temperatures (130 °C). This provided chiral diamine 4-27 in good yield with 
enantiopurity intact. Chiral diamine 4-27 was further elaborated by reaction with 1,1′-
carbonyldiimidazole so that the enantiopurity could be evaluated by chiral HPLC.   
 





4.7 Synthesis of Authentic Sample for Determining Absolute Configuration 
 The synthesis of an authentic sample of 4-33 was accomplished beginning with 
L-phenylalanine methyl ester hydrochloride as shown in Scheme 4.7. First, the amine is 
alkylated with BnBr followed by reduction of the methyl ester to the alcohol (66% yield 
over two steps). Then, sulfonylation with the requisite oxazolidinone proceeded to give 
the desired intermediate 4-32 albeit in low yield (9%). The low yield likely derives from 
competing sulfonylation of the alcohol which produces undesired side products. Then, a 
one pot tosylation/alkylation sequence formed the desired authentic sample 4-33.  
 The synthesis of this authentic sample highlights the advantage of utilizing the 
Pd-catalyzed method described for the synthesis of chiral cyclic sulfamides. Only two 
steps (starting from commercially available N-tert-butyl allylamine) are required to 
generate chiral cyclic sulfamides whereas the synthesis outlined in Scheme 4.7 
requires 4 steps from the already protected amino acid. Additionally, the method 
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described in this chapter expands the chemical space which the use of amino acids 
otherwise restricts for generating chiral cyclic sulfamides.   
 
Scheme 4.7 Synthesis of an Authentic Sample 
 
 
4.8 Asymmetric Synthesis of Monocyclic 6-Membered Cyclic Sulfamides 
 Currently, no methods are available to generate 6-membered cyclic sulfamides 
asymmetrically despite the abundance of methods available for generating the racemic 
counterparts. Therefore, the development of an asymmetric synthesis of 6-membered 
sulfamides could prove useful to the synthetic community, especially since these 
sulfamides could also serve as precursors to enantiopure 1,3-diamines. Also, the 
substrate scope for the synthesis of 5-membered cyclic sulfamides was limited in that 
only one sulfamide was competent for the reaction.  
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In an attempt to expand the substrate scope of the reaction described in Scheme 
4.8, substrate 4-34 bearing a homoallyl chain was synthesized in order to test under the 
reaction conditions. This substrate failed to achieve desirable reactivity. Because the 
cyclization of 5-membered sulfamides relies heavily on the tert-butyl group for 
successful cyclization, substrate 4-36 was synthesized to test the plausibility of a 
Thorpe-Ingold-induced asymmetric cyclization to form monocyclic 6-membered cyclic 
sulfamides. The geminal substitution of substrate 4-36 enabled the successful 
cyclization to form 4-37, the first enantiopure monocyclic 6-membered sulfamide 
generated via asymmetric catalysis. The yield (87%) and er (97:3) were remarkably 
high, so no further optimization of the reaction conditions took place.  
 
Scheme 4.8 Cyclization of Sulfamides Bearing Homoallyl Chains 
 
 
In most instances, the substrates for making 6-membered cyclic sulfamides were 
synthesized in the same fashion as for making 5-membered cyclic sulfamides (in this 
case, sulfonylation of the homoallylamine is required to form the substrate). While most 
allyl amines were made by alkylation of allylamine or allylbromide, the synthesis of 




The homoallylamines were made by the two-step protocol shown n Scheme 4.9. 
First, an imine is formed by reacting a ketone with an amine in the presence of 
molecular sieves and methylene chloride. Then, the imine is subjected to a Grignard 
reaction with allylmagnesium bromide (or other Grignard reagent). This forms the 
desired homoallyl amine which is then subjected to sulfonylation in the presence of N-
benzyl-2-oxooxazolidine-3-sulfonamide to generate the desired sulfamide precursor. 
 
Scheme 4.9 Synthesis of Homoallyl amine Precursors for  
Synthesizing Sulfamide Substrates 
 
 
 Thus far, the electrophile scope of the reaction is quite expansive. The use of 
electron-rich or electron poor electrophiles generates sulfamides with greater than 95:5 
er. The use of ortho-substituted electrophiles causes the enantioselectivity to drop to 
85:15 er, and the use of aryl iodides forms sulfamides with lower and irreproducible 
enantiomeric ratios. The essential geminal substitution can also be changed to either 
ethyl or cyclohexyl while maintaining great results (entry 9, 11-13). Future studies will be 
directed towards the use of alkenyl halides as electrophiles in this reaction. 
 
Table 4.4 Substrate Scope for Synthesis of  
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Enantiopure 6-membered Cyclic Sulfamidesa 
 
 
Like the 5-membered cyclic sulfamides, the cyclization to form 6-membered 
cyclic sulfamides suffers from limitations. First, attempted cyclizations of substrate 4-43 
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which contains geminal substitution in the allylic position did not undergo desired 
reactivity. Additionally, substrate 4-45 which contained a 1,1-disubstituted alkene failed. 
 
Scheme 4.10 Substrate Scope Limitations for Synthesis of  
6-Membered Cyclic Sulfamides 
 
 
Moreover, efforts to cleave the sulfamide functional group have thus far proven 
unsuccessful (Scheme 4.11). Reaction of cyclic sulfamides in the presence of 
hydrobromic acid and phenol at elevated temperatures (which was successfully used in 
the deprotection of the 5-membered cyclic sulfamides) causes the starting material to 
decompose. Also, attempts to reduce the sulfamide functional group in refluxing lithium 
aluminum hydride leads to complete recovery of the starting material. Efforts are still 
underway to find a suitable means for accessing the 1,3-diamines while maintaining the 
enantiopurity of the compound.  
 




 The assignment of the absolute configuration of these compounds is currently 
under investigation. Current efforts are directed towards the use of Ellman’s auxiliary to 
generate enantiopure tert-butyl (4-methyl-1-phenylpentan-2-yl)carbamate. We have 
successfully synthesized this compound by Grignard addition of benzyl magnesium 
chloride, but current levels of enantiopurity are unsatisfactory for determining absolute 
configuration. Grignard addition of isobutylmagnesium bromide should provide better 
levels of enantiopurity. Then, sulfonylation followed by selective removal of the Cbz 
group under reductive conditions should provide the sulfamide needed for the Rh-
catalyzed C-H activation cyclization reaction. After successful cyclization, the boc group 
will be removed followed by alkylation to give the authentic sample.  
 
Scheme 4.12 Proposed Synthesis of Authentic Sample for Determining Absolute 






4.9 Desymmetrization of Meso-2,5-Diallylpyrrolidinyl Sulfamides for the Synthesis 
of Bicyclic Sulfamides 
As described in chapter 3 and shown retrosynthetically in Figure 4.2, a key 
bicyclic intermediate is pivotal in the retrosynthesis of the batzelladine alkaloids. The 
synthesis of this key intermediate either through the use of ureas or sulfamides in the 
Pd-catalyzed carboamination reaction can enable access to the whole family of 
batzelladine alkaloids by capitalizing on the divergent reactivity syn and anti 
aminopalladation mechanism. The synthesis of racemic bicyclic sulfamides was 
accomplished recently with hopes of applications en route to the batzelladine alkaloids.8 
In order to achieve an enantioselective synthesis of the batzelladine alkaloids bearing 
hydrogens on the same face, a desymmetrization strategy akin to a strategy devised by 
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Wolfe and coworkers2b was considered. This desymmetrization strategy would utilize 
meso-2,5-diallylpyrrolidinyl sulfamides as substrates and utilize conditions that facilitate 
anti aminopalladations pathways in order to access stereoselectively the bicyclic 
scaffold required for advancement to the natural products. Key to the success of this 
proposition was finding a chiral ligand which could bias the mechanistic pathway of the 
reaction and achieve high levels of enantio-induction.  
 




Model substrate 4-47 was made in four steps with a sulfamide bearing a readily 
deprotected p-methoxybenzyl protecting group on the cyclizing nitrogen of the 
sulfamide. Then, evaluation of the carboamination reaction under anti aminopalladation 
conditions with phenyl triflate electrophile, lithium tert butoxide base and tBuOH solvent 
unveiled axially chiral Buchwald ligand KenPhos9 as a potential scaffold for catalyst 
development. It is unsurprising that the other chiral ligands were unsuccessful in the 
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reaction because ligands that promote anti aminopalladation often bear electron-rich 
Buchwald ligands in order to promote the generation of the cationic palladium complex. 
  
Scheme 4.13 Initial Screen of Chiral Ligands 
 
 
While ligands like KenPhos are not commercially available, other groups have 
investigated their use in other asymmetric reactions like dearomative arylations of 
phenols,10 arylation of imines,11  arylation of ester enolates,13a and arylation of 
fluoroketones.12b This body of work describes a sequence for generating small libraries 
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of this ligand scaffold which can be utilized to pinpoint which aspects of the chiral ligand 
influence the enantioselectivity. This four step sequence begins by a Pd-catalyzed 
cross-coupling of the desired phosphine oxide with commercially available enantio-
enriched [1,1'-binaphthalene]-2,2'-diyl bis(trifluoromethanesulfonate). Then, the triflate is 
hydrolyzed and alkylated. The new alkyl group at R2 in Scheme 4.14 often changes the 
enantioselectivity and thus serves as an accessible handle for testing new ligands. After 
alkylation, the phosphine oxide is reduced in the presence of trichlorosilane and 
triethylamine. 
 
Scheme 4.14 Synthesis of Axially Chiral Buchwald Ligands 
 
 
 Using the route outlined above (Scheme 4.14), ligands that have been previously 
made in the literature were made and tested in the Pd-catalyzed carboamination 
reaction under anti aminopalladation conditions. Replacing the dimethylamino group of 
Kenphos with a methoxy group improved er (up to 84:16 er) and yield (up to 80%). 
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Unfortunately, further manipulations of the ligand scaffold failed to improve the 
enantioselectivity. This was somewhat disappointing as the examples from the literature 
demonstrate that increased steric bulk on the electron rich aryl ring improve 
enantioselectivity, whereas the products generated in Scheme 4.15 were provided with 
diminished enantioselectivity as steric bulk of the ligand was increased. 
 
Scheme 4.15 Enantioinduction via Anti Aminopalladation Pathways 
 
 
Future work will investigate other manipulations of the chiral ligand scaffold. 
These manipulations might include changing the ligand backbone while maintaining the 
electron-rich phosphine. Also, further explorations of the reaction conditions may 
improve enantiomeric ratios to synthetically useful ratios. Finally, alterations of the 





 This chapter describes the development of asymmetric methods towards the 
synthesis of chiral 1,2- and 1,3-diamines through Pd-catalyzed carboamination 
reactions of sulfamides. The reaction relies on commercially available ligand (S)-
Siphos-PE to achieve high levels of enantioinduction. In addition, preliminary results 
have demonstrated the potential of axially chiral Buchwald ligands for developing 
enantio-induction under anti pathways. Further work in this area may unveil a chiral 
ligand or conditions which might achieve acceptable levels of enantioselectivity. 
 Future directions for this project should answer the following questions. What is 
the role of water in enhancing the product yield for the synthesis of 5-membered cyclic 
sulfamides? How can the monocyclic 6-membered cyclic sulfamides be deprotected 
without decomposing? What other protecting groups could be used to facilitate the 
asymmetric synthesis of the monocyclic 6-membered cyclic sulfamides? What ligands 
need to be developed for generating synthetically acceptable levels of enantioselectivity 
for the desymmetrization of meso-2,5-diallylpyrrolidinyl sulfamides? Is there erosion of 
enantioselectivity over time due to ligand decomposition under basic conditions? While 
the present work has not answered these questions, it is the hope of the author that 
future developments will be directed towards answering these questions. 
 





4.11 Experimental Section 
 
General: Reactions were carried out under nitrogen in flame-dried or oven-dried 
glassware unless otherwise specified. Tris(dibenzylideneacetone)dipalladium and (S)-
SIPHOS-PE were purchased from Strem Chemical Co. and used without further 
purification. Dichloromethane and toluene were purified using a GlassContour solvent 
system. Xylenes were purified by distillation over CaH2 prior to use in reactions. 1-Allyl-
1,3-bisbenzylsulfamide14 was prepared according to published procedures. All other 
solvents and aryl halides were purchased from commercial sources and used as 
received. Yields refer to isolated yields of compounds that are estimated to be >95% 
pure as judged by 1H NMR or GC analysis. Unless otherwise noted, yields reported in 
4.11 Experimental Section describe the result of a single experiment, whereas yields 
reported in Tables 4.2, Table 4.3 and Table 4.4 are average yields of two or more 
experiments. Thus, the yields reported in the supporting information may differ from 
those in the manuscript.  
 
Synthesis of Substrates: 
General procedure 1 for the synthesis of substrates: 
A flame dried two neck round bottom flask equipped with a stir bar, condenser, and 
septum was cooled under a stream of nitrogen and charged with DMAP (0.20 equiv.) 
and oxazolidin-2-one substrate (1.0 equiv.). Anhydrous acetonitrile (5 mL/mmol) was 
added followed by triethylamine (3.0 equiv.). The reaction mixture was heated at 80 °C 
for 15 min, and then the allyl amine was added dropwise. The resulting mixture was 
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stirred for 16-18 h at 80 °C. The reaction mixture was cooled to rt, and the solvent was 
removed under reduced pressure. The crude product was purified by flash 
chromatography on silica gel using hexanes/ethyl acetate as eluant. 
 
 
N-Allyl-N’-(4-methoxyphenyl)-N-tert-butylsulfamide. General procedure 1 was used 
to sulfonylate N-(tert-butyl)prop-2-en-1-amine (1.2 g, 10.5 mmol) with 3-[(4-
methoxyphenyl)sulfonyl]oxazolidin-2-one (2.6 g, 9.5 mmol) to afford the title compound 
(2.2 g, 79%) as a yellow solid, mp 77–81 °C. 1H NMR (500 MHz, CDCl3)  7.17–7.11 
(m, 2 H), 6.87–6.82 (m, 2 H), 6.22 (s, br, 1 H), 5.78 (m, 1 H), 5.12–5.06 (m, 1 H), 5.02 
(dd, J = 10.3, 1.2 Hz, 1 H), 3.89 (dd, J = 6.0, 1.3 Hz, 2 H), 3.80 (s, 3 H), 1.40 (s, 9 H); 
13C NMR (175 MHz, CDCl3)  157.6, 137.4, 130.1, 124.7, 116.9, 114.5, 59.7, 55.6, 50.1, 
30.0; IR (neat) 3289, 2934, 1510, 1128 cm-1; MS (ESI+) 299.1422 (299.1424 calcd for 
C14H22N2O3S, M + H+). 
 
 
N-Allyl-N’-(4-chlorophenyl)-N-tert-butylsulfamide. General procedure 1 was used to 
acylate N-(tert-butyl)prop-2-en-1-amine (1.2 g, 10.5 mmol) with 3-((4-
chlorophenyl)sulfonyl)oxazolidin-2-one (2.6 g, 9.5 mmol) to afford the title compound 
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(2.0 g, 68%) as a colorless solid, mp 74–78 °C. 1H NMR (500 MHz, CDCl3)  7.22–7.35 
(m, 2 H), 7.04–7.14 (m, 2 H), 6.58 (s, 1 H), 5.71–5.84 (m, 1 H), 5.14 (dd, J = 17.2, 0.7 
Hz, 1 H), 5.07 (dd, J = 10.3, 0.5 Hz, 1 H), 3.95 (d, J = 5.9 Hz, 2 H), 1.40 (s, 9 H); 13C 
NMR (175 MHz, CDCl3)  136.9, 136.1, 130.0, 129.5, 121.8, 116.9, 60.0, 50.1, 29.9; IR 
(neat) 3327, 3253, 2978, 1317, 1132 cm-1; MS (ESI+) 325.0747 (325.0748 calcd for 




N-Allyl-N’-benzyl-N-tert-butylsulfamide. General procedure 1 was used to sulfonylate 
N-(tert-butyl)prop-2-en-1-amine (3.1 mL, 20.9 mmol) with 3-(benzylsulfonyl)oxazolidin-2-
one (4.87 g, 19 mmol) to afford the title compound (3.3 g, 61%) as a colorless solid. 
Spectra were identical to those previously reported.[15] 
 
 
N-Allyl-N’-(4-methoxybenzyl)-N-tert-butylsulfamide. General procedure 1 was used 
to sulfonylate N-(tert-butyl)prop-2-en-1-amine (1.2 g, 10.5 mmol) with 3-[(4-
methoxybenzyl)sulfonyl]oxazolidin-2-one (2.7 g, 9.5 mmol) to afford the title compound 
(2.6 g, 87%) as a colorless solid, mp 66–69 °C. 1H NMR (500 MHz, CDCl3)  7.27–7.22 
(m, 2 H), 6.89–6.85 (m, 2 H), 6.03–5.92 (m, 1 H), 5.22 (dd, J = 17.4, 1.5 Hz, 1 H), 5.13 
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(dd, J = 10.3, 1.5 Hz, 1 H), 4.20–4.14 (m, 1 H), 4.08 (d, J = 6.1 Hz, 2 H), 3.95 (dt, J = 
5.9, 1.4 Hz, 2 H), 3.80 (s, 3 H), 1.46 (s, 9 H); 13C NMR (175 MHz, CDCl3)  159.5, 
137.5, 129.6, 128.9, 116.6, 114.3, 59.4, 55.5, 49.5, 47.0, 29.9; IR (neat) 3325, 1513, 




N-Allyl-N’-(3-methoxybenzyl)-N-tert-butylsulfamide. General procedure 1 was used 
to sulfonylate N-(tert-butyl)prop-2-en-1-amine (1.2 g, 10.5 mmol) with 3-[(3-
methoxybenzyl)sulfonyl]oxazolidin-2-one (2.7 g, 9.5 mmol) to afford the title compound 
(1.7 g, 58%) as a yellow oil. 1H NMR (500 MHz, CDCl3)  7.25 (t, J = 7.8 Hz, 1 H), 6.92–
6.86 (m, 2 H), 6.83 (dd, J = 8.3, 2.4 Hz, 1 H), 6.02–5.92 (m, 1 H), 5.22 (dd, J = 17.2, 1.3 
Hz, 1 H), 5.13 (dd, J = 10.3, 1.2 Hz, 1 H), 4.35 (t, J = 5.0 Hz, 1 H), 4.11 (d, J = 6.1 Hz, 2 
H), 3.95 (dt, J = 6.0, 1.3 Hz, 2 H), 3.80 (s, 3 H), 1.46 (s, 9 H); 13C NMR (175 MHz, 
CDCl3)  160.0, 138.5, 137.5, 129.9, 120.4, 116.7, 113.7, 113.6, 59.4, 55.4, 49.5, 47.4, 
29.8; IR (neat) 3320, 3250, 1317, 1135 cm-1; MS (ESI+) 313.1576 (313.158 calcd for 
C15H24N2O3S, M + H+). 
 
 
N-Allyl-N’-benzyl-N-(4-methoxyphenyl)sulfamide. General procedure 1 was used to 
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sulfonylate N-allyl-4-methoxyaniline (1.71 g, 10.5 mmol) with 3-
(benzylsulfonyl)oxazolidin-2-one (2.5 g, 9.5 mmol) to afford the title compound (2.2 g, 
70%) as a light brown solid, mp 58–61 °C. 1H NMR (500 MHz, CDCl3)  7.36–7.32 (m, 2 
H), 7.31–7.27 (m, 3 H), 7.27–7.23 (m, 2 H), 6.89–6.85 (m, 2 H), 5.86–5.77 (m, 1 H), 
5.13–5.10 (m, 1 H), 5.08 (t, J = 1.2 Hz, 1 H), 4.52 (t, J = 6.0 Hz, 1 H), 4.23 (d, J = 6.1 
Hz, 2 H), 4.18 (dt, J = 6.5, 1.1 Hz, 2 H), 3.80 (s, 3 H); 13C NMR (175 MHz, CDCl3)  
159.2, 136.8, 133.4, 132.8, 130.2, 128.9, 128.1, 128.1, 119.0, 114.5, 55.6, 55.3, 47.8; 
IR (neat) 3289, 1510, 1331, 1146 cm-1; MS (ESI+) 333.1624 (333.1627 calcd for 
C17H20N2O3S, M + H+). 
 
 
N-Allyl-N’-benzyl-N-(4-chlorophenyl)sulfamide. General procedure 1 was used to 
sulfonylate N-allyl-4-chloroaniline (1.76 g, 10.5 mmol) with 3-(benzylsulfonyl)oxazolidin-
2-one (2.5 g, 9.5 mmol) to afford the title compound (1.39 g, 43%) as a colorless solid, 
mp 61–63 °C. 1H NMR (500 MHz, CDCl3)  7.37–7.28 (m, 5 H), 7.28–7.22 (m, 4 H), 
5.83–5.73 (m, 1 H), 5.12 (s, 1 H), 5.11–5.07 (m, 1 H), 4.58 (s, br, 1 H), 4.22 (d, J = 5.9 
Hz, 2 H), 4.19 (dd, J = 6.5, 1.1 Hz, 2 H); 13C NMR (175 MHz, CDCl3)  138.8, 136.6, 
133.6, 133.0, 129.8, 129.5, 129.0, 128.3, 128.1, 119.4, 54.9, 47.8; IR (neat) 3294, 1488, 





N-Allyl-N-benzhydryl-N’-benzylsulfamide. General procedure 1 was used to 
sulfonylate N-benzhydrylprop-2-en-1-amine (1.52 g, 6.8 mmol) with 3-
(benzylsulfonyl)oxazolidin-2-one (1.59 g, 6.2 mmol) to afford the title compound (1.2 g, 
48%) as a colorless solid, mp 100–102 °C. 1H NMR (500 MHz, CDCl3)  7.39–7.27 (m, 
12 H), 7.19–7.15 (m, 2 H), 6.39 (s, 1 H), 5.40 (ddt, J = 17.0, 10.3, 6.5 Hz, 1 H), 4.98 (dd, 
J = 17.2, 1.3 Hz, 1 H), 4.92 (dd, J = 10.1, 1.1 Hz, 1 H), 4.23 (t, J = 6.0 Hz, 1 H), 4.05 (d, 
J = 6.1 Hz, 2 H), 3.95 (d, J = 6.4 Hz, 2 H); 13C NMR (175 MHz, CDCl3)  139.5, 136.6, 
134.6, 129.2, 128.9, 128.7, 128.2, 128.1, 128.0, 118.2, 65.9, 49.5, 47.4; IR (neat) 3300, 
1433, 1324, 1142 cm-1; MS (ESI+) 393.1628 (393.1631 calcd for C23H24N2O2S, M + 
H+). 
 
N’-Benzyl-N-(tert-butyl)-N-(2-methylallyl)sulfamide. A flame-dried round-bottom flask 
equipped with a stirbar and a septum was cooled under a stream of nitrogen and 
charged with tert-butylamine (6.3 mL, 60 mmol), 3-bromo-2-methylprop-1-ene (1.51, 15 
mmol), and solid potassium carbonate (2.5 g, 18 mmol). The resulting mixture was 
stirred at rt for 24 h, then the mixture was filtered through celite. The celite was washed 
3 x 20 mL diethyl ether. The organic layers were combined, and the solvent was 
removed under reduced pressure to afford crude N-(tert-butyl)-2-methylprop-2-en-1-
amine (1.5 g, 80%) as a colorless oil which was carried on without further purification. 
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1H NMR (400 MHz, CDCl3) 4.86 (s, 1 H), 4.79 (s, 1 H), 3.10 (s, 2 H), 1.77 (s, 3 H), 
1.11 (s, 9 H) 
General procedure 1 was used to sulfonylate N-(tert-butyl)-2-methylprop-2-en-1-
amine (1.34 g, 10.5 mmol) with 3-(benzylsulfonyl)oxazolidin-2-one (2.5 g, 9.5 mmol) to 
afford the title compound (1.3 g, 47%) as a colorless solid, mp 76–80 °C. 1H NMR (400 
MHz, CDCl3)  7.38–7.27 (m, 5 H), 5.07 (d, J = 0.7 Hz, 1 H), 4.93 (d, J = 1.2 Hz, 1 H), 
4.21 (s, 3 H), 3.86 (s, 2 H), 1.77 (s, 3 H), 1.49–1.43 (m, 9 H); 13C NMR (175 MHz, 
CDCl3)  144.0, 137.1, 128.9, 128.3, 128.1, 111.2, 59.6, 52.4, 47.8, 29.6, 20.5; IR (neat) 




N’-Benzyl-N-(tert-butyl)-N-(2-phenylallyl)sulfamide. The alkylation of tert-butylamine 
(6.3 mL, 60 mmol) with (3-bromoprop-1-en-2-yl)benzene (2.96 g, 15 mmol) in the 
presence of potassium carbonate (2.5 g, 18 mmol) was accomplished using a 
procedure analogous to that described above for the formation of 4a. This procedure 
afforded N-(tert-butyl)-2-phenylprop-2-en-1-amine (2.4 g, 83%), which was carried on 
without further purification. 1H NMR (500 MHz, CDCl3)  7.46 (d, J = 7.3 Hz, 2 H), 7.37–
7.31 (m, 2 H), 7,29 (d, J = 7.3 Hz, 1 H), 5.38 (s, 1 H), 5.28 (s, 1 H), 3.62 (s, 2 H), 1.15 
(s, 9 H). 
General procedure 1 was used to sulfonylate N-(tert-butyl)-2-phenylprop-2-en-1-
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amine (2.0 g, 10.5 mmol) with 3-(benzylsulfonyl)oxazolidin-2-one (2.5 g, 9.5 mmol) to 
afford the title compound (2.4 g, 71%) as a colorless solid, mp 64–68 °C. 1H NMR (500 
MHz, CDCl3)  7.44–7.25 (m, 10 H), 5.55–5.43 (m, 2 H), 4.31 (s, 2 H), 4.24–4.17 (m, 3 
H), 1.53 (s, 9 H); 13C NMR (175 MHz, CDCl3)  146.7, 140.0, 137.0, 128.9, 128.6, 
128.2, 128.1, 128.1, 126.4, 113.2, 59.9, 50.4, 47.9, 29.2; IR (neat) 3330, 2969, 1320, 
1137 cm-1; MS (ESI+) 359.1783 (359.1788 calcd for C20H26N2O2S, M + H+). 
 
General procedure 2 for asymmetric Pd-catalyzed carboamination reactions.  
An oven-dried test tube equipped with a stir bar and a rubber septum was cooled under 
a stream of nitrogen and charged with Pd2(dba)3 (1 mol %), S-SIPHOS-PE (5 mol %), 
the sulfamide substrate (1.0 equiv), and NaOtBu (2.0 equiv). The septum-capped tube 
was purged with N2, and then the aryl or alkenyl halide (2.0 equiv), water (0 or 2.0 
equiv.), and xylenes (0.125 M) were added. The resulting mixture was heated to 120 °C 
with stirring for 18 h. The reaction mixture was then cooled to rt and saturated aqueous 
ammonium chloride (6 mL/mmol substrate) was added. The mixture was extracted with 
ethyl acetate (3 x 2 mL) and then the combined organic layers were dried over 
anhydrous Na2SO4, filtered through a plug of celite, and concentrated in vacuo. The 
crude product was purified by flash chromatography on silica gel using hexanes/ethyl 






thiadiazolidine-1,1-dioxide (Table 4.1, entry 6). The general procedure 2 was 
employed for the coupling of N-allyl-N’-(4-methoxyphenyl)-N-tert-butylsulfamide (89.0 
mg, 0.30 mmol) and 1-bromo-4-(tert-butyl)benzene (104 μL, 0.60 mmol) using a catalyst 
composed of Pd2(dba)3 (2.8 mg, 0.003 mmol) and (S)-SIPHOS-PE (7.6 mg, 0.015 
mmol), sodium tert-butoxide (58.0 mg, 0.60 mmol), a reaction temperature of 120 °C, 
and a reaction time of 18 h in 2.4 mL of xylenes. This procedure afforded the title 
compound (61 mg, 47%) as a yellow oil: [α]23D –21.5 (c 1.9, CH2Cl2); 1H NMR (500 
MHz, CDCl3)  7.37–7.33 (m, 2 H), 7.32–7.28 (m, 2 H), 7.02 (d, J = 8.3 Hz, 2 H), 6.96–
6.92 (m, 2 H), 4.12–4.05 (m, 1 H), 3.82 (s, 3 H), 3.32 (dd, J = 8.7, 6.0 Hz, 1 H), 3.24–
3.18 (m, 1 H), 2.95 (dd, J = 13.7, 4.2 Hz, 1 H), 2.63 (dd, J = 13.8, 9.8 Hz, 1 H), 1.42 (s, 
9 H), 1.30 (s, 9 H); 13C NMR (125 MHz, CDCl3)  159.2, 150.1, 132.9, 128.9, 128.7, 
128.4, 125.8, 115.0, 57.4, 56.6, 55.7, 46.4, 38.0, 34.6, 31.5, 27.5; IR (neat) 2963, 1509, 
1149 cm-1; MS (ESI+) 431.2359 (431.2363 calcd for C24H34N2O3S, M + H+). The 
enantiopurity was determined to be 81:19 er by chiral HPLC analysis (Chiralcel ODH, 




1,1-dioxide (Table 4.1, entry 7). The general procedure 2 was employed for the 
coupling of N-allyl-N’-(4-chlorophenyl)-N-tert-butylsulfamide (76.0 mg, 0.25 mmol) and 
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1-bromo-4-(tert-butyl)benzene (87 μL, 0.50 mmol) using a catalyst composed of 
Pd2(dba)3 (2.8 mg, 0.003 mmol) and (S)-SIPHOS-PE (7.6 mg, 0.015 mmol), sodium 
tert-butoxide (48.0 mg, 0.60 mmol), a reaction temperature of 120 °C, and a reaction 
time of 18 h in 2.4 mL of xylenes. This procedure afforded the title compound (12 mg, 
11%) yellow oil: [α]23D –10.0 (c 0.1, CH2Cl2); 1H NMR (700 MHz, CDCl3)  7.36 (d, J = 
8.5 Hz, 2 H), 7.30 (t, J = 7.9 Hz, 4 H), 7.03 (d, J = 8.0 Hz, 2 H), 4.20–4.14 (m, 1 H), 
3.36–3.40 (m, 1 H), 3.25 (t, J = 8.2 Hz, 1 H), 3.00 (dd, J = 13.9, 3.8 Hz, 1 H), 2.70 (dd, J 
= 13.8, 9.7 Hz, 1 H), 1.43 (s, 9 H), 1.31 (s, 9 H); 13C NMR (176 MHz, CDCl3)  150.3. 
135.3, 132.7, 132.3, 129.8, 128.9, 125.9, 125.7, 57.0, 56.4, 46.0, 37.8, 34.7, 31.5, 27.6; 
IR (film) 2966, 1491, 1150 cm-1. MS (ESI+) 435.1865 (435.1868 calcd for 
C23H31ClN2O2S, M + H+). The enantiopurity was determined to be 73:27 er by chiral 
HPLC analysis (Chiralcel ADH, 25 cm x 4.6 mm, 10% IPA/Hexanes, 0.8 mL/min, λ 254 




dioxide (Table 4.1, entry 5). The general procedure 2 was employed for the coupling of 
N-allyl-N’-benzyl-N-tert-butylsulfamide (85.0 mg, 0.30 mmol) and 1-bromo-4-(tert-
butyl)benzene (104 μL, 0.60 mmol) using a catalyst composed of Pd2(dba)3 (2.8 mg, 
0.003 mmol) and (S)-SIPHOS-PE (7.6 mg, 0.015 mmol), water (11 μL, 0.60 mmol), 
sodium tert-butoxide (58.0 mg, 0.60 mmol), a reaction temperature of 120 °C, and a 
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reaction time of 18 h in 2.4 mL of xylenes. This procedure afforded the title compound 
(112 mg, 90%) as a colorless solid, mp 114–118 °C: [α]23D –2.5 (c 10.1, CH2Cl2); 1H 
NMR (400 MHz, CDCl3)  7.43–7.38 (m, 2 H), 7.37–7.32 (m, 2 H), 7.31–7.23 (m, 3 H), 
6.91 (d, J = 8.2 Hz, 2 H), 4.38 (d, J = 14.9 Hz, 1 H), 4.21 (d, J = 14.9 Hz, 1 H), 3.47–
3.38 (m, 1 H), 3.18 (dd, J = 8.8, 6.5 Hz, 1 H), 3.06 (dd, J = 8.9, 6.2 Hz, 1 H), 2.93 (dd, J 
= 13.5, 4.3 Hz, 1 H), 2.61 (dd, J = 13.4, 10.1 Hz, 1 H), 1.40 (s, 9 H), 1.28 (s, 9 H); 13C 
NMR (125 MHz, CDCl3)  150.0, 136.0, 133.5, 129.0, 128.8, 128.7, 128.0, 125.8, 56.6, 
56.3, 50.0, 45.8, 38.0, 34.6, 31.5, 27.5; IR (neat) 2962, 1455, 1309, 1148 cm-1; MS 
(ESI+) 437.2233 (437.2233 calcd for C24H34N2O2S, M + Na+). The enantiopurity was 
determined to be 94:6 er by chiral HPLC analysis (Chiralcel ODH, 15 cm x 4.6 mm, 7% 




thiadiazolidine-1,1-dioxide (Table 4.1, entry 8). The general procedure 2 was 
employed for the coupling of N-allyl-N’-(4-methoxybenzyl)-N-tert-butylsulfamide (94.0 
mg, 0.30 mmol) and 1-bromo-4-(tert-butyl)benzene (104 μL, 0.60 mmol) using a catalyst 
composed of Pd2(dba)3 (2.8 mg, 0.003 mmol) and (S)-SIPHOS-PE (7.6 mg, 0.015 
mmol), sodium tert-butoxide (58.0 mg, 0.60 mmol), a reaction temperature of 120 °C, 
and a reaction time of 18 h in 2.4 mL of xylenes. This procedure afforded the title 
compound (103 mg, 77%) as a colorless solid, mp 82–86 °C: [α]23D –9.6 (c 7.5, CH2Cl2); 
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1H NMR (500 MHz, CDCl3)  7.33 (d, J = 8.6 Hz, 2 H), 7.30–7.27 (m, 2 H), 6.94 (d, J = 
8.3 Hz, 2 H), 6.90–6.86 (m, 2 H), 4.30 (d, J = 14.7 Hz, 1 H), 4.20 (d, J = 14.7 Hz, 1 H), 
3.81 (s, 3 H), 3.46–3.39 (m, 1 H), 3.18 (dd, J = 8.9, 6.5 Hz, 1 H), 3.05 (dd, J = 8.9, 6.0 
Hz, 1 H), 2.95 (dd, J = 13.5, 4.3 Hz, 1 H), 2.62 (dd, J = 13.4, 10.0 Hz, 1 H), 1.40 (s, 9 
H), 1.30 (s, 9 H); 13C NMR (125 MHz, CDCl3)  159.5, 150.0, 133.6, 130.4, 128.9, 
127.8, 125.8, 114.3, 56.3, 56.2, 55.4, 49.4, 45.7, 38.0, 34.6, 31.5, 27.6; IR (neat) 2966, 
1514, 1150 cm-1; MS (ESI+) 445.2510 (445.2519 calcd for C25H36N2O3S, M + H+). The 
enantiopurity was determined to be 91:9 er by chiral HPLC analysis (Chiralcel ODH, 15 




thiadiazolidine-1,1-dioxide (Table 4.1, entry 10). The general procedure 2 was 
employed for the coupling of N-allyl-N’-(3-methoxybenzyl)-N-tert-butylsulfamide (94.0 
mg, 0.30 mmol) and 1-bromo-4-(tert-butyl)benzene (104 μL, 0.60 mmol) using a catalyst 
composed of Pd2(dba)3 (2.8 mg, 0.003 mmol) and (S)-SIPHOS-PE (7.6 mg, 0.015 
mmol), sodium tert-butoxide (58.0 mg, 0.60 mmol), a reaction temperature of 120 °C, 
and a reaction time of 18 h in 2.4 mL of xylenes. This procedure afforded the title 
compound (80 mg, 60%) as a yellow oil: [α]23D –4.4 (c 6.3, CH2Cl2); 1H NMR (400 MHz, 
CDCl3)  7.29–7.22 (m, 3 H), 7.00–6.92 (m, 2 H), 6.92 (d, J = 8.2 Hz, 2 H), 6.85–6.81 
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(m, 1 H), 4.35 (d, J = 14.7 Hz, 1 H), 4.18 (d, J = 14.7 Hz, 1 H), 3.80 (s, 3 H), 3.47–3.39 
(m, 1 H), 3.18 (dd, J = 8.8, 6.5 Hz, 1 H), 3.05 (dd, J = 8.9, 6.2 Hz, 1 H), 2.93 (dd, J = 
13.5, 4.3 Hz, 1 H), 2.61 (dd, J = 13.4, 10.1 Hz, 1 H), 1.39 (s, 9 H), 1.27 (s, 9 H); 13C 
NMR (101 MHz, CDCl3)  160.0, 150.0, 137.6, 133.5, 129.7, 128.9, 125.8, 121.2, 114.2, 
113.8, 56.6, 56.3, 55.4, 50.0, 45.8, 37.9, 34.6, 31.5, 27.3; IR (neat) 2963, 1600, 1150 
cm-1; MS (ESI+) 445.2513 (445.2519 calcd for C25H36N2O3S, M + H+). The enantiopurity 
was determined to be 91:9 er by chiral HPLC analysis (Chiralcel ODH, 15 cm x 4.6 mm, 
7% IPA/Hexanes, 1.00 mL/min, λ 230 nm, RT= 5.2 and 7.3 min). 
 
 
(–)-(S)-2,3-Dibenzyl-5-(tert-butyl)-1,2,5-thiadiazolidine-1,1-dioxide (Table 4.2, entry 
1). The general procedure 2 was employed for the coupling of N-allyl-N’-benzyl-N-tert-
butylsulfamide (85.0 mg, 0.30 mmol) and bromobenzene (63 μL, 0.60 mmol) using a 
catalyst composed of Pd2(dba)3 (2.8 mg, 0.003 mmol) and (S)-SIPHOS-PE (7.6 mg, 
0.015 mmol), water (11 μL, 0.60 mmol), sodium tert-butoxide (58.0 mg, 0.60 mmol), a 
reaction temperature of 120 °C, and a reaction time of 18 h in 2.4 mL of xylenes. This 
procedure afforded the title compound (101 mg, 94%) as a colorless solid, mp 108–111 
°C: [α]23D –8.5 (c 4.6, CH2Cl2); 1H NMR (500 MHz, CDCl3)  7.43 (d, J = 7.3 Hz, 2 H), 
7.36 (t, J = 7.3 Hz, 2 H), 7.33–7.19 (m, 4 H), 7.00 (d, J = 7.3 Hz, 2 H), 4.39 (d, J = 14.7 
Hz, 1 H), 4.22 (d, J = 15.2 Hz, 1 H), 3.49–3.42 (m, 1 H), 3.19–3.13 (m, 1 H), 3.05 (dd, J 
= 8.1, 7.1 Hz, 1 H), 2.98 (dd, J = 13.7, 4.4 Hz, 1 H), 2.64 (dd, J = 13.2, 10.3 Hz, 1 H), 
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1.40 (s, 9 H); 13C NMR (125 MHz, CDCl3)  136.6, 136.0, 129.2, 129.0, 128.9, 128.8, 
128.1, 127.1, 56.6, 56.4, 50.1, 45.7, 38.6, 27.5; IR (neat) 2962, 1314, 1150 cm-1; MS 
(ESI+) 381.1607 (381.1607 calcd for C20H26N2O2S, M + Na+). The enantiopurity was 
determined to be 93:7 er by chiral HPLC analysis (Chiralcel ODH, 15 cm x 4.6 mm, 4% 




1,1-dioxide (Table 4.2, entry 3). The general procedure 2 was employed for the 
coupling of N-allyl-N’-benzyl-N-tert-butylsulfamide (85.0 mg, 0.30 mmol) and 4-
bromobiphenyl (140.0 mg, 0.60 mmol) using a catalyst composed of Pd2(dba)3 (2.8 mg, 
0.003 mmol) and (S)-SIPHOS-PE (7.6 mg, 0.015 mmol), water (11 μL, 0.60 mmol), 
sodium tert-butoxide (58.0 mg, 0.60 mmol), a reaction temperature of 120 °C, and a 
reaction time of 18 h in 2.4 mL of xylenes. This procedure afforded the title compound 
(122 mg, 94%) as a colorless solid, mp 109–113 °C: [α]23D +0.51 (c 3.1, CH2Cl2); 1H 
NMR (500 MHz, CDCl3)  7.58–7.54 (m, 2 H), 7.50 (d, J = 8.1 Hz, 2 H), 7.46–7.41 (m, 4 
H), 7.40–7.30 (m, 4 H), 7.08 (d, J = 8.1 Hz, 2 H), 4.43 (d, J = 14.9 Hz, 1 H), 4.24 (d, J = 
14.9 Hz, 1 H), 3.51 (d, J = 5.1 Hz, 1 H), 3.23 (dd, J = 8.9, 6.5 Hz, 1 H), 3.10 (dd, J = 8.8, 
6.1 Hz, 1 H), 3.03 (dd, J = 13.4, 4.6 Hz, 1 H), 2.70 (dd, J = 13.4, 10.0 Hz, 1 H), 1.42 (s, 
9 H); 13C NMR (125 MHz, CDCl3)  140.7, 140.0, 136.0, 135.6, 129.6, 129.0, 129.0, 
128.8, 128.1, 127.6, 127.5, 127.1, 56.6, 56.4, 50.2, 45.8, 38.3, 27.6; IR (neat) 2974, 
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1487, 1311, 1151 cm-1; MS (ESI+) 435.2094 (435.2101 calcd for C26H30N2O2S, M + H+). 
The enantiopurity was determined to be 94:6 er by chiral HPLC analysis (Chiralcel 





1,1-dioxide (Table 4.2, entry 5). The general procedure 2 was employed for the 
coupling of N-allyl-N’-benzyl-N-tert-butylsulfamide (85.0 mg, 0.30 mmol) and 4-bromo-
N,N-dimethylaniline (120.0 mg, 0.60 mmol) using a catalyst composed of Pd2(dba)3 (2.8 
mg, 0.003 mmol) and (S)-SIPHOS-PE (7.6 mg, 0.015 mmol), water (11 μL, 0.60 mmol), 
sodium tert-butoxide (58.0 mg, 0.60 mmol), a reaction temperature of 120 °C, and a 
reaction time of 18 h in 2.4 mL of xylenes. This procedure afforded the title compound 
(91 mg, 76%) as a red solid, mp 118–122 °C: [α]23D +17.3 (c 5.1, CH2Cl2); 1H NMR (500 
MHz, CDCl3)  7.46 (d, J = 7.8 Hz, 2 H), 7.37 (t, J = 7.7 Hz, 2 H), 7.34–7.29 (m, 1 H), 
6.88 (d, J = 8.1 Hz, 2 H), 6.64 (d, J = 7.8 Hz, 2 H), 4.42 (d, J = 14.9 Hz, 1 H), 4.23 (d, J 
= 15.1 Hz, 1 H), 3.40 (d, J = 5.9 Hz, 1 H), 3.17 (dd, J = 8.2, 7.2 Hz, 1 H), 3.04–3.10 (m, 
1 H), 2.88–2.95 (m, 7 H), 2.54 (dd, J = 13.3, 10.4 Hz, 1 H), 1.41 (s, 9 H); 13C NMR (125 
MHz, CDCl3)  149.7, 136.2, 129.8, 128.9, 128.7, 128.0, 124.0, 113.0, 57.0, 56.3, 49.9, 
45.8, 40.8, 37.6, 27.5; IR (neat) 2900, 1615, 1524, 1303 cm-1; MS (ESI+) 402.2206 
(402.2210 calcd for C22H31N3O2S, M + H+). The enantiopurity was determined to be 95:5 
er by chiral HPLC analysis (Chiralcel ODH, 15 cm x 4.6 mm, 7% IPA/Hexanes, 1.00 
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dioxide (Table 4.2, entry 6). The general procedure 2 was employed for the coupling of 
N-allyl-N’-benzyl-N-tert-butylsulfamide (85.0 mg, 0.30 mmol) and 4-(4-
bromophenyl)morpholine (145.0 mg, 0.60 mmol) using a catalyst composed of 
Pd2(dba)3 (2.8 mg, 0.003 mmol) and (S)-SIPHOS-PE (7.6 mg, 0.015 mmol), water (11 
μL, 0.60 mmol), sodium tert-butoxide (58.0 mg, 0.60 mmol), a reaction temperature of 
120 °C, and a reaction time of 18 h in 2.4 mL of xylenes. This procedure afforded the 
title compound (105 mg, 79%) as a yellow solid, mp 95–99 °C: [α]23D –11.5 (c 5.5, 
CH2Cl2); 1H NMR (500 MHz, CDCl3)  7.44–7.41 (m, 2 H), 7.38–7.33 (m, 2 H), 7.31 (d, J 
= 7.1 Hz, 1 H), 6.90 (d, J = 8.6 Hz, 2 H), 6.80 (d, J = 8.6 Hz, 2 H), 4.40 (d, J = 14.9 Hz, 
1 H), 4.20 (d, J = 14.9 Hz, 1 H), 3.87–3.82 (m, 4 H), 3.40 (d, J = 5.6 Hz, 1 H), 3.15 (dd, 
J = 8.8, 6.6 Hz, 1 H), 3.13–3.09 (m, 4 H), 3.03 (dd, J = 8.9, 6.5 Hz, 1 H), 2.91 (dd, J = 
13.6, 4.5 Hz, 1 H), 2.56 (dd, J = 13.4, 10.0 Hz, 1 H), 1.39 (s, 9 H); 13C NMR (125 MHz, 
CDCl3)  150.3, 136.1, 129.9, 129.0, 128.7, 128.0, 127.7, 116.1, 67.0, 56.8, 56.3, 50.1, 
49.5, 45.8, 37.7, 27.5; IR (neat) 2814, 1598, 1516, 1151 cm-1; MS (ESI+) 444.2311 
(444.2315 calcd for C24H33N3O3S, M + H+). The enantiopurity was determined to be 94:6 
er by chiral HPLC analysis (Chiralcel ODH, 15 cm x 4.6 mm, 7% IPA/Hexanes, 1.00 
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dioxide (Table 4.2, entry 7). The general procedure 2 was employed for the coupling of 
N-allyl-N’-benzyl-N-tert-butylsulfamide (85.0 mg, 0.30 mmol) and 4-bromo-1,2-
dimethoxybenzene (86 μL, 0.60 mmol) using a catalyst composed of Pd2(dba)3 (2.8 mg, 
0.003 mmol) and (S)-SIPHOS-PE (7.6 mg, 0.015 mmol), water (11 μL, 0.60 mmol), 
sodium tert-butoxide (58.0 mg, 0.60 mmol), a reaction temperature of 120 °C, and a 
reaction time of 18 h in 2.4 mL of xylenes. This procedure afforded the title compound 
(99 mg, 79%) as a yellow oil: [α]23D –5.8 (c 5.3, CH2Cl2); 1H NMR (500 MHz, CDCl3)  
7.41–7.36 (m, 2 H), 7.36–7.23 (m, 3 H), 6.73 (d, J = 8.2 Hz, 1 H), 6.54 (dd, J = 8.1, 1.9 
Hz, 1 H), 6.42 (d, J = 1.8 Hz, 1 H), 4.36 (d, J = 14.9 Hz, 1 H), 4.18 (d, J = 14.9 Hz, 1 H), 
3.82 (s, 3 H), 3.76 (s, 3 H), 3.44–3.36 (m, 1 H), 3.16 (dd, J = 8.8, 6.5 Hz, 1 H), 3.02 (dd, 
J = 8.9, 6.2 Hz, 1 H), 2.90 (dd, J = 13.4, 4.6 Hz, 1 H), 2.56 (dd, J = 13.5, 9.6 Hz, 1 H), 
1.38 (s, 9 H); 13C NMR (125 MHz, CDCl3)  149.2, 148.1, 136.0, 129.1, 129.0, 128.7, 
128.0, 121.2, 112.2, 111.5, 56.7, 56.3, 56.1, 56.0, 50.2, 45.8, 38.3, 27.5; IR (neat) 2976, 
1661, 1514, 1150 cm-1; MS (ESI+) 419.1997 (419.1999 calcd for C22H30N2O4S, M + H+). 
The enantiopurity was determined to be 94:6 er by chiral HPLC analysis (Chiralcel 








thiadiazolidine-1,1-dioxide (Table 4.2, entry 12). The general procedure 2 was 
employed for the coupling of N-Allyl-N’-benzyl-N-tert-butylsulfamide (85.0 mg, 0.30 
mmol) and 5-bromobenzo[d][1,3]dioxole (72 μL, 0.60 mmol) using a catalyst composed 
of Pd2(dba)3 (2.8 mg, 0.003 mmol) and (S)-SIPHOS-PE (7.6 mg, 0.015 mmol), water 
(11 μL, 0.60 mmol), sodium tert-butoxide (58.0 mg, 0.60 mmol), a reaction temperature 
of 120 °C, and a reaction time of 18 h in 2.4 mL of xylenes. This procedure afforded the 
title compound (88 mg, 73%) as a colorless solid, mp 99–102 °C: [α]23D –14.2 (c 4.7, 
CH2Cl2); 1H NMR (500 MHz, CDCl3)  7.44–7.39 (m, 2 H), 7.36 (t, J = 7.3 Hz, 2 H), 7.31 
(d, J = 7.3 Hz, 1 H), 6.69 (d, J = 7.8 Hz, 1 H), 6.48–6.42 (m, 2 H), 5.92 (s, 2 H), 4.40 (d, 
J = 14.9 Hz, 1 H), 4.19 (d, J = 14.9 Hz, 1 H), 3.42–3.34 (m, 1 H), 3.21–3.15 (m, 1 H), 
3.03 (dd, J = 8.6, 6.4 Hz, 1 H), 2.88 (dd, J = 13.6, 4.5 Hz, 1 H), 2.54 (dd, J = 13.4, 10.0 
Hz, 1 H), 1.40 (s, 9 H); 13C NMR (125 MHz, CDCl3)  148.0, 146.7, 136.0, 130.2, 129.0, 
128.8, 128.1, 122.2, 109.3, 108.7, 101.2, 56.8, 56.4, 50.3, 45.7, 38.4, 27.6; IR (neat) 
2976, 1493, 1313, 1150 cm-1; MS (ESI+) 403.1688 (403.1686 calcd for C21H26N2O4S, M 
+ H+). The enantiopurity was determined to be 92:8 er by chiral HPLC analysis 
(Chiralcel ODH, 15 cm x 4.6 mm, 10% IPA/Hexanes, 1.00 mL/min, λ 280 nm, RT= 7.0 






yl]methyl}phenyl)(phenyl)methanone (Table 4.2, entry 8). The general procedure 2 
was employed for the coupling of N-allyl-N’-benzyl-N-tert-butylsulfamide (85.0 mg, 0.30 
mmol) and 4-bromobenzophenone (157 mg, 0.60 mmol) using a catalyst composed of 
Pd2(dba)3 (2.8 mg, 0.003 mmol) and (S)-SIPHOS-PE (7.6 mg, 0.015 mmol), water (11 
μL, 0.60 mmol), sodium tert-butoxide (58.0 mg, 0.60 mmol), a reaction temperature of 
120 °C, and a reaction time of 18 h in 2.4 mL of xylenes. This procedure afforded the 
title compound (106 mg, 76%) as a colorless solid, mp 119–121 °C: [α]23D –3.3 (c 10.0, 
CH2Cl2); 1H NMR (400 MHz, CDCl3)  7.76 (dd, J = 8.1, 1.2 Hz, 2 H), 7.70 (d, J = 8.1 
Hz, 2 H), 7.61–7.56 (m, 1 H), 7.49–7.45 (m, 2 H), 7.42–7.38 (m, 2 H), 7.37–7.28 (m, 3 
H), 7.11 (d, J = 8.1 Hz, 2 H), 4.40 (d, J = 14.9 Hz, 1 H), 4.21 (d, J = 14.9 Hz, 1 H), 3.51 
(d, J = 4.4 Hz, 1 H), 3.23 (dd, J = 8.8, 6.6 Hz, 1 H), 3.08–3.02 (m, 2 H), 2.75 (dd, J = 
13.4, 9.5 Hz, 1 H), 1.40 (s, 9 H); 13C NMR (125 MHz, CDCl3)  196.2, 141.5, 137.6, 
136.4, 135.7, 132.6, 130.7, 130.1, 129.2, 128.9, 128.8, 128.4, 128.1, 56.4, 56.3, 50.5, 
45.7, 38.7, 27.5; IR (neat) 2976, 1661, 1311, 1151 cm-1; MS (ESI+) 463.2048 (463.2050 
calcd for C27H30N2O3S, M + H+). The enantiopurity was determined to be 90:10 er by 
chiral HPLC analysis (Chiralcel ODH, 15 cm x 4.6 mm, 7% IPA/Hexanes, 1.00 mL/min, 






1,1-dioxide (Table 4.2, entry 9). The general procedure 2 was employed for the 
coupling of N-allyl-N’-benzyl-N-tert-butylsulfamide (85.0 mg, 0.30 mmol) and 4-
bromobenzotrifluoride (84 μL, 0.60 mmol) using a catalyst composed of Pd2(dba)3 (2.8 
mg, 0.003 mmol) and (S)-SIPHOS-PE (7.6 mg, 0.015 mmol), water (11 μL, 0.60 mmol), 
sodium tert-butoxide (58.0 mg, 0.60 mmol), a reaction temperature of 120 °C, and a 
reaction time of 18 h in 2.4 mL of xylenes. This procedure afforded the title compound 
(95 mg, 74%) as a colorless solid, mp 139–142 °C: [α]23D –16.5 (c 8.7, CH2Cl2); 1H NMR 
(500 MHz, CDCl3)  7.50 (d, J = 8.1 Hz, 2 H), 7.37–7.28 (m, 5 H), 7.10 (d, J = 8.1 Hz, 2 
H), 4.39 (d, J = 14.7 Hz, 1 H), 4.17 (d, J = 14.7 Hz, 1 H), 3.50–3.43 (m, 1 H), 3.23 (dd, J 
= 9.0, 6.6 Hz, 1 H), 3.05–2.99 (m, 2 H), 2.72 (dd, J = 13.4, 9.3 Hz, 1 H), 1.40 (s, 9 H); 
13C NMR (125 MHz, CDCl3)  140.8, 135.7, 129.6, 129.6 (q, J = 65.4 Hz), 129.0, 128.8, 
128.2, 125.8 (q, J = 3.77 Hz), 124.2 (q, J = 271.6 Hz), 56.4, 56.3, 50.8, 45.8, 38.7, 27.6; 
19F NMR (471 MHz, CDCl3) –62.56; IR (neat) 2975, 1314, 1152 cm-1; MS (ESI+) 
427.1660 (427.1662 calcd for C21H25F3N2O2S, M + H+). The enantiopurity was 
determined to be 88:12 er by chiral HPLC analysis (Chiralcel ODH, 15 cm x 4.6 mm, 7% 






(Table 4.2, entry 10). The general procedure 2 was employed for the coupling of N-
allyl-N’-benzyl-N-tert-butylsulfamide (85.0 mg, 0.30 mmol) and 1-bromo-4-
fluorobenzene (66 μL, 0.60 mmol) using a catalyst composed of Pd2(dba)3 (2.8 mg, 
0.003 mmol) and (S)-SIPHOS-PE (7.6 mg, 0.015 mmol), water (11 μL, 0.60 mmol), 
sodium tert-butoxide (58.0 mg, 0.60 mmol), a reaction temperature of 120 °C, and a 
reaction time of 18 h in 2.4 mL of xylenes. This procedure afforded the title compound 
(81 mg, 72%) as a colorless solid, mp 100–102 °C: [α]23D –15.6 (c 7.8, CH2Cl2); 1H NMR 
(500 MHz, CDCl3)  7.41–7.37 (m, 2 H), 7.35 (t, J = 7.2 Hz, 2 H), 7.31 (d, J = 7.1 Hz, 1 
H), 6.97–6.92 (m, 4 H), 4.38 (d, J = 14.7 Hz, 1 H), 4.18 (d, J = 14.9 Hz, 1 H), 3.45–3.38 
(m, 1 H), 3.18 (dd, J = 8.8, 6.6 Hz, 1 H), 3.02 (dd, J = 8.8, 6.1 Hz, 1 H), 2.94 (dd, J = 
13.7, 4.9 Hz, 1 H), 2.62 (dd, J = 13.6, 9.7 Hz, 1 H), 1.40 (s, 9 H); 13C NMR (125 MHz, 
CDCl3)  162.0 (d, J = 246.5 Hz), 135.9, 132.3 (d, J = 2.5 Hz), 130.7 (d, J = 8.8 Hz), 
128.9 (d, J = 18.9 Hz), 128.1, 115.9, 115.7, 56.6, 56.4, 50.4, 45.7, 38.0, 27.5; 19F NMR 
(471 MHz, CDCl3)  –115.7; IR (neat) 2974, 1509, 1315, 1152 cm-1; MS (ESI+) 
377.1694 (377.1694 calcd for C20H25FN2O2S, M + H+). The enantiopurity was 
determined to be 90:10 er by chiral HPLC analysis (Chiralcel ODH, 15 cm x 4.6 mm, 7% 






thiadiazolidine-1,1-dioxide (Table 4.2, entry 11). The general procedure 2 was 
employed for the coupling of N-allyl-N’-benzyl-N-tert-butylsulfamide (85.0 mg, 0.30 
mmol) and 1-benzyl-5-bromo-1H-indole (172.0 mg, 0.60 mmol) using a catalyst 
composed of Pd2(dba)3 (2.8 mg, 0.003 mmol) and (S)-SIPHOS-PE (7.6 mg, 0.015 
mmol), water (11 μL, 0.60 mmol), sodium tert-butoxide (58.0 mg, 0.60 mmol), a reaction 
temperature of 120 °C, and a reaction time of 18 h in 2.4 mL of xylenes. This procedure 
afforded the title compound (122 mg, 83%) as a colorless solid, mp 158–161 °C: [α]23D –
1.6 (c 8.6, CH2Cl2); 1H NMR (500 MHz, CDCl3)  7.46 (d, J = 7.8 Hz, 2 H), 7.40–7.34 
(m, 2 H), 7.34–7.25 (m, 5 H), 7.20–7.09 (m, 4 H), 6.79 (d, J = 8.5 Hz, 1 H), 6.49 (d, J = 
2.4 Hz, 1 H), 5.31 (s, 2 H), 4.44 (d, J = 14.9 Hz, 1 H), 4.26 (d, J = 14.9 Hz, 1 H), 3.55–
3.48 (m, 1 H), 3.19–3.08 (m, 3 H), 2.72 (dd, J = 13.3, 10.4 Hz, 1 H), 1.41 (s, 9 H); 13C 
NMR (125 MHz, CDCl3)  137.5, 136.2, 135.5, 129.2, 129.0, 129.0, 128.9, 128.7, 128.0, 
127.8, 127.5, 126.9, 123.0, 121.3, 110.1, 101.5, 57.2, 56.3, 50.4, 50.0, 45.8, 38.7, 27.6; 
IR (neat) 2974, 1314, 1152 cm-1; MS (ESI+) 488.2366 (488.2366 calcd for 
C29H33N3O2S, M + H+). The enantiopurity was determined to be 92:8 er by chiral HPLC 
analysis (Chiralcel ODH, 15 cm x 4.6 mm, 7% IPA/Hexanes, 1.00 mL/min, λ 220 nm, 




(Table 4.2, entry 16). The general procedure 2 was employed for the coupling of N-
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allyl-N’-benzyl-N-tert-butylsulfamide (85.0 mg, 0.30 mmol) and 2-bromotoluene (72 μL, 
0.60 mmol) using a catalyst composed of Pd2(dba)3 (2.8 mg, 0.003 mmol) and (S)-
SIPHOS-PE (7.6 mg, 0.015 mmol), water (11 μL, 0.60 mmol), sodium tert-butoxide 
(58.0 mg, 0.60 mmol), a reaction temperature of 120 °C, and a reaction time of 18 h in 
2.4 mL of xylenes. This procedure afforded the title compound (61 mg, 54%) as a 
colorless solid, mp 75–78 °C: [α]23D +19.3 (c 4.0, CH2Cl2); 1H NMR (500 MHz, CDCl3)  
7.44–7.39 (m, 2 H), 7.37–7.32 (m, 2 H), 7.30 (d, J = 6.8 Hz, 1 H), 7.15–7.07 (m, 3 H), 
6.99 (d, J = 6.8 Hz, 1 H), 4.40–4.34 (m, 1 H), 4.27–4.21 (m, 1 H), 3.51–3.43 (m, 1 H), 
3.20–3.14 (m, 1 H), 3.10 (dd, J = 8.8, 5.9 Hz, 1 H), 3.02 (dd, J = 13.6, 4.5 Hz, 1 H), 2.69 
(dd, J = 13.6, 10.1 Hz, 1 H), 2.05 (s, 3 H), 1.41 (s, 9 H); 13C NMR (125 MHz, CDCl3)  
136.5, 136.0, 134.9, 130.8, 130.2, 128.9, 128.8, 128.1, 127.3, 126.3, 56.4, 54.9, 50.1, 
45.8, 36.1, 27.6, 19.4; IR (neat) 2977, 1290, 1148 cm-1; MS (ESI+) 373.1946 (373.1944 
calcd for C21H28N2O2S, M + H+). The enantiopurity was determined to be 68:32 er by 
chiral HPLC analysis (Chiralcel ODH, 15 cm x 4.6 mm, 5% IPA/Hexanes, 1.00 mL/min, 





1,1-dioxide (Table 4.2, entry 15). The general procedure 2 was employed for the 
coupling of N-allyl-N’-benzyl-N-tert-butylsulfamide (85.0 mg, 0.30 mmol) and 2-
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bromobenzotrifluoride (82 μL, 0.60 mmol) using a catalyst composed of Pd2(dba)3 (2.8 
mg, 0.003 mmol) and (S)-SIPHOS-PE (7.6 mg, 0.015 mmol), water (11 μL, 0.60 mmol), 
sodium tert-butoxide (58.0 mg, 0.60 mmol), a reaction temperature of 120 °C, and a 
reaction time of 18 h in 2.4 mL of xylenes. This procedure afforded the title compound 
(30 mg, 23%) as a yellow oil: [α]23D +18.2 (c 4.1, CH2Cl2); 1H NMR (500 MHz, CDCl3)  
7.60 (d, J = 7.8 Hz, 1 H), 7.48–7.42 (m, 1 H), 7.38–7.32 (m, 1 H), 7.31–7.22 (m, 6 H), 
4.33 (d, J = 14.9 Hz, 1 H), 4.14 (d, J = 14.9 Hz, 1 H), 3.63–3.54 (m, 1 H), 3.28–3.19 (m, 
2 H), 3.10 (dd, J = 8.9, 5.7 Hz, 1 H), 2.91–2.84 (m, 1 H), 1.41 (s, 9 H); 13C NMR (125 
MHz, CDCl3)  135.8, 135.1, 132.8, 132.0, 128.9, 128.9 (q, J = 28.8 Hz), 128.7, 127.9, 
127.3, 126.6 (q, J = 4.4 Hz), 124.5 (q, J = 273.8 Hz), 56.4, 56.0, 51.3, 46.1, 36.1, 27.6; 
19F NMR (471 MHz, CDCl3) –59.4; IR (neat) 2978, 1312, 1150, 1113 cm-1; MS (ESI+) 
427.1664 (427.1662 calcd for C21H25F3N2O2S, M + H+). The enantiopurity was 
determined to be 62:38 er by chiral HPLC analysis (Chiralcel ODH, 15 cm x 4.6 mm, 7% 




1,1-dioxide (Table 4.2, entry 13). The general procedure 2 was employed for the 
coupling of N-allyl-N’-benzyl-N-tert-butylsulfamide (85.0 mg, 0.30 mmol) and (E)-1-(2-
bromovinyl)-4-methoxybenzene (128 mg, 0.60 mmol) using a catalyst composed of 
Pd2(dba)3 (2.8 mg, 0.003 mmol) and (S)-SIPHOS-PE (7.6 mg, 0.015 mmol), water (11 
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μL, 0.60 mmol), sodium tert-butoxide (58.0 mg, 0.60 mmol), a reaction temperature of 
120 °C, and a reaction time of 18 h in 2.4 mL of xylenes. This procedure afforded the 
title compound (56 mg, 45%) as a yellow oil: [α]23D +31.6 (c 4.4, CH2Cl2); 1H NMR (500 
MHz, CDCl3)  7.43 (d, J = 7.3 Hz, 2 H), 7.37–7.31 (m, 2 H), 7.29 (d, J = 7.3 Hz, 1 H), 
7.22 (d, J = 8.6 Hz, 2 H), 6.83 (d, J = 8.6 Hz, 2 H), 6.31 (d, J = 15.9 Hz, 1 H), 5.84–5.77 
(m, 1 H), 4.48 (d, J = 15.2 Hz, 1 H), 4.13 (d, J = 15.2 Hz, 1 H), 3.80 (s, 3 H), 3.42–3.36 
(m, 2 H), 3.15–3.08 (m, 1 H), 2.51–2.43 (m, 1 H), 2.35–2.27 (m, 1 H), 1.41 (s, 9 H); 13C 
NMR (125 MHz, CDCl3)  159.4, 136.3, 133.3, 129.8, 128.8, 128.7, 128.0, 127.5, 121.5, 
114.2, 56.4, 55.6, 55.5, 50.2, 45.8, 36.2, 27.5; IR (neat) 2975, 1606, 1510, 1246, 1148 
cm-1; MS (ESI+) 415.2050 (415.205 calcd for C23H30N2O3S, M + H+). The enantiopurity 
was determined to be 94:6 er by chiral HPLC analysis (Chiralcel ODH, 15 cm x 4.6 mm, 




dioxide (Table 4.2, entry 14). The general procedure 2 was employed for the coupling 
of N-allyl-N’-benzyl-N-tert-butylsulfamide (85.0 mg, 0.30 mmol) and (E)-(2-
bromovinyl)trimethylsilane (92 μL, 0.60 mmol) using a catalyst composed of Pd2(dba)3 
(2.8 mg, 0.003 mmol) and (S)-SIPHOS-PE (7.6 mg, 0.015 mmol), water (11 μL, 0.60 
mmol), sodium tert-butoxide (58.0 mg, 0.60 mmol), a reaction temperature of 120 °C, 
and a reaction time of 18 h in 2.4 mL of xylenes. This procedure afforded the title 
154 
 
compound (46 mg, 40%) as a yellow oil: [α]23D +22.3 (c 2.1, CH2Cl2); 1H NMR (500 
MHz, CDCl3)  7.41 (d, J = 7.1 Hz, 2 H), 7.36–7.31 (m, 2 H), 7.28 (d, J = 7.3 Hz, 1 H), 
5.82–5.67 (m, 2 H), 4.42 (d, J = 15.2 Hz, 1 H), 4.10 (d, J = 15.2 Hz, 1 H), 3.39–3.30 (m, 
2 H), 3.08–3.04 (m, 1 H), 2.43–2.37 (m, 1 H), 2.28–2.21 (m, 1 H), 1.42 (s, 9 H), 0.02 (s, 
9 H); 13C NMR (125 MHz, CDCl3)  140.1, 136.3, 135.9, 128.7, 128.7, 127.9, 56.4, 55.0, 
50.0, 45.6, 39.6, 27.5, –1.2; IR (neat) 2954, 1617, 1293, 1247, 1149 cm-1; MS (ESI+) 
381.2029 (381.2027 calcd for C19H32N2O2SSi, M + H+). The enantiopurity was 
determined to be 95:5 er by chiral HPLC analysis (Chiralcel ODH, 15 cm x 4.6 mm, 7% 
IPA/Hexanes, 1.00 mL/min, λ 220 nm, RT= 2.9 and 7.5 min). 
 
Deuterium Labeling Studies 
The configuration of deuterated products were assigned on the basis of 1D NOESY 
experiments carried out with the all-proteo analogs of these compounds. The key nOe 
signals are shown below. 
 
The configuration of the deuterated products was then assigned by examining which 
signal was absent from the 1H NMR. 
 





(Z)-1-(3-d-Allyl)-1-benzyl-3-tert-butylsulfamide (4-21). The procedure previously 
described by our group for the preparation of (Z)-1-(3-d-Allyl)-1,3-dibenzylsulfamide was 
used for the synthesis of 8.[15,16] A flame dried round bottom flask equipped with a stir 
bar was cooled to rt under a stream of nitrogen and charged with N-(tert-butyl)prop-2-
en-1-amine (10.0 mmol, 1.13 g) and Et2O (20 mL). The resulting solution was cooled to 
–42 °C using a CO2/CH3CN bath and stirred for 5 min. A solution of n-BuLi in hexanes 
(4.8 mL, 2.5 M, 12 mmol) was added slowly, and the resulting mixture was stirred at –42 
°C for 20 min. A solution of t-BuLi in pentanes (13.0 mL, 1.7 M, 22 mmol) was added 
slowly and the resulting solution was stirred at –42 °C for 30 min. The CO2/CH3CN bath 
was replaced with a brine/ice bath, and the reaction mixture was allowed to slowly warm 
to rt as the ice melted. The bath was removed and the mixture was stirred at rt for 1 h. 
The reaction mixture was then cooled to –78 °C, and D2O (3.6 mL, 200 mmol) was 
added dropwise. The resulting mixture was warmed to rt and stirred overnight. The 
reaction mixture was cooled to 0 °C, quenched with H2O (15 mL) and transferred to a 
separatory funnel. The mixture was extracted with Et2O (3 x 10 mL). The combined 
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organic layers were dried with anhydrous Na2SO4, filtered, and concentrated in vacuo to 
yield crude (Z)-N-(tert-butyl)prop-2-en-3-d-1-amine. 
A flame dried two necked flask equipped with stir bar and condenser was then 
charged with N-benzyl-2-oxooxazolidine-3-sulfonamide (2.56 g, 10 mmol), 4-
dimethylaminopyridine (244 mg, 2 mmol), acetonitrile (50mL) and Et3N (4.2 mL, 30 
mmol). The reaction vessel was placed in an oil bath at 80 ºC and the mixture was 
stirred for 15 min. Neat (Z)-N-(tert-butyl)prop-2-en-3-d-1-amine was added, and the 
resulting mixture was stirred at 80 °C for ca. 6 h. The mixture was cooled to rt, and the 
solvent was removed under reduced pressure. The resulting crude product was purified 
by flash chromatography on silica gel using hexanes/ethyl acetate as eluant to yield 770 
mg (27%) of a yellow solid, mp 73–75 °C: 1H NMR (500 MHz, CDCl3)  7.44–7.28 (m, 5 
H), 6.01–5.91 (m, 1 H), 5.12 (d, J = 10.3 Hz, 1 H), 4.27–4.19 (m, 1 H), 4.15 (d, J = 6.1 
Hz, 2 H), 3.96 (dd, J = 6.0, 1.1 Hz, 2 H), 1.47 (s, 9 H); 13C NMR (125 MHz, CDCl3)  
137.4, 136.9, 128.9, 128.3, 128.1, 116.5 (t, J = 23.9 Hz), 59.4, 49.5, 47.5, 29.9; IR 
(neat) 3328, 2970, 1317, 1137 cm-1; MS (ESI+) 306.1358 (306.1357 calcd for 




thiadiazolidine-1,1-dioxide (Table 4.3, entry 1). The general procedure 2 was 
employed for the coupling of (Z)-1-(3-d-allyl)-1-benzyl-3-tert-butylsulfamide (71.0 mg, 
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0.25 mmol) and 1-bromo-4-tert-butylbenzene (87 μL, 0.50 mmol) using a catalyst 
composed of Pd2(dba)3 (2.3 mg, 0.0025 mmol) and (S)-SIPHOS-PE (6.3 mg, 0.0125 
mmol), sodium tert-butoxide (48.0 mg, 0.50 mmol), a reaction temperature of 120 °C, 
and a reaction time of 18 h in 2.0 mL of xylenes. This procedure afforded the title 
compound (60 mg, 58%) as a colorless solid, mp 86–90 °C: [α]23D –2.4 (c 5.4, CH2Cl2); 
1H NMR (500 MHz, CDCl3)  7.43–7.40 (m, 2 H), 7.36 (t, J = 7.3 Hz, 2 H), 7.33–7.25 (m, 
3 H), 6.92 (d, J = 8.1 Hz, 2 H), 4.39 (d, J = 14.9 Hz, 1 H), 4.22 (d, J = 14.9 Hz, 1 H), 
3.44 (d, J = 10.0 Hz, 1 H), 3.20 (dd, J = 8.8, 6.6 Hz, 1 H), 3.08 (dd, J = 8.8, 6.1 Hz, 1 H), 




dioxide (Table 4.3, entry 2). The general procedure 2 was employed for the coupling of 
(Z)-1-(3-d-allyl)-1-benzyl-3-tert-butylsulfamide (71.0 mg, 0.25 mmol) and bromobenzene 
(53 μL, 0.50 mmol) using a catalyst composed of Pd2(dba)3 (2.3 mg, 0.0025 mmol) and 
(S)-SIPHOS-PE (6.3 mg, 0.0125 mmol), sodium tert-butoxide (48.0 mg, 0.50 mmol), a 
reaction temperature of 120 °C, and a reaction time of 18 h in 2.0 mL of xylenes. This 
procedure afforded the title compound (60 mg, 67%) as a colorless solid, mp 108–111 
°C: [α]23D –10.0 (c 4.7, CH2Cl2); 1H NMR (500 MHz, CDCl3)  7.45–7.40 (m, 2 H), 7.36 
(t, J = 7.5 Hz, 2 H), 7.33–7.19 (m, 4 H), 7.00 (d, J = 7.8 Hz, 2 H), 4.39 (d, J = 14.9 Hz, 1 
H), 4.21 (d, J = 14.9 Hz, 1 H), 3.48–3.41 (m, 1 H), 3.16 (dd, J = 8.4, 6.7 Hz, 1 H), 3.05 
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(dd, J = 8.7, 6.5 Hz, 1 H), 3.02–2.95 (m, 0.12 H), 2.62 (d, J = 10.0 Hz, 1 H), 1.40 (s, 9 
H); 13C NMR (125 MHz, CDCl3)  136.6, 136.0, 129.2, 129.0, 128.9, 128.8, 128.1, 
127.1, 56.6, 56.4, 50.1, 45.7, 38.4 (t, J = 21.0 Hz), 27.6; IR (neat) 2976, 1325, 1153 cm-
1; MS (ESI+) 360.1852 (360.1851 calcd for C20H25DN2O2S, M + Na+). The 
diastereoselectivity was determined to be 8:1 by comparing the products obtained from 
separate reactions of the deuterated and non-deuterated substrates. The enantiopurity 
was determined to be 95:5 er by chiral HPLC analysis (Chiralcel ODH, 15 cm x 4.6 mm, 




thiadiazolidine 1,1-dioxide (Table 4.3, entry 3). The general procedure 2 was 
employed for the coupling of (Z)-1-(3-d-allyl)-1-benzyl-3-tert-butylsulfamide (71.0 mg, 
0.25 mmol) and 4-bromobiphenyl (117 mg, 0.50 mmol) using a catalyst composed of 
Pd2(dba)3 (2.3 mg, 0.0025 mmol) and (S)-SIPHOS-PE (6.3 mg, 0.0125 mmol), sodium 
tert-butoxide (48.0 mg, 0.50 mmol), a reaction temperature of 120 °C, and a reaction 
time of 18 h in 2.0 mL of xylenes. This procedure afforded the title compound (71 mg, 
65%) as a yellow solid, mp 116–121 °C: [α]23D +0.2 (c 5.7, CH2Cl2); 1H NMR (500 MHz, 
CDCl3)  7.58–7.53 (m, 2 H), 7.51–7.47 (m, 2 H), 7.46–7.40 (m, 4 H), 7.40–7.29 (m, 4 
H), 7.09–7.04 (m, 2 H), 4.42 (d, J = 14.9 Hz, 1 H), 4.23 (d, J = 14.9 Hz, 1 H), 3.52–3.45 
(m, 1 H), 3.23 (dd, J = 8.8, 6.6 Hz, 1 H), 3.12–3.07 (m, 1 H), 3.06–2.99 (m, 0.11 H), 2.67 
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(d, J = 9.8 Hz, 1 H), 1.42 (s, 9 H); 13C NMR (125 MHz, CDCl3)  140.7, 140.0, 136.0, 
135.6, 129.6, 129.0, 128.8, 128.1, 127.6, 127.5, 127.1, 56.6, 56.4, 50.3, 45.8, 38.0 (t, J 
= 20.0 Hz), 27.6, 1 carbon signal is missing due to incidental equivalence; IR (neat) 
2974, 1488, 1320, 1151 cm-1; MS (ESI+) 436.2162 (436.2164 calcd for C26H29DN2O2S, 
M + H+). The diastereoselectivity was determined to be 9:1 by comparing the products 
obtained from separate reactions of the deuterated and non-deuterated substrates. The 
enantiopurity was determined to be 92:8 er by chiral HPLC analysis (Chiralcel ODH, 15 




thiadiazolidine-1,1-dioxide (Table 4.3, entry 4). The general procedure 2 was 
employed for the coupling of (Z)-1-(3-d-allyl)-1-benzyl-3-tert-butylsulfamide (71.0 mg, 
0.25 mmol) and 4-bromobenzotrifluoride (70 μL, 0.50 mmol) using a catalyst composed 
of Pd2(dba)3 (2.3 mg, 0.0025 mmol) and (S)-SIPHOS-PE (6.3 mg, 0.0125 mmol), 
sodium tert-butoxide (48.0 mg, 0.50 mmol), a reaction temperature of 120 °C, and a 
reaction time of 18 h in 2.0 mL of xylenes. This procedure afforded the title compound 
(60.0 mg, 56%) as a colorless solid, mp 128–132 °C: [α]23D –16.6 (c 5.6, CH2Cl2); 1H 
NMR (500 MHz, CDCl3)  7.50 (d, J = 8.1 Hz, 2 H), 7.39–7.28 (m, 4 H), 7.09 (d, J = 7.8 
Hz, 2 H), 4.39 (d, J = 14.7 Hz, 1 H), 4.16 (d, J = 14.9 Hz, 1 H), 3.46 (d, J = 9.0 Hz, 1 H), 
3.23 (dd, J = 8.8, 6.6 Hz, 1 H), 3.03 (dd, J = 8.9, 5.7 Hz, 1 H), 2.70 (d, J = 9.3 Hz, 1 H), 
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1.40 (s, 9 H); 1H NMR (500 MHz, C6D6)  7.13–7.21 (m, 4 H), 6.99–7.09 (m, 3 H), 6.57 
(d, J = 8.1 Hz, 2 H), 4.28 (d, J = 14.9 Hz, 1 H), 3.91–3.97(d, J = 14.9 Hz, 1 H), 3.02–
3.10 (m, 1 H), 2.76 (dd, J = 8.8, 6.8 Hz, 1 H), 2.64–2.70 (m, 0.15 H), 2.61 (dd, J = 8.8, 
5.6 Hz, 1 H), 2.30 (d, J = 8.8 Hz, 1 H), 1.24 (s, 9 H); 13C NMR (125 MHz, CDCl3)  
140.8, 135.7, 129.6, 129.4, 129.0, 128.8, 128.2, 125.8 (q, J = 3.90 Hz), 124.2 (q, J = 
272.8 Hz), 56.5, 56.2, 50.8, 45.8, 38.4 (t, J = 19.1 Hz), 27.6; IR (neat) 2972, 1322, 1124 
cm-1; MS (ESI+) 428.1723 (428.1724 calcd for C21H24DF3N2O2S, M + H+). The 
diastereoselectivity was determined to be 7:1 by comparing the products obtained from 
separate reactions of the deuterated and non-deuterated substrates. The enantiopurity 
was determined to be 88:12 er by chiral HPLC analysis (Chiralcel ODH, 15 cm x 4.6 
mm, 7% IPA/Hexanes, 1.00 mL/min, λ 210 nm, RT= 6.0 and 8.3 min). When the 
reaction was conducted in the presence of water (2 equivalents), the desired product 9d 
was obtained with 78% yield 5:1 dr and 89:11 er. 
 
Determination of absolute configuration: 
The absolute configuration of the cyclic sulfamide products were assigned by preparing 
an authentic sample of 4-33 from L-phenylalanine methyl ester hydrochloride as 
described below. The optical rotation was of the same sign (–) as that of the separate 




Reaction Sequence for Authentic Sample 
 
(–)-(S)-2,3-Dibenzyl-5-(tert-butyl)-1,2,5-thiadiazolidine 1,1-dioxide (4-33): A 250 mL 
round bottomed flask equipped with stir bar was flame dried, back filled with nitrogen, 
and then charged with methyl benzyl-L-phenylalaninate[17] (8.4 mmol, 2.3 g). Anhydrous 
ether (25 mL) was added, and the reaction mixture was cooled to 0 °C. Lithium 
aluminum hydride (25 mL of a 1 M solution in ether) was added dropwise then the 
reaction was warmed to rt and stirred at rt for 24 h. The mixture was then cooled to 0 
°C, water (1 mL) was added dropwise followed by sodium hydroxide (1.3 mL of 3 M 
solution), and additional water (3 mL). The resulting mixture was filtered through celite 
and concentrated to afford (S)-2-(benzylamino)-3-phenylpropan-1-ol as a white solid 
that was carried onto the next step. 
The sulfonylation was performed using a modification of the procedure described 
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by Wolfe and co-workers.15 A 100 mL 2-necked round bottom flask equipped with a stir 
bar, condenser and septum was flame dried and charged with N-(tert-butyl)-2-
oxooxazolidine-3-sulfonamide (890 mg, 4 mmol) and 4-dimethylaminopyridine (100 mg, 
0.8 mmol). Anhydrous acetonitrile (20 mL) and triethylamine (1.7 mL, 12 mmol) were 
added and the resulting mixture was heated to 80 °C with stirring for 15 min. A solution 
of (S)-2-(benzylamino)-3-phenylpropan-1-ol (1.0 g, 4 mmol) in anhydrous acetonitrile (5 
mL) was added dropwise, and the mixture was stirred at 80 °C for 6 h. The mixture was 
then cooled to rt, the solvent was removed under reduced pressure, and the crude 
product was purified by flash chromatography on silica gel to afford 130 mg (9%): 1H 
NMR (400 MHz, CDCl3)  7.44 (d, J = 6.8 Hz, 2 H), 7.35–7.15 (m, 6 H), 7.06 (d, J = 6.8 
Hz, 2 H), 4.41 (s, 2 H), 4.19–4.10 (m, 1 H), 3.99 (s, 1 H), 3.73–3.65 (m, 1 H), 3.53 (d, J 
= 4.1 Hz, 1 H), 2.83 (d, J = 6.5 Hz, 1 H), 2.62 (dd, J = 14.0, 8.5 Hz, 1 H), 1.88 (t, J = 5.5 
Hz, 1 H), 1.27 (s, 9 H). 
A 10 mL flame-dried round bottom flask equipped with a stir bar was cooled 
under a stream of nitrogen and charged with the sulfamide prepared above (130.0 mg, 
0.35 mmol) and THF (3 mL). The solution was cooled to -10 °C in a brine/ice bath then 
potassium tert-butoxide (80.0 mg, 0.70 mmol) was added in one portion, and the 
resulting mixture was stirred at –10 °C for 5 min. A solution of tosyl chloride (73.0 mg, 
0.39 mmol) THF (1.3 mL) was then added dropwise and the mixture was stirred at –10 
°C for 10 min at which time TLC analysis indicated the starting material had been 
completely consumed. The mixture was warmed to rt, quenched with 5 mL water, and 
extracted with ether (2 x 5 mL). The organic layers were combined, filtered through a 
plug of celite, and the solvent was removed under reduced pressure. The crude product 
163 
 
was purified by flash chromatography on silica gel using hexanes/ethyl acetate as 
eluant. This procedure afforded the title compound (91.0 mg, 73 %) as a colorless solid. 
[α]23D –10.7 (c 8.4, CHCl3); The spectroscopic properties of this compound were 
identical to the compound synthesized via the Pd-catalyzed carboamination reaction. 
The enantiopurity was determined to be >99:1 er by chiral HPLC analysis (Chiralcel 




Cleavage of N-tert-butyl group 
 
(–)-(S)-2,3-Dibenzyl-1,2,5-thiadiazolidine-1,1-dioxide (4-25). A round bottom flask 
equipped with a stirbar and a septum was charged with 4-24 (55.2 mg, 0.15 mmol), 
hexanes (1.0 mL) and trifluoroacetic acid (0.75 mL). The resulting mixture was stirred at 
rt for 24 h, and then the solvent was removed under reduced pressure. The crude 
material was purified by flash chromatography on silica gel to afford the title compound 
(44.0 mg, 98%) as a colorless solid, mp 69–73 °C: [α]23D –9.1 (c 3.9, CH2Cl2); 1H NMR 
(500 MHz, CDCl3)  7.44–7.21 (m, 8 H), 7.07–7.02 (m, 2 H), 4.35–4.25 (m, 2 H), 4.22 (t, 
J = 7.5 Hz, 1 H), 3.62 (ddt, J = 8.8, 6.7, 4.6 Hz, 1 H), 3.35 (ddd, J = 11.9, 7.9, 6.6 Hz, 1 
H), 3.19 (ddd, J = 11.7, 7.2, 4.3 Hz, 1 H), 2.87 (dd, J = 13.6, 5.0 Hz, 1 H), 2.62 (dd, J = 
13.6, 8.7 Hz, 1 H); 13C NMR (125 MHz, CDCl3)  136.1, 135.7, 129.4, 129.1, 129.0, 
128.9, 128.4, 127.3, 61.6, 49.8, 45.1, 39.3; IR (neat) 3302, 2921, 1287, 1145 cm-1; MS 
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(ESI+) 303.1161 (303.1162 calcd for C16H18N2O2S, M + H+). The enantiopurity was 
determined to be 6:94 er by chiral HPLC analysis (Chiralcel ODH, 15 cm x 4.6 mm, 7% 
IPA/Hexanes, 0.5 mL/min, λ 210 nm, RT= 51.5 and 54.9 min). 
 
Cleavage of N-tert-butyl group and sulfonyl group 
 
(+)-(S)-3-([1,1'-Biphenyl]-4-yl)-N2-benzylpropane-1,2-diamine (4-27). A 10 mL round 
bottom flask equipped with a reflux condenser and a stir bar was charged with (S)-3-
([1,1'-biphenyl]-4-ylmethyl)-2-benzyl-5-(tert-butyl)-1,2,5-thiadiazolidine-1,1-dioxide (74.1 
mg, 0.17 mmol) and phenol (50.0 mg, 0.53 mmol). Aqueous 2 M hydrobromic acid (2 
mL, 4 mmol) was added, the reaction mixture was heated at 130 °C for 24 h, then was 
cooled to rt. The mixture was diluted with water (5 mL) and ether (5 mL) then solid 
sodium hydroxide (~2.3 g) was added until the mixture reached pH ≥ 10. The layers 
were separated, and the aqueous layer was extracted with ether (3 x 5 mL). The 
combined organic layers were dried with sodium sulfate, and then passed through a 
plug of celite. The solvent was removed under reduced pressure to afford the title 
compound (46 mg, 85%) as a yellow oil: [α]23D +1.6 (c 4.4, CH2Cl2); 1H NMR (500 MHz, 
CDCl3)  7.61–7.55 (m, 2 H), 7.52 (d, J = 8.2 Hz, 2 H), 7.43 (t, J = 7.6 Hz, 2 H), 7.36–
7.19 (m, 8 H), 3.86–3.77 (m, 2 H), 2.90–2.79 (m, 3 H), 2.78–2.69 (m, 1 H), 2.63–2.54 
(m, 1 H), 1.53–1.38 (m, 3 H); 13C NMR (125 MHz, CDCl3)  141.1, 140.8, 139.3, 138.4, 
129.8, 128.9, 128.5, 128.2, 127.3, 127.3, 127.1, 127.0, 60.5, 51.5, 44.6, 38.7; IR (neat) 
3292, 3025, 1486, 1451, 696 cm-1; MS (ESI+) 317.2015 (317.2012 calcd for C22H24N2, 
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M + H+). The enantiopurity was determined by further elaborating diamine 7 to urea S2 
by reaction with CDI as outlined below.  
 
 
(+)-(S)-5-([1,1'-Biphenyl]-4-ylmethyl)-1-benzylimidazolidin-2-one (4-28). A flame-
dried round bottom flask equipped with a stirbar and reflux condenser was charged with 
4-27 (46 mg, 0.15 mmol) and THF (1 mL). A solution of 1,1'-carbonyldiimidazole (35 mg, 
0.22 mmol) THF (1 mL) was added the resulting mixture was heated to reflux with 
stirring for 24 h. The mixture was then cooled to rt and the solvent was removed under 
reduced pressure. The crude product was purified by flash chromatography on silica gel 
using dichloromethane/methanol as eluant to afford the title compound (46 mg, 89%) as 
a colorless solid, mp 110–114 °C: [α]23D +29.4 (c 3.6, CH2Cl2); 1H NMR (400 MHz, 
CDCl3)  7.57–7.51 (m, 2 H), 7.48 (d, J = 8.2 Hz, 2 H), 7.45–7.39 (m, 2 H), 7.37–7.25 
(m, 6 H), 7.10 (d, J = 8.2 Hz, 2 H), 4.99 (s, br, 1 H), 4.87 (d, J = 15.3 Hz, 1 H), 4.09 (d, J 
= 15.5 Hz, 1 H), 3.74 (tdd, J = 8.8, 6.9, 4.5 Hz, 1 H), 3.28 (t, J = 8.6 Hz, 1 H), 3.18–3.05 
(m, 2 H), 2.65 (dd, J = 13.5, 9.2 Hz, 1 H); 13C NMR (101 MHz, CDCl3)  162.5, 140.8, 
139.9, 137.3, 135.9, 129.7, 128.9, 128.8, 128.3, 127.7, 127.5, 127.5, 127.1, 56.0, 45.5, 
43.8, 38.4; IR (neat) 3215, 1690, 1486, 1487, 1449 cm-1; MS (ESI+) 343.1804 
(343.1805 calcd for C23H22N2O, M + H+). The enantiopurity was determined to be 94:6 
er by chiral HPLC analysis (Chiralcel ODH, 15 cm x 4.6 mm, 7% IPA/Hexanes, 1.0 




Asymmetric Synthesis of 6-Membered Cyclic Sulfamides 
 
Synthesis of Substrates: 
General procedure 3 for the synthesis of secondary amines: 
Secondary amines were prepared from the corresponding ketones by a two-step 
procedure involving imine formation followed by Grignard addition to the imine. 
  
Symmetrical ketone (1 equiv.), primary amine (1 equiv.), 4 Å molecular sieves (200 
mg/mmol), and dichloromethane (2 M) were added to a flame-dried flask equipped with 
stir bar. The mixture was vigorously stirred until complete consumption of the starting 
materials as determined by TLC. Then, the mixture was filtered through celite and the 
solvent was removed under reduced pressure. 
 
A flame-dried round bottom flask was equipped with stir bar and then charged with 
allylmagnesium bromide (1M in ether). This solution was cooled to 0 °C and then a 
solution of imine (0.4 M in THF) was added dropwise. The reaction was allowed to 
come to rt, and then stirred overnight. Then, the flask was cooled to 0 °C in an ice bath 
and slowly quenched with saturated aqueous ammonium chloride (0.5 mL/mmol). The 
mixture was transferred to a separatory funnel, the layers were separated, and the 
aqueous layer was extracted with diethyl ether (3 x 10 mL/mmol). The organic layers 
were combined and washed with brine (10 mL/ mmol), dried with anhydrous sodium 
sulfate, filtered, and concentrated under reduced pressure. The crude product was 
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purified by flash chromatography on silica gel. 
 
General procedure 4 for the synthesis of substrates: 
A flame dried two neck round bottom flask equipped with stir bar, condenser, and 
septum was cooled under a stream of nitrogen. This flask was charged with DMAP 
(0.20 equiv.) and oxazolidin-2-one substrate (1.0 equiv.). Anhydrous acetonitrile (5 
mL/mmol) was added followed by triethylamine (3.0 equiv.). This mixture was heated at 
80 °C for 15 minutes, and then the allyl amine was added dropwise. This was allowed to 
stir for 16-18 h. The reaction mixture was brought to room temperature, and then the 
solvent was removed under reduced pressure. The material was redissolved in ethyl 
acetate (2.5 mL/mmol) and washed 2x 1 M HCl (2.5 mL/mmol), and 1x brine (2.5 
mL/mmol). The organic layer was dried with sodium sulfate, filtered, and the solvent 
was removed under reduced pressure. The crude material was purified by column 
chromatography using hexanes/ethyl acetate as eluant. 
 
N’-benzyl-N-(tert-butyl)-N-(but-3-en-1-yl)sulfamide (4-34). The general procedure 4 
was employed for the sulfonylation of N-(tert-butyl)but-3-en-1-amine (1.34 g, 10.5 mmol) 
with 3-(benzylsulfonyl)oxazolidin-2-one (2.43 g, 9.5 mmol). This procedure afforded the 
title compound (670 mg, 24%) as a colorless solid, mp 44–47 °C: 1H NMR (700 MHz, 
CDCl3)  7.38–7.33 (m, 4 H), 7.33–7.29 (m, 1 H), 5.80–5.73 (m, 1 H), 5.09 (dd, J = 17.0, 
1.5 Hz, 1 H), 5.04 (d, J = 10.2 Hz, 1 H), 4.21 (t, J = 6.1 Hz, 2 H), 4.16 (d, J = 6.1 Hz, 2 
H), 3.34–3.30 (m, 2 H), 2.46–2.41 (m, 2 H), 1.46 (s, 9 H); 13C NMR (175 MHz, CDCl3)  
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136.8, 135.2, 129.0, 128.3, 128.1, 116.9, 58.9, 47.6, 46.6, 36.8, 29.6; IR (neat) 3322, 
1317, 1135, 1088 cm-1. MS (ESI+) 297.1629 (297.1631 calcd for C15H24N2O2S, M + H+).  
 
N-Benzyl-N’-benzyl-N-(2-methylpent-4-en-2-yl)sulfamide (4-36).  
General procedure 3 was used to generate N-benzyl-2-methylpent-4-en-2-amine. 
Acetone (4.4 mL, 60 mmol) and benzylamine (6.6 ml, 60 mmol) were stirred in the 
presence of 4 Å molecular sieves (12 g) and dichloromethane (30 mL) for 4 h. The 
solution was filtered through celite, and the solvent was removed under reduced 
pressure to afford crude N-benzylpropan-2-imine which was used without further 
purification.  
The Grignard reaction was performed according to general procedure 3 by adding crude 
N-benzylpropan-2-imine in 150 mL THF to allylmagnesium bromide (150 mmol, 1M 
solution in ether). Workup and subsequent purification by column chromatography 
afforded N-benzyl-2-methylpent-4-en-2-amine as a yellow oil (9.9 g, 87% over two 
steps). 
1H NMR (500 MHz, CDCl3)  7.36–7.28 (m, 4H), 7.25–7.21 (m, 1H), 5.93–5.82 (m, 1H), 
5.15–5.08 (m, 2H), 3.72 (s, 2H), 2.25 (d, J = 7.4 Hz, 2H), 1.15 (s, 6H). 
General procedure 4 was used to sulfonylate N-benzyl-2-methylpent-4-en-2-amine (4.3 
g, 22.5 mmol) with 3-(benzylsulfonyl)oxazolidin-2-one (5.2 g, 20.4 mmol) to afford the 
title compound (3.0 g, 41%) as a colorless solid, mp 75–77 °C: 1H NMR (500 MHz, 
CDCl3)  7.42 (d, J = 7.5 Hz, 2H), 7.36–7.20 (m, 8H), 5.92–5.80 (m, 1H), 5.12 (s, 1H), 
5.09 (s, 1H), 4.58 (s, 2H), 4.17 (t, J = 5.5 Hz, 1H), 4.13 (d, J = 5.4 Hz, 2H), 2.64 (d, J = 
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7.3 Hz, 2H), 1.44 (s, 6H); 13C NMR (125 MHz, CDCl3)  140.08, 136.88, 134.50, 128.90, 
128.64, 128.23, 128.07, 127.22, 118.74, 62.58, 50.79, 47.73, 45.95, 27.88; IR (neat) 
3330, 1453, 1320, 1132 cm-1; MS (ESI+) 359.1791 (359.1788 calcd for C20H26N2O2S, M 
+ H+). 
 
N-Benzyl-N’-benzyl-N-(3-ethylhex-5-en-3-yl)sulfamide. General procedure 3 was 
used to generate N-benzyl-3-ethylhex-5-en-3-amine. 3-Pentanone (3.2 mL, 30 mmol) 
and benzylamine (3.3 ml, 30 mmol) were stirred in the presence of 4 Å molecular sieves 
(6 g) and dichloromethane (15 mL) for 24 h. The solution was filtered through celite, and 
the solvent was removed under reduced pressure to afford crude N-benzylpentan-3-
imine which was used without further purification.  
The Grignard reaction was performed according to general procedure 3 by adding crude 
N-benzylpentan-3-imine in 75 mL THF to allylmagnesium bromide (75 mmol, 1M 
solution in ether). Workup and subsequent purification by column chromatography 
afforded N-benzyl-3-ethylhex-5-en-3-amine as a yellow oil (2.6 g, 40% over two steps). 
1H NMR (500 MHz, CDCl3)  7.36 (d, J = 6.9 Hz, 2H), 7.31 (t, J = 7.6 Hz, 2H), 7.25–7.21 
(m, 1H), 5.89–5.79 (m, 1H), 5.17–5.05 (m, 2H), 3.61 (s, 2H), 2.17 (dt, J = 7.4, 1.3 Hz, 
2H), 1.42 (qd, J = 7.4, 2.2 Hz, 4H), 0.86 (t, J = 7.4 Hz, 6H). 
General procedure 4 was used to sulfonylate N-benzyl-3-ethylhex-5-en-3-amine (2.64 g, 
12.2 mmol) with 3-(benzylsulfonyl)oxazolidin-2-one (2.83 g, 11 mmol) to afford the title 
compound (450 mg, 11%) as a colorless oil. 1H NMR (700 MHz, CDCl3)  7.45 (d, J = 
7.5 Hz, 2 H), 7.34–7.31 (m, 2 H), 7.30–7.24 (m, 4 H), 7.18–7.15 (m, 2 H), 5.90 (ddt, J = 
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17.1, 10.2, 7.2 Hz, 1 H), 5.14–5.12 (m, 1 H), 5.12–5.10 (m, 1 H), 4.59 (s, 2 H), 4.14 (d, J 
= 6.1 Hz, 2 H), 4.08 (t, J = 6.1 Hz, 1 H), 2.64 (d, J = 7.3 Hz, 2 H), 1.89–1.78 (m, 4 H), 
0.94 (t, J = 7.4 Hz, 6 H); 13C NMR (175 MHz, CDCl3)  140.3, 137.1, 134.5, 128.8, 
128.6, 128.2, 128.0, 127.6, 127.2, 118.5, 69.9, 50.8, 48.0, 39.7, 28.4, 8.9; IR (neat) 
3296, 1318, 1144 cm-1; MS (ESI+) 387.2106 (387.2101 calcd for C22H30N2O2S, M + 
H+). 
 
N-Benzyl-N’-benzyl-N-(1-allylcyclohexyl)sulfamide. General procedure 3 was used 
to generate 1-allyl-N-benzylcyclohexan-1-amine. Cyclohexanone (2.1 mL, 20 mmol) and 
benzylamine (2.2 ml, 20 mmol) were stirred in the presence of 4 Å molecular sieves (4 
g) and dichloromethane (10 mL) for 4 h. The solution was filtered through celite, and the 
solvent was removed under reduced pressure to afford crude N-benzylcyclohexanimine 
which was used without further purification.  
The Grignard reaction was performed according to general procedure 3 by adding crude 
N-benzylcyclohexanimine in 50 mL THF to allylmagnesium bromide (50 mmol, 1M 
solution in ether). Workup and subsequent purification by column chromatography 
afforded 1-allyl-N-benzylcyclohexan-1-amine as a yellow oil (3.1 g, 68% over two 
steps). 
1H NMR (500 MHz, CDCl3)  7.37 (d, J = 6.9 Hz, 2H), 7.31 (t, J = 7.6 Hz, 2H), 7.25–7.21 
(m, 1H), 5.14–5.07 (m, 2H), 3.65 (s, 2H), 2.26 (d, J = 7.4 Hz, 2H), 1.72–1.30 (m, 10H). 
General procedure 4 was used to sulfonylate 1-allyl-N-benzylcyclohexan-1-amine (3.1 
g, 13.9 mmol) with 3-(benzylsulfonyl)oxazolidin-2-one (3.2 g, 12.5 mmol) to afford the 
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title compound (1.23 g, 25%) as a colorless solid, mp 77–79 °C: 1H NMR (500 MHz, 
CDCl3)  7.43 (d, J = 7.4 Hz, 2H), 7.35–7.22 (m, 6H), 7.18–7.15 (m, 2H), 6.03–5.93 (m, 
1H), 5.19–5.11 (m, 1H), 4.59 (s, 2H), 4.11 (d, J = 5.7 Hz, 2H), 4.06 (t, J = 5.7 Hz, 1H), 
2.79 (d, J = 7.2 Hz, 2H), 2.19 (d, J = 12.8 Hz, 2H), 1.81 (td, J = 12.7, 3.7 Hz, 2H), 1.67–
1.53 (m, 3H), 1.48–1.35 (m, 2H), 1.27–1.15 (m, 1H); 13C NMR (125 MHz, CDCl3)  
140.3, 137.0, 134.6, 128.8, 128.6, 128.2, 128.0, 127.3, 127.2, 118.5, 66.4, 50.2, 47.8, 
38.4, 35.3, 25.3, 23.1; IR (neat) 3333, 1455, 1414, 1333, 1148 cm-1; MS (ESI+) 
399.2103 (399.2101 calcd for C23H30N2O2S, M + H+). 
 
N-Benzyl-N’-benzyl-N-(2,4-dimethylpent-4-en-2-yl)sulfamide (4-45). General 
procedure 3 was used to generate N-benzyl-2,4-dimethylpent-4-en-2-amine. Acetone 
(4.4 mL, 60 mmol) and benzylamine (6.6 mL, 60 mmol) were stirred in the presence of 4 
Å molecular sieves (12 g) and dichloromethane (30 mL) for 4 h. The solution was 
filtered through celite, and the solvent was removed under reduced pressure to afford 
crude N-benzylpropan-2-imine which was used without further purification.  
The Grignard reaction was performed according to general procedure 3 by adding crude 
N-benzylpropan-2-imine in 150 mL THF to allylmagnesium chloride (150 mmol, 1M 
solution in ether). Workup and subsequent purification by column chromatography 
afforded N-benzyl-2,4-dimethylpent-4-en-2-amine as a yellow oil (3.05 g, 25% over two 
steps). 
1H NMR (400 MHz, CDCl3)  7.36 (d, J = 6.7 Hz, 2H), 7.31 (t, J = 7.5 Hz, 2H), 7.23 (t, J 
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= 7.1 Hz, 1H), 4.91 (s, 1H), 4.73 (s, 1H), 3.76 (s, 2H), 2.24 (s, 2H), 1.85 (s, 3H), 1.18 (s, 
6H). 
General procedure 4 was used to sulfonylate N-benzyl-2,4-dimethylpent-4-en-2-amine 
(2.4 g, 12 mmol) with 3-(benzylsulfonyl)oxazolidin-2-one (2.56 g, 10.0 mmol) to afford 
the title compound (1.4 g, 37%) as a viscous oil. 1H NMR (500 MHz, CDCl3)  7.43 (d, J 
= 7.4 Hz, 2H), 7.35–7.21 (m, 8H), 4.93–4.91 (m, 1H), 4.79 (s, 1H), 4.60 (s, 2H), 4.23 (t, 
J = 6.1 Hz, 1H), 4.12 (d, J = 6.1 Hz, 2H), 2.64 (s, 2H), 1.81 (s, 3H), 1.50 (s, 6H); 13C 
NMR (125 MHz, CDCl3)  142.2, 140.1, 137.0, 128.9, 128.6, 128.2, 128.0, 127.3, 127.2, 
116.2, 63.3, 50.8, 48.3, 47.7, 28.3, 25.3; IR (neat) 3300, 1317, 1134 cm-1; MS (ESI+) 
373.1948 (373.1944 calcd for C21H28N2O2S, M + H+). 
 
N-benzyl-N’-benzyl-N-(2,2-dimethylbut-3-en-1-yl)sulfonamide (4-43). 2,2-
Dimethylbut-3-enoic acid18 (1.1 g, 10 mmol) was suspended in dichloromethane (30 mL) 
and trimethylamine was added (2.8 mL, 20 mmol). The mixture was cooled to 0 °C, and 
then ethyl chloroformate (0.96 mL, 10 mmol) was added dropwise. The solution was 
stirred 30 minutes, and then benzylamine was added dropwise (1.3 mL, 12 mmol). The 
reaction was allowed to come to rt, and then stirred overnight. The reaction was 
quenched with saturated sodium bicarbonate (3 mL/mmol). The mixture was transferred 
to a separatory funnel, the layers were separated, and the aqueous layer was extracted 
with dichloromethane (3 x 30 mL/mmol). The organic layers were combined and 
washed with brine (10 mL/ mmol), dried with anhydrous sodium sulfate, filtered, and 
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concentrated under reduced pressure. The crude product was purified by flash 
chromatography on silica gel to afford N-benzyl-2,2-dimethylbut-3-enamide as a yellow 
oil (1.3 g, 65%). 
1H NMR (500 MHz, CDCl3)  7.36–7.31 (m, 2H), 7.30–7.27 (m, 1H), 7.25–7.21 (m, 3H), 
6.02 (dd, J = 17.4, 10.6 Hz, 1H), 5.23 (d, J = 17.5 Hz, 1H), 5.19 (d, J = 10.6 Hz, 1H), 
4.41 (d, J = 5.7 Hz, 2 H), 1.33 (s, 6H).  
N-benzyl-2,2-dimethylbut-3-enamide was added to a flame dried three-necked round 
bottom flask equipped with reflux condenser. Anhydrous diethyl ether (13 mL) was 
added, and then the solution was brought to 0 °C. Lithium aluminum hydride (20 mL of a 
1 M solution in diethyl ether, 20 mmol) was added dropwise, and then the mixture was 
refluxed overnight. The crude product was purified by flash chromatography on silica gel 
to afford N-benzyl-2,2-dimethylbut-3-en-1-amine as a yellow oil (1.0 g, 82%). 
1H NMR (500 MHz, CDCl3)  7.34–7.29 (m, 4H), 7.26–7.21 (m, 1H), 5.78 (dd, J = 17.2, 
11.1 Hz, 1H), 5.02–4.95 (m, 2H), 3.79 (s, 2H), 2.43 (s, 2H), 1.03 (s, 6H). 
General procedure 4 was used to sulfonylate N-benzyl-2,2-dimethylbut-3-en-1-amine 
(1.0 g, 5.3 mmol) with 3-(benzylsulfonyl)oxazolidin-2-one (1.24 g, 4.85 mmol) to afford 
the title compound (1.61 g, 93%) as a colorless solid, mp 69–71 °C. 1H NMR (500 MHz, 
CDCl3)  7.40 (d, J = 7.4 Hz, 2H), 7.37–7.27 (m, 6H), 7.22–7.18 (m, 2H), 5.93 (dd, J = 
17.5, 10.7 Hz, 1H), 5.06 (d, J = 17.5 Hz, 1H), 5.02 (d, J = 10.6 Hz, 1H), 4.50 (s, 2H), 
4.10 (d, J = 6.0 Hz, 2H), 4.07–4.01 (t, J = 6.1 Hz, 1H), 3.21 (s, 2H), 1.09 (s, 6H);13C 
NMR (125 MHz, CDCl3)  147.3, 136.9, 136.6, 128.9, 128.9, 128.8, 128.1, 128.1, 112.4, 
58.2, 53.5, 47.7, 39.5, 25.5, one peak is missing due to incidental equivalence; IR (neat) 





General procedure 5 for asymmetric Pd-catalyzed carboamination reactions.  
An oven-dried test tube tube equipped with a stir bar and septum was cooled under a 
stream of nitrogen and charged with Pd2(dba)3 (1 mol %), (S)-SIPHOS-PE (5 mol %), 
the sulfamide substrate (1.0 equiv), and NaOtBu (2.0 equiv). The flask was purged with 
N2, and then the aryl or alkenyl halide (1.40–2.0 equiv), water (0 or 2.0 equiv.), and 
xylenes (0.125 M) were added. The resulting mixture was heated to 120 °C with stirring 
for 18 h. The reaction mixture was then cooled to rt, saturated aqueous ammonium 
chloride (6 mL/mmol substrate) was added. The mixture was extracted with ethyl 
acetate (3 x 2 mL) and then the combined organic layers were dried over anhydrous 
Na2SO4, filtered through a celite plug, and concentrated in vacuo. The crude product 




dioxide (Table 4.4, entry 1). The general procedure 5 was employed for the coupling of 
N-benzyl-N’-benzyl-N-(2-methylpent-4-en-2-yl)sulfamide (72.0 mg, 0.20 mmol) and 4-
bromobiphenyl (104 μL, 0.40 mmol) using a catalyst composed of Pd2(dba)3 (1.8 mg, 
0.002 mmol) and (S)-SIPHOS-PE (5.1 mg, 0.010 mmol), sodium tert-butoxide (38.0 mg, 
0.40 mmol), a reaction temperature of 120 °C, and a reaction time of 18 h in 1.6 mL of 
xylenes. This procedure afforded the title compound (80 mg, 78%) as a white solid, mp 
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174–178 °C: [α]23D -154.5 (c 1.98, CH2Cl2); 1H NMR (500 MHz, CDCl3)  7.56 (d, J = 8.3 
Hz, 2H), 7.46 (d, J = 8.1 Hz, 2H), 7.43 (t, J = 7.2 Hz, 6H), 7.36–7.29 (m, J = 7.7 Hz, 5H), 
7.27–7.22 (m, 2H), 7.12 (d, J = 8.0 Hz, 2H), 4.72 (d, J = 15.8 Hz, 1H), 4.64 (d, J = 16.8 
Hz, 1H), 4.41–4.49 (m, 1H), 4.32 (d, J = 15.8 Hz, 1H), 4.15 (d, J = 16.8 Hz, 1H), 2.92 
(dd, J = 13.7, 5.0 Hz, 1H), 2.64 (dd, J = 13.6, 10.0 Hz, 1H), 2.07 (t, J = 10 Hz, 1H), 1.46 
(dd, J = 14.3, 2.6 Hz, 1H), 1.32 (s, 3H), 1.14 (s, 3H); 13C NMR (125 MHz, CDCl3)  
140.9, 140.4, 139.7, 138.3, 136.4, 129.6, 129.0, 128.6, 128.6, 128.1, 127.5, 127.5, 
127.4, 127.2, 127.1, 60.5, 57.2, 50.1, 45.8, 40.46, 38.87, 31.0, 23.0, 1 carbon signal is 
missing due to incidental equivalence; IR (neat) 1488, 1452, 1332, 1153, 1137 cm-1. MS 
(ESI+) 511.2413 (511.2414 calcd for C32H34N2O2S, M + H+). The enantiopurity was 
determined to be 97:3 er by chiral HPLC analysis when 4-bromobiphenyl served as 
electrophile (Chiralcel ODH, 15 cm x 4.6 mm, 7% IPA/Hexanes, 1.00 mL/min, λ 254 nm, 
RT= 16.5 and 29.7 min). When 4-iodobiphenyl was used as the electrophile, the 
enantioselectivity was less reproducible providing enantiomeric ratios that ranged from 
82:18 er to 91.5:8.5 er. 
 
 
(S)-2,5,6-tribenzyl-3,3-dimethyl-1,2,6-thiadiazinane 1,1-dioxide (Table 4.4, entry 4). 
The general procedure 5 was employed for the coupling of N-benzyl-N’-benzyl-N-(2-
methylpent-4-en-2-yl)sulfamide (72.0 mg, 0.20 mmol) and bromobenzene (42 μL, 0.4 
mmol) using a catalyst composed of Pd2(dba)3 (1.8 mg, 0.002 mmol) and (S)-SIPHOS-
PE (5.1 mg, 0.010 mmol), sodium tert-butoxide (38.0 mg, 0.60 mmol), a reaction 
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temperature of 120 °C, and a reaction time of 18 h in 1.6 mL of xylenes. This procedure 
afforded the title compound (80 mg, 92%) as a colorless solid, mp 149–153 °C: [α]23D -
65 (c 1.6, CH2Cl2); 1H NMR (500 MHz, CDCl3)  7.43 (d, J = 7.9 Hz, 5H), 7.32 (td, J = 
7.5, 2.6 Hz, 6H), 7.28–7.21 (m, 4H), 7.21–7.17 (m, 1H), 7.06 (d, J = 7.0 Hz, 2H), 4.71 
(d, J = 15.8 Hz, 1H), 4.64 (d, J = 16.8 Hz, 1H), 4.41 (dddd, J = 12.7, 10.1, 4.8, 2.9 Hz, 
1H), 4.30 (d, J = 15.8 Hz, 1H), 4.14 (d, J = 16.8 Hz, 1H), 2.89 (dd, J = 13.6, 4.8 Hz, 1H), 
2.58 (dd, J = 13.6, 10.2 Hz, 1H), 2.03 (dd, J = 14.3, 12.2 Hz, 1H), 1.39 (dd, J = 14.3, 2.9 
Hz, 1H), 1.28 (s, 3H), 1.12 (s, 3H); 13C NMR (125 MHz, CDCl3)  140.4, 138.4, 137.4, 
129.2, 128.8, 128.6, 128.5, 128.1, 127.5, 127.4, 127.2, 126.9, 60.4, 57.3, 50.1, 45.8, 
40.9, 38.7, 31.0, 22.9.; IR (neat) 1495, 1452, 1330, 1151, 1136 cm-1. MS (ESI+) 
435.2106 (435.2101 calcd for C26H30N2O2S, M + H+). The enantiopurity was determined 
to be 95:5 er by chiral HPLC analysis (Chiralcel ODH, 15 cm x 4.6 mm, 3% 
IPA/Hexanes, 0.8 mL/min, λ 210 nm, RT= 16.7 and 22.3 min). 
 
(S)-2,6-dibenzyl-5-(4-methoxybenzyl)-3,3-dimethyl-1,2,6-thiadiazinane 1,1-dioxide 
(Table 4.4, entry 3). The general procedure 5 was employed for the coupling of N-
benzyl-N’-benzyl-N-(2-methylpent-4-en-2-yl)sulfamide (72.0 mg, 0.20 mmol) and 4-
bromoanisole (50 μL, 0.40 mmol) using a catalyst composed of Pd2(dba)3 (1.8 mg, 
0.002 mmol) and (S)-SIPHOS-PE (5.1 mg, 0.010 mmol), sodium tert-butoxide (38.0 mg, 
0.40 mmol), a reaction temperature of 120 °C, and a reaction time of 18 h in 1.6 mL of 
xylenes. This procedure afforded the title compound (55 mg, 59%) as a colorless solid, 
mp 135–138 °C: [α]23D -78 (c 1.2, CH2Cl2); 1H NMR (500 MHz, CDCl3)  7.42 (d, J = 7.6 
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Hz, 4H), 7.32 (td, J = 7.5, 1.4 Hz, 4H), 7.27–7.21 (m, 2H), 6.97 (d, J = 8.6 Hz, 2H), 6.77 
(d, J = 8.5 Hz, 2H), 4.70 (d, J = 15.9 Hz, 1H), 4.63 (d, J = 16.8 Hz, 1H), 4.35 (dddd, J = 
12.5, 10.1, 4.8, 2.8 Hz, 1H), 4.28 (d, J = 15.8 Hz, 1H), 4.13 (d, J = 16.8 Hz, 1H), 3.77 (s, 
3H), 2.82 (dd, J = 13.7, 4.8 Hz, 1H), 2.52 (dd, J = 13.7, 10.2 Hz, 1H), 2.00 (dd, J = 14.3, 
12.3 Hz, 1H), 1.39 (dd, J = 14.3, 2.8 Hz, 1H), 1.28 (s, 3H), 1.11 (s, 3H); 13C NMR (125 
MHz, CDCl3)  158.5, 140.4, 138.4, 130.1, 129.3, 128.6, 128.5, 128.1, 127.5, 127.4, 
127.2, 114.2, 60.4, 57.5, 55.4, 50.0, 45.7, 40.0, 38.7, 31.0, 22.8.; IR (neat) 1604, 1512, 
1494, 1454, 1329, 1152, 1136 cm-1. MS (ESI+) 465.2204 (465.2206 calcd for 
C27H32N2O3S, M + H+). The enantiopurity was determined to be 98:2 er by chiral HPLC 
analysis (Chiralcel ADH, 25 cm x 4.6 mm, 4% IPA/Hexanes, 1.00 mL/min, λ 205 nm, 




dioxide (Table 4.4, entry 2). The general procedure 5 was employed for the coupling of 
N-benzyl-N’-benzyl-N-(2-methylpent-4-en-2-yl)sulfamide (72.0 mg, 0.20 mmol) and 2-
bromonapthalene (83 mg, 0.40 mmol) using a catalyst composed of Pd2(dba)3 (1.8 mg, 
0.002 mmol) and (S)-SIPHOS-PE (5.1 mg, 0.010 mmol), sodium tert-butoxide (38.0 mg, 
0.40 mmol), a reaction temperature of 120 °C, and a reaction time of 18 h in 1.6 mL of 
xylenes. This procedure afforded the title compound (72 mg, 74%) as a colorless solid, 
168–172 °C: [α]23D -43 (c 1.7, CH2Cl2); 1H NMR (500 MHz, CDCl3)  7.81–7.77 (m, 1H), 
7.75–7.70 (m, 2H), 7.48–7.41 (m, 7H), 7.35–7.28 (m, 4H), 7.25–7.19 (m, 2H), 4.75 (d, J 
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= 15.8 Hz, 1H), 4.64 (d, J = 16.8 Hz, 1H), 4.51 (dddd, J = 12.6, 10.0, 4.8, 2.8 Hz, 1H), 
4.35 (d, J = 15.8 Hz, 1H), 4.14 (d, J = 16.8 Hz, 1H), 3.05 (dd, J = 13.5, 4.8 Hz, 1H), 2.73 
(dd, J = 13.6, 10.2 Hz, 1H), 2.08 (dd, J = 14.3, 12.2 Hz, 1H), 1.41 (dd, J = 14.4, 2.9 Hz, 
1H), 1.26 (s, 3H), 1.11 (s, 3H); 13C NMR (125 MHz, CDCl3)  140.4, 138.4, 134.9, 
133.6, 132.5, 128.6, 128.6, 128.5, 128.1, 128.0, 127.8, 127.7, 127.6, 127.5, 127.2, 
127.2, 126.3, 125.8, 60.5, 57.4, 50.2, 45.8, 41.1, 38.8, 31.0, 22.9; IR (neat) 1495, 1452, 
1331, 1151, 1136 cm-1. MS (ESI+) 485.2260 (485.2257 calcd for C30H32N2O2S, M + H+). 
The enantiopurity was determined to be 96.5:3.5 er by chiral HPLC analysis (Chiralcel 




dioxide (Table 4.4, entry 5). The general procedure 5 was employed for the coupling of 
N-benzyl-N’-benzyl-N-(2-methylpent-4-en-2-yl)sulfamide (72.0 mg, 0.20 mmol) and 4-
bromobenzotrifluoride (56 μL, 0.40 mmol) using a catalyst composed of Pd2(dba)3 (1.8 
mg, 0.001 mmol) and (S)-SIPHOS-PE (5.1 mg, 0.010 mmol), sodium tert-butoxide (38.0 
mg, 0.40 mmol), a reaction temperature of 120 °C, and a reaction time of 18 h in 1.6 mL 
of xylenes. This procedure afforded the title compound (74 mg, 73%) as a colorless 
solid, mp 159–161 °C: [α]23D -77 (c 1.5, CH2Cl2); 1H NMR (400 MHz, CDCl3)  7.44 (dd, 
J = 11.0, 7.8 Hz, 4H), 7.36–7.20 (m, 8H), 7.12 (d, J = 8.0 Hz, 2H), 4.64 (t, J = 16.3 Hz, 
2H), 4.42 (dddd, J = 12.0, 9.1, 6.1, 3.1 Hz, 1H), 4.31 (d, J = 15.8 Hz, 1H), 4.18 (d, J = 
16.8 Hz, 1H), 2.92 (dd, J = 14.0, 6.1 Hz, 1H), 2.68 (dd, J = 14.0, 9.0 Hz, 1H), 2.09 (dd, J 
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= 14.3, 11.9 Hz, 1H), 1.41 (dd, J = 14.3, 3.1 Hz, 1H), 1.32 (s, 3H), 1.16 (s, 3H); 13C 
NMR (176 MHz, CDCl3)  141.4, 140.2, 137.8, 129.4, 129.1 (q, JCF = 31.7 Hz), 128.6, 
128.6, 128.1, 127.6, 127.4, 127.2, 125.6 (q, JCF = 3.5 Hz), 124.3 (q, JCF = 272.8 Hz), 
60.4, 56.9, 50.4, 45.8, 40.5, 39.0, 30.7, 23.4; 19F NMR (377 MHz, CDCl3)  –62.54; IR 
(neat) 1495, 1452, 1328, 1154, 1136 cm-1. MS (ESI+) 503.1977 (503.1975 calcd for 
C27H29F3N2O2S, M + H+). The enantiopurity was determined to be 96.5:3.5 er by chiral 
HPLC analysis (Chiralcel ODH, 15 cm x 4.6 mm, 4% IPA/Hexanes, 0.50 mL/min, λ 210 
nm, RT= 15.6 and 17.9 min). 
 
(S)-2,6-dibenzyl-5-(4-fluorobenzyl)-3,3-dimethyl-1,2,6-thiadiazinane 1,1-dioxide 
(Table 4.4, entry 6). The general procedure 5 was employed for the coupling of N-
benzyl-N’-benzyl-N-(2-methylpent-4-en-2-yl)sulfamide (72.0 mg, 0.20 mmol) and 1-
bromo-4-fluorobenzene (44 μL, 0.40 mmol) using a catalyst composed of Pd2(dba)3 (1.8 
mg, 0.001 mmol) and (S)-SIPHOS-PE (5.1 mg, 0.010 mmol), sodium tert-butoxide (38.0 
mg, 0.40 mmol), a reaction temperature of 120 °C, and a reaction time of 18 h in 1.6 mL 
of xylenes. This procedure afforded the title compound (82 mg, 91%) as a colorless 
solid, mp 132–133 °C: [α]23D -68 (c 1.7, CH2Cl2); 1H NMR (500 MHz, CDCl3)  7.42 (d, J 
= 7.2 Hz, 2H), 7.39 (d, J = 7.1 Hz, 2H), 7.28–7.35 (m, 4H), 7.27–7.22 (m, 2H), 7.02–
6.96 (m, 2H), 6.91 (t, J = 8.6 Hz, 2H), 4.69 (d, J = 15.8 Hz, 1H), 4.63 (d, J = 16.8 Hz, 
1H), 4.36 (dddd, J = 12.3, 8.8, 5.3, 2.9 Hz, 1H), 4.28 (d, J = 15.8 Hz, 1H), 4.15 (d, J = 
16.8 Hz, 1H), 2.84 (dd, J = 13.8, 5.4 Hz, 1H), 2.56 (dd, J = 13.9, 9.6 Hz, 1H), 2.04 (dd, J 
= 14.3, 12.1 Hz, 1H), 1.39 (dd, J = 14.3, 2.9 Hz, 1H), 1.30 (s, 3H), 1.14 (s, 3H); 13C 
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NMR (125 MHz, CDCl3)  161.8 (d, 243.8 Hz), 140.30, 138.16, 133.0 (d, JCF = 3.8 Hz), 
130.5 (d, JCF = 7.5 Hz), 128.60, 128.55, 128.1, 127.6, 127.4, 127.2, 115.56 (d, JCF = 
21.2 Hz), 60.4, 57.3, 50.2, 45.8, 39.9, 38.8, 30.9, 23.1; 19F NMR (471 MHz, CDCl3)  –
116.35– –116.21 (m); IR (neat) 1495, 1452, 1330, 1153, 1137 cm-1. MS (ESI+) 
453.2007 (453.2007 calcd for C26H29FN2O2S, M + H+). The enantiopurity was 
determined to be 96.5:3.5 er by chiral HPLC analysis (Chiralcel ODH, 15 cm x 4.6 mm, 
4% IPA/Hexanes, 0.50 mL/min, λ 210 nm, RT= 16.1 and 17.7 min). 
 
2,6-dibenzyl-5-(4-chlorobenzyl)-3,3-dimethyl-1,2,6-thiadiazinane 1,1-dioxide (Table 
4.4, entry 8). The general procedure 5 was employed for the coupling of N-benzyl-N’-
benzyl-N-(2-methylpent-4-en-2-yl)sulfamide (72.0 mg, 0.20 mmol) and 1-bromo-4-
chlorobenzene (77 mg, 0.4 mmol) using a catalyst composed of Pd2(dba)3 (1.8 mg, 
0.002 mmol) and (S)-SIPHOS-PE (5.1 mg, 0.010 mmol), sodium tert-butoxide (38.0 mg, 
0.60 mmol), a reaction temperature of 120 °C, and a reaction time of 18 h in 1.6 mL of 
xylenes. This procedure afforded the title compound (72 mg, 77%) as a colorless solid, 
mp 145–148 °C: [α]23D -80 (c 1.5, CH2Cl2); 1H NMR (500 MHz, CDCl3)  7.45–7.40 (m, 
2H), 7.38 (d, J = 7.0 Hz, 2H), 7.31 (ddd, J = 9.8, 8.4, 6.7 Hz, 4H), 7.27–7.22 (m, 2H), 
7.20–7.16 (m, 2H), 6.98–6.94 (m, 2H), 4.69 (d, J = 15.8 Hz, 1H), 4.63 (d, J = 16.8 Hz, 
1H), 4.36 (dddd, J = 12.3, 8.8, 5.4, 2.9 Hz, 1H), 4.28 (d, J = 15.8 Hz, 1H), 4.15 (d, J = 
16.8 Hz, 1H), 2.84 (dd, J = 13.8, 5.4 Hz, 1H), 2.56 (dd, J = 13.9, 9.5 Hz, 1H), 2.04 (dd, J 
= 14.3, 12.1 Hz, 1H), 1.38 (dd, J = 14.3, 3.0 Hz, 1H), 1.30 (s, 3H), 1.14 (s, 3H), contains 
5-10% of an inseparable impurity; 13C NMR (125 MHz, CDCl3)  140.3, 138.1, 135.8, 
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132.6, 130.4, 128.9, 128.6, 128.6, 128.0, 127.6, 127.4, 127.2, 60.4, 57.1, 50.2, 45.7, 
40.1, 38.7, 30.9, 23.1.; IR (neat) 1493, 1452, 1320, 1136 cm-1. MS (ESI+) 469.1710 
(469.1711 calcd for C26H29ClN2O2S, M + H+). The enantiopurity was determined to be 
97:3 er by chiral HPLC analysis (Chiralcel ADH, 15 cm x 4.6 mm, 4% IPA/Hexanes, 1.0 




dioxide (Table 4.4, entry 9). The general procedure 5 was employed for the coupling of 
N-benzyl-N’-benzyl-N-(3-ethylhex-5-en-3-yl)sulfamide (77.0 mg, 0.20 mmol) and 1-
bromonapthalene (56 μL, 0.40 mmol) using a catalyst composed of Pd2(dba)3 (1.8 mg, 
0.002 mmol) and (S)-SIPHOS-PE (5.1 mg, 0.010 mmol), sodium tert-butoxide (38.0 mg, 
0.40 mmol), a reaction temperature of 120 °C, and a reaction time of 18 h in 1.6 mL of 
xylenes. This procedure afforded the title compound (89 mg, 86%) as a colorless solid, 
mp 58–62 °C: [α]23D -59 (c 2.2, CH2Cl2); 1H NMR (500 MHz, CDCl3)  7.82–7.78 (m, 
1H), 7.70 (d, J = 8.2 Hz, 1H), 7.61–7.57 (m, 2H), 7.51 (d, J = 7.4 Hz, 2H), 7.48–7.40 (m, 
4H), 7.40–7.35 (m, 2H), 7.34–7.28 (m, 3H), 7.27–7.22 (m, 2H), 4.59 (d, J = 15.1 Hz, 
1H), 4.51 (d, J = 15.1 Hz, 1H), 4.47 (d, J = 16.6 Hz, 1H), 4.36 (d, J = 16.6 Hz, 1H), 4.15 
(ddt, J = 14.4, 9.4, 4.3 Hz, 1H), 3.34 (dd, J = 13.7, 4.6 Hz, 1H), 3.08 (dd, J = 13.7, 10.0 
Hz, 1H), 2.35 (dd, J = 14.9, 12.1 Hz, 1H), 1.67 (dq, J = 15.1, 7.6 Hz, 1H), 1.60–1.37 (m, 
3H), 1.31 (dd, J = 15.0, 4.1 Hz, 1H), 0.70 (t, J = 7.3 Hz, 3H), 0.35 (t, J = 7.5 Hz, 3H); 13C 
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NMR (125 MHz, CDCl3)  140.1, 137.8, 134.0, 133.7, 131.9, 129.0, 128.8, 128.8, 128.5, 
128.1, 127.9, 127.6, 127.6, 127.2, 126.3, 125.8, 125.5, 123.6, 66.0, 56.3, 52.8, 46.2, 
39.2, 30.5, 29.4, 29.0, 9.2, 7.9.; IR (neat) 1495, 1454, 1331, 1153 cm-1. MS (ESI+) 
513.2572 (513.2570 calcd for C32H36N2O2S, M + H+). The enantiopurity was determined 
to be 95:5 er by chiral HPLC analysis (Chiralcel ODH, 15 cm x 4.6 mm, 2% 
IPA/Hexanes, 0.75 mL/min, λ 210 nm, RT= 17.1 and 20.2min). 
 
(S)-1,3-dibenzyl-4-(3-(trifluoromethyl)benzyl)-2-thia-1,3-diazaspiro[5.5]undecane 
2,2-dioxide (Table 4.4, entry 11). The general procedure 5 was employed for the 
coupling of N-Benzyl-N’-benzyl-N-(1-allylcyclohexyl)sulfamide (80.0 mg, 0.20 mmol) and 
3-bromobenzotrifluoride (56 μL, 0.40 mmol) using a catalyst composed of Pd2(dba)3 
(1.8 mg, 0.002 mmol) and (S)-SIPHOS-PE (5.1 mg, 0.010 mmol), sodium tert-butoxide 
(38.0 mg, 0.40 mmol), a reaction temperature of 120 °C, and a reaction time of 18 h in 
1.6 mL of xylenes. This procedure afforded the title compound (98 mg, 90%) as a 
colorless solid, mp 119–121 °C: [α]23D -70 (c 1.6, CH2Cl2); 1H NMR (500 MHz, CDCl3)  
7.46–7.39 (m, 3H), 7.38–7.20 (m, 11H), 4.68 (d, J = 2.5 Hz, 1H), 4.65 (d, J = 4.7 Hz, 
1H), 4.37–4.25 (m, 3H), 2.95 (dd, J = 14.0, 5.7 Hz, 1H), 2.69 (dd, J = 14.0, 9.2 Hz, 1H), 
2.17 (d, J = 11.7 Hz, 1H), 2.06 (dd, J = 14.6, 3.0 Hz, 1H), 1.83 (t, J = 13.2 Hz, 1H), 
1.65–1.42 (m, 6H), 1.18 (q, J = 13.0 Hz, 1H), 1.00 (q, J = 13.0 Hz, 1H), 0.83 (q, J = 12.8 
Hz, 1H); 13C NMR (125 MHz, CDCl3)  140.5, 138.5, 137.8, 132.3, 130.96 (q, J = 32.5 
Hz), 129.18, 128.6, 128.5, 128.1, 127.7, 127.1, 125.78 (q, J = 3.75 Hz), 124.14 (q, J = 
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270 Hz), 123.70 (q, J = 3.75 Hz), 63.9, 56.6, 50.7, 44.9, 40.5, 38.1, 31.1, 29.80, 25.3, 
22.9, 22.6, 1 carbon signal is missing due to incidental equivalence; 19F NMR (471 MHz, 
CDCl3)  –62.65 (s); IR (neat) 1495, 1453, 1327, 1154, 1116, 1074 cm-1. MS (ESI+) 
543.2292 (543.2288 calcd for C30H33F3N2O2S, M + H+). The enantiopurity was 
determined to be 96.5:3.5 er by chiral HPLC analysis (Chiralcel ADH, 25 cm x 4.6 mm, 
6% IPA/Hexanes, 1.0 mL/min, λ 210 nm, RT= 15.4 and 18.9 min). 
 
(S)-1,3-dibenzyl-4-(3-(4-fluorophenoxy)benzyl)-2-thia-1,3-diazaspiro[5.5]undecane 
2,2-dioxide (Table 4.4, entry 12). The general procedure 5 was employed for the 
coupling of N-Benzyl-N’-benzyl-N-(1-allylcyclohexyl)sulfamide (80.0 mg, 0.20 mmol) and 
3-Bromo-4′-fluorodiphenyl ether (107 mg, 0.40 mmol) using a catalyst composed of 
Pd2(dba)3 (1.8 mg, 0.002 mmol) and (S)-SIPHOS-PE (5.1 mg, 0.010 mmol), sodium 
tert-butoxide (38.0 mg, 0.40 mmol), a reaction temperature of 120 °C, and a reaction 
time of 18 h in 1.6 mL of xylenes. This procedure afforded the title compound (98 mg, 
84%) as a colorless solid, mp 122–125 °C: [α]23D -65 (c 1.6, CH2Cl2); 1H NMR (700 
MHz, CDCl3)  7.43–7.38 (m, 4H), 7.34–7.28 (m, 4H), 7.26–7.20 (m, 3H), 7.04–6.99 (m, 
2H), 6.92–6.88 (m, 2H), 6.85–6.81 (m, 2H), 6.67 (t, J = 2.0 Hz, 1H), 4.67 (dd, J = 16.5, 
11.7 Hz, 2H), 4.31 (d, J = 15.7 Hz, 1H), 4.28–4.21 (m, 2H), 2.86 (dd, J = 13.6, 4.9 Hz, 
1H), 2.57 (dd, J = 13.6, 10.0 Hz, 1H), 2.20–2.14 (m, 1H), 2.07 (dd, J = 14.6, 2.9 Hz, 
1H), 1.74 (t, J = 14.1 Hz, 1H), 1.63–1.47 (m, 5H), 1.41 (d, J = 13.1 Hz, 1H), 1.17 (qt, J = 
13.4, 3.7 Hz, 1H), 1.02 (qt, J = 13.8, 4.0 Hz, 1H), 0.84 (qt, J = 13.4, 4.6 Hz, 1H); 13C 
NMR (176 MHz, CDCl3)  158.9 (d, JCF = 242.9 Hz), 157.9, 153.05 (d, JCF = 3.5 Hz), 
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140.6, 139.6, 138.2, 130.1, 128.6, 128.5, 128.1, 127.5, 127.1, 127.0, 124.0, 120.45 (d, 
JCF = 8.8 Hz), 119.1, 117.0, 116.5 (d, JCF = 22.9 Hz), 63.8, 56.8, 50.4, 44.9, 40.7, 38.2, 
31.0, 29.5, 25.3, 23.0, 22.6; 19F NMR (471 MHz, CDCl3)  –120.00– –120.07 (m); IR 
(neat) 1497, 1441, 1330, 1198, 1157, 1110 cm-1. MS (ESI+) 585.2582 (585.2582 calcd 
for C35H37FN2O3S, M + H+). The enantiopurity was determined to be 95.5:4.5 er by 
chiral HPLC analysis (Chiralcel ADH, 25 cm x 4.6 mm, 6% IPA/Hexanes, 1.0 mL/min, λ 
210 nm, RT= 24.6 and 33.5 min). 
 
(S)-1,3-dibenzyl-4-(3-methoxybenzyl)-2-thia-1,3-diazaspiro[5.5]undecane 2,2-
dioxide (Table 4.4, entry 13). The general procedure 5 was employed for the coupling 
of N-Benzyl-N’-benzyl-N-(1-allylcyclohexyl)sulfamide (80.0 mg, 0.20 mmol) and 3-
bromoanisole (51 μL, 0.40 mmol) using a catalyst composed of Pd2(dba)3 (1.8 mg, 
0.002 mmol) and (S)-SIPHOS-PE (5.1 mg, 0.010 mmol), sodium tert-butoxide (38.0 mg, 
0.40 mmol), a reaction temperature of 120 °C, and a reaction time of 18 h in 1.6 mL of 
xylenes. This procedure afforded the title compound (89 mg, 88%) as a colorless solid, 
mp 141–144 °C: [α]23D -52 (c 1.9, CH2Cl2); 1H NMR (400 MHz, CDCl3)  7.43 (d, J = 7.5 
Hz, 1H), 7.32 (t, J = 7.6 Hz, 1H), 7.24 (q, J = 7.1 Hz, 0H), 7.17 (t, J = 7.9 Hz, 0H), 6.74 
(dd, J = 8.2, 2.5 Hz, 0H), 6.70 – 6.66 (m, 0H), 6.60 (t, J = 2.0 Hz, 0H), 4.68 (dd, J = 
16.4, 13.1 Hz, 0H), 4.29 (dd, J = 30.4, 16.6 Hz, 1H), 3.76 (s, 1H), 2.89 (dd, J = 13.5, 4.6 
Hz, 1H), 2.58 (dd, J = 13.5, 10.3 Hz, 1H), 2.18 (d, J = 12.2 Hz, 1H), 2.09 (dd, J = 14.6, 
2.6 Hz, 1H), 1.74 (t, J = 12.0 Hz 1H), 1.65–1.36 (m, 6H), 1.24–1.08 (m, 1H), 1.07–0.91 
(m, 1H), 0.90–0.73 (m, 1H); 13C NMR (100 MHz, CDCl3)  159.9, 140.7, 139.1, 138.4, 
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129.7, 128.6, 128.5, 128.1, 127.5, 127.1, 127.0, 121.4, 114.6, 112.5, 63.9, 56.9, 55.4, 
50.4, 44.9, 41.0, 38.2, 31.1, 29.5, 25.3, 22.9, 22.6; IR (neat) 1584, 1496, 1452, 1327, 
1150, 1111 cm-1. MS (ESI+) 505.2523 (505.2519 calcd for C30H36N2O3S, M + H+). The 
enantiopurity was determined to be 97:3 er by chiral HPLC analysis (Chiralcel ADH, 25 
cm x 4.6 mm, 6% IPA/Hexanes, 1.0 mL/min, λ 210 nm, RT= 32.5 and 35.2 min). 
 
Determination Of Absolute Configuration for 6-Membered Cyclic Sulfamides 
The absolute configuration is currently under investigation. The following reaction 









(2S,5R)-2,5-diallyl-N-(4-methoxybenzyl)pyrrolidine-1-sulfonamide (4-47). The title 
compound was prepared by employing the following two-step procedure. A round-
bottom flask equipped with a stir bar was charged with (±)-(E,2R*,5S*)-tert-butyl 2-allyl-
5-[3-(trimethylsilyl)allyl]pyrrolidine-1-carboxylate (1.94 g, 6 mmol) and dichloroethane 
(30 mL, 0.2 M). Trifluoroacetic acid (6 mL, 1.0 M) was added to the flask and the 
mixture was stirred at reflux overnight. The solution was then concentrated in vacuo. 
Toluene was added and the resulting solution was concentrated in vacuo to remove any 
excess TFA. The crude amine (TFA salt) was used without additional purification. 
A separate flame dried flask was charged with N-(4-methoxybenzyl)-2-
oxooxazolidine-3-sulfonamide (1.89 g, 6.6 mmol), 4-dimethylaminopyridine (147 mg, 1.2 
mmol), and a stirbar, then was evacuated and backfilledwith N2. Acetonitrile (24 mL) 
was added, followed by Et3N (2.3 mL, 16.5 mmol)), and then the reaction vessel was 
placed in an oil bath at 75 °C. The appropriate amine TFA salt as prepared above was 
added and the resulting mixture was stirred at 75 °C overnight (approximately 16 
hours). The mixture was cooled to rt, solvent was removed via rotary evaporation, and 
the residue was partitioned between CH2Cl2 and 1 M HCl. The aqueous layer was 
extracted with CH2Cl2 and the combined organic layers were washed with brine and 
dried over anhydrous Na2SO4. Solvent was removed in vacuo, and the resulting residue 
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was purified by flash chromatography on silica gel. This procedure afforded the title 
compound (1.58 g, 75%) as a yellow oil: 1H NMR (500 MHz, CDCl3)  7.25 (d, J = 7.4 
Hz, 2H), 6.88 (d, J = 8.7 Hz, 2H), 5.78 (ddt, J = 17.2, 10.2, 7.1 Hz, 2H), 5.12–5.03 (m, 
4H), 4.23 (s, 1H), 4.18 (s, 2H), 3.90–3.82 (m, 2H), 3.80 (s, 3H), 2.55 (dddd, J = 12.4, 





b][1,2,6]thiadiazine 1,1-dioxide (4-48). An oven-dried test tube was cooled under a 
stream of nitrogen and charged with (2S,5R)-2,5-diallyl-N-(4-methoxybenzyl)pyrrolidine-
1-sulfonamide, Pd(OAc)2 (0.9 mg, 4 mol%), chiral ligand (4 mol%), phenyl triflate (45 
mg, 0.2 mmol), and LiOtBu (16 mg, 0.5 mmol). The tube was purged with nitrogen, then 
either tBuOH or PhCF3 (1 mL, 0.25 M) was added via syringe. The mixture was heated 
to 82 °C or 100 °C with stirring for 16 h. The reaction mixture was cooled to room 
temperature, quenched with saturated aqueous NH4Cl (1 ml) and diluted with EtOAc (5 
ml). The layers were separated and the aqueous layer was extracted with EtOAc (2 x 5 
ml). The combined organic layers were dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo. The crude product was purified by flash chromatography on 
silica gel to afford the title compound as a pale yellow oil: 1H NMR (500 MHz, CDCl3)  
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7.31 (d, J = 8.4 Hz, 2H), 7.25–7.22 (m, 2H), 7.22–7.17 (m, 1H), 7.11–7.07 (m, 2H), 6.83 
(d, J = 8.7 Hz, 2H), 5.80 (ddt, J = 17.3, 10.2, 7.0 Hz, 1H), 5.14–5.05 (m, 2H), 4.54 (d, J 
= 16.3 Hz, 1H), 4.28 (td, J = 11.4, 10.3, 4.2 Hz, 1H), 3.94 (d, J = 16.4 Hz, 1H), 3.78 (s, 
3H), 3.74 (dq, J = 8.8, 4.8, 4.0 Hz, 1H), 3.25 (ddt, J = 11.3, 4.9, 3.4 Hz, 1H), 2.89 (dd, J 
= 13.4, 4.5 Hz, 1H), 2.64–2.57 (m, 1H), 2.54 (dd, J = 13.4, 10.7 Hz, 1H), 2.44–2.36 (m, 
1H), 1.91–1.79 (m, 2H), 1.71–1.63 (m, 2H), 1.51–1.40 (m, 2H). The enantiomeric 
excess for compounds in Scheme 4.13 and Scheme 4.15 were determined by chiral 
HPLC analysis (Chiralcel ADH, 0.46 cm x 25 cm, 10% iPrOH/hexanes, 0.8 mL/min, RT 
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Synthesis of Cyclic Ethers Via Metal-Catalyzed  
Alkene Difunctionalization Reactions 
 
5.1 Background 
 New catalytic reactions which functionalize olefins have been extensively 
targeted for the development of oxidation, hydroformylation, and polymerization 
reactions. For example, the venerable Wacker oxidation functionalizes an olefin by 
oxidation in the presence of water and a Pd catalyst.1 Transition metal catalysis remains 
a powerful area of organic chemistry for the expedient formation of new carbon-carbon 
bonds and carbon-heteroatom bonds. 
 





Efforts in transition metal catalysis towards the synthesis of cyclic ethers is also 
an important area of research because cyclic ethers are commonly occurring elements 
in natural products and biologically active molecules. Specifically, cyclic ether 
substructures can be found in lignans, polyether ionophores, macrodiolides, and marine 
polyether terpenes.2 The synthesis of tetrahydrofurans has been reviewed previously.3 
In the chapter below, several recent developments in the synthesis of tetrahydrofurans 
(5-membered cyclic ethers), as well as other cyclic ethers, are described. This summary 
is not meant to be comprehensive, but instead will give a flavor of the current research 
in the functionalization of olefins by carboalkoxylation reactions. 
 
5.2 Metal-Catalyzed Carboalkoxylation of Olefins 
The Pd-catalyzed carboalkoxylation reaction of olefins tethered to an olefin has 
been widely investigated by the Wolfe group.4 Building off pioneering reports by 
Semmelhack,5 Wolfe and coworkers reported the first carboalkoxylation reaction in 
2004 which achieves carbon-oxygen bond formation along with sp3 carbon-sp2 carbon 
bond formation.4a Since then, the substrate scope of this reaction has broadened to 
include new syntheses of isoxazolidines, attached-ring bis-tetrahydrofurans, 2-indan-1-
yltetrahydrofuran, and chromans as shown in Scheme 5.1. Many of these reactions 
undergo a key syn-oxypalladation step which enables the products to be obtained in 
high diastereoselectivity.  
The expansion and improvement of substrate scope for this reaction has required 
the invention of new catalysts. For example, initial carboalkoxylation reactions of 1,2-
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trans substituted alkenes unveiled a deleterious mechanistic pathway (reversible β-
hydride elimination/insertion) which scrambled the stereocenters that were formed. This 
resulted in low diastereoselectivity. Therefore, the invention of a new catalyst (shown in 
Scheme 5.1 using SPhos as ligand at elevated temperatures) was required for 
achieving carboalkoxylation reactions with high diastereoselectivity. Continued 
improvements to carboalkoxylation reactions will require the development of new 
catalysts and ligands. 
   





A copper-catalyzed synthesis of fused-ring and bridged-ring tetrahydrofurans by 
intramolecular carboetherification was demonstrated by Chemler and coworkers 
(Scheme 5.2).6 The reaction proceeds by initial syn-oxycupration followed by homolytic 
cleavage of the akyl-cuprate to form a primary radical. The radical rapidly undergoes 
intramolecular addition to a tethered aryl ring. After further oxidation, the new polycyclic 
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tetrahydrofuran is formed. The reaction proceeds in good yields for a variety of different 
heterocycles, although the diastereoselectivity is modest at best.  
 
Scheme 5.2 Cu-Catalyzed Carboalkoxylation Reactions 
 
 
 A novel Pd-catalyzed sequence for the synthesis of amino alcohols has been 
recently developed by Waser and coworkers (Scheme 5.3).7 This reaction describes a 
new strategy which uses 5-11 as a nucleophilic tether which enables the 
carboetherification reaction. The reaction is tolerant of a wide variety of electrophiles 
and allylamines, although different ligands were required for optimal results depending 
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on electrophile and allylamine. Notably, the reaction proceeds in >20:1 dr for the 
synthesis of 5-12-2 which is derived from a 1,1-disubstituted alkene. The reaction has 
yet to be rendered enantioselective, although an asymmetric variant of this strategy 
would be a welcome addition to this field. The amino alcohols are useful compounds 
because they contain orthogonally protected functional groups which can be unveiled by 
further manipulation. 
 
Scheme 5.3 One-Pot Pd-Catalyzed Alkoxylation Reaction 




Recent work from the Dai group has provided a new Pd-catalyzed 
alkoxycarbonylative macrolactonization reaction (Scheme 5.4).8 Many important 
macrocyclic compounds contain tetrahydropyran and tetrahydrofuran components 
embedded within the macrocycle. As such, a new alkene difunctionalization reaction 
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which achieves both cyclic ether formation and macrocycle formation in one step is an 
attractive disconnection to target. The Dai group has found that use of Pd(OAc)2 as a 
catalyst in the presence of carbon monoxide and 3 equiv of copper (II) chloride can 
achieve this lofty goal. The reaction is competent for the formation of a variety of 
macrocycles with good yield and moderate diastereoselectivity. Different size 
macrocycles can be formed, and the backbone of the macrocycle can contain different 
functional groups like phenol ethers or olefins.  
 
Scheme 5.4 Pd-Catalyzed Alkoxylation/Carbonylation for the  






While carboalkoxylation reactions have been developed in many instances for 
racemic transformations, asymmetric reactions are also needed. Described in the 
upcoming section are the recent efforts towards this end. 
 
5.3 Asymmetric Metal-Catalyzed Carboalkoxylation of Olefins 
 The use of chiral catalysts for the asymmetric functionalization of olefins is an 
important area of research because unsaturated functional groups are especially 
situated for forging new carbon-carbon and carbon-heteroatom bonds. In addition, 
enantiopure compounds are highly desirable compounds in the pharmaceutical industry 
because only one enantiomer is therapeutically relevant (and sometimes the other 
exhibits dangerous properties). The topic of asymmetric Pd-catalyzed functionalization 
of olefins has been reviewed before,9 and described below are a few examples of 
recent developments in enantioselective metal-catalyzed carboalkoxylation reactions.  
Sigman expanded the scope of nucleophiles for enantioselective 
difunctionalization reactions developed in their lab10 by examining indole as a 
nucleophile.11 High levels of enantioselectivity are obtained by the use of iPrQuinox as a 
ligand. As shown in Scheme 5.5, different substituted indoles and pyrroles can be 
utilized in this reaction to obtain enantiomeric ratios up to 98:2. Perhaps the only 
unsatisfactory aspect of this reaction is the use of 15 equiv of nucleophile. The reaction 
proceeds through an intermediate quinone methide that is generated by intramolecular 
nucleopalladation with Pd(II). The quinone methide is trapped by the indole via 
electrophilic aromatic substitution (EAS) and ultimately re-aromatized by deprotonation 
to form the difunctionalized products. This reaction is also unique in that the Pd catalyst 
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is only used to build the carbon-oxygen bond, and not both bonds, during the course of 
the functionalization of the olefin. In this regard, without the phenol, it is unlikely that this 
reaction would be operative. 
 




 The Chemler group recently demonstrated the first asymmetric 
carboetherification reaction of unactivated alkenes using a chiral copper catalyst 
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(Scheme 5.6).12 The reaction is successful with 20 mol% copper(II) triflate and 25 mol% 
(S,S)-tBu-box ligand, and it likely proceeds through radical intermediates akin to the 
other transformations developed by the Chemler group.6 The radical nature of the 
reaction also explains the use of radical acceptors derived from styrene and its 
derivatives for functionalizing the olefin by formation of a new carbon-carbon bond. The 
high enantioselectivity imparted by the chiral catalyst is achieved because of the 
concerted syn-alkoxycupration step in which the alkoxy-cuprate adds in a concerted 
fashion across the double bond. After this occurs, homolytic cleavage produces a 
primary radical which can add intramolecularly to tethered aryl rings or intermolecularly 
to radicalphiles in solution. 
 





 Recently, Tang and coworkers utilized a new Pd catalyst with a P-chiral ligand to 
perform asymmetric carboalkoylation reactions for the synthesis of chromans and 1,4-
dioxanes (Scheme 5.7).13 High levels of enantio-induction were achieved with ligand 5-
30 at 60 °C with hexafluorobenzene solvent. Importantly, hexafluorobenzene solvent 
was required for achieving greater than 90:10 er. The reaction performs most efficiently 
for 1,1-disubstituted alkenes due to competing formation of undesired Heck arylation 
products which the authors isolate and identify in this work. The reaction proceeds in up 
to 97.5:2.5 er and up to 85% yield. The synthesis of chromans like 5-29-3 suffered from 
lower enantioselectivity suggesting that the heteroatom in the backbone is important for 
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high enantio-induction. Also, cyclization to form benzofurans was achieved albeit in low 
enantioselectivity (57.5:42.5 er, not shown).   
 
Scheme 5.7 Asymmetric Pd-Catalyzed Synthesis of 1,4-Dioxanes and Chromans 
 
 
 A novel Pd-catalyzed intermolecular carboetherification of dihydrofurans was 
developed by Mazet and coworkers (Table 5.1).14 This unique reaction differs from 
many of the reactions described above in that the electrophile is tethered to the 
nucleophile, a strategy reminiscent of the Larock indole synthesis.15 The reaction can be 
accomplished asymmetrically using chiral ligand 5-34 which is generated in situ with the 
addition of water. The reaction achieves the synthesis of a variety of fused 
tetrahydrofurobenzofurans in excellent dr (>20:1 dr) and good enantiomeric excess (up 
to 97% ee).   
 






5.4 Conclusion  
Despite remarkable developments in the synthesis of cyclic ethers, only recently 
has the synthetic community been able to invent catalysts which achieve asymmetric 
carboalkoxylation reactions of unactivated alkenes. Beginning with the work of the 
Chemler group in 2014, the synthetic community has witnessed several unique 
contributions to the field of asymmetric alkene difunctionalization reactions including the 
work described in the next chapter. The next chapter describes the development of a 
new chiral TADDOL phosphite ligand which enables the carboalkoxylation of olefins 






(1)  Jira, R. Angew. Chem. Int. Ed. 2009, 48, 9034. 
(2)  (a) Saleem, M.; Kim, H. J.; Ali, M. S.; Lee, Y. S. Nat. Prod. Rep. 2005, 696; (b) 
Faul, M. M.; Huff, B. E. Chem. Rev. 2000, 100, 2407; (c) Kang, E. J.; Lee, E. 
Chem. Rev. 2005, 105, 4348; (d) Fernández, J.J.; Souto, M.L.; Norte, M. Nat. 
Prod. Rep. 2000, 17, 235. 
(3)  Wolfe, J.P.; Hay, M.B. Tetrahedron, 2007, 63, 261. 
(4)  (a) Wolfe, J.P.; Rossi, M.A. J. Am. Chem. Soc. 2004, 126, 1620; (b) Hay, M.R.; 
Hardin, A. R.; Wolfe, J.P. J. Org. Chem. 2005, 70, 3099; (c) Hay, M.R.; Wolfe, 
J.P. J. Am. Chem. Soc. 2005, 127, 16468; (d) Hay, M.R.; Wolfe, J.P. 
Tetrahedron Lett. 2006, 47, 2793; (e) Nakhla, J.S.; Kampf, J.W.; Wolfe, J.P. J. 
Am. Chem. Soc. 2006, 128, 2893; (f) Hay, M.R.; Wolfe, J.P. Angew. Chem. Int. 
Ed. 2007, 46, 6492; (g) Lemen, G.S.; Giampietro, N.C.; Hay, M.B.; Wolfe J.P. J. 
Org. Chem. 2009, 74, 2533; (h) Ward, A.F. Wolfe, J.P. Org. Lett. 2010, 12, 1268; 
(i) Ward, A.F.; Xu, Y.; Wolfe, J.P. Chem. Commun. 2012, 48, 609. 
(5)  (a) Semmelhack, M. F.; Bodurow, C. J. Am. Chem. Soc. 1984, 106, 1496; (b) 
Semmelhack, M. F.; Kim, C.; Zhang, N.; Bodurow, C.; Sanner, M.; Dobler, W.; 
Meier, M. Pure Appl. Chem. 1990, 62, 2035; (c) Semmelhack, M. F.; Epa, W. R. 
Tetrahedron Lett. 1993, 34, 7205; (d) Mikami, K.; Shimizu, M. Tetrahedron, 1996, 
52, 7287. 





(7)  Orcel, U.; Waser, J. Angew. Chem. 2015, 127, 5339; Angew. Chem. Int. Ed. 
2015, 54, 5250. 
(8)  Bai, Y.; Davis, D.C.; Dai, M. Angew. Chem. 2015, 126, 6637; Bai, Y.; Davis, 
D.C.; Dai, M. Angew. Chem. Int. Ed. 2014, 53, 6519. 
(9)  (a) McDonald, R.I.; Liu, G.; Stahl, S.S. Chem. Rev. 2011, 111, 2981; (b) Sun, Y.-
w.; Zhu, P.-l.; Xu, Q.; Shi, M. RSC Adv. 2013, 3, 3153. 
(10)  Jensen, K. H.; Pathak, T. P.; Zhang, Y.; Sigman, M. S. J. Am. Chem. Soc. 2009, 
131, 17074. 
(11)  Pathak, T.P.; Gligorich, K.M.; Welm, B.E.; Sigman, M.S. J. Am. Chem. Soc. 
2010, 132, 7870. 
(12)  Bovino, M.T.; Liwosz, T.W.; Kendel, N.E.; Miller, Y.; Tyminska, N.; Zurek, E.; 
Chemler, S.R. Angew. Chem. Int. Ed. 2014, 53, 6383. 
(13)  (a) Hu, N.; Li, Ke.; Wang, Z.; Tang, W. Angew. Chem. Int. Ed. 2016, 55, 5044; (b) 
Hu, N.; Li, Ke.; Wang, Z.; Tang, W. Angew. Chem. 2016, 128, 5128. 
(14)  Borrajo-Calleja, G.M.; Bizet, V.; Mazet, C. J. Am. Chem. Soc. 2016, 138, 4014. 






Chapter 6  
Asymmetric Synthesis of Tetrahydrofurans by a  
Pd-Catalyzed Alkene Difunctionalization Reaction 
 
6.1 Introduction 
Cyclic ethers with substitution at C2 are widely prevalent in many biologically 
active compounds.1 Due to the high prevalence of this functional group motif, 
considerable effort has been targeted at the development of methods for the 
asymmetric synthesis of cyclic ethers.2 Previous reports from the Wolfe group detail the 
development of a Pd-catalyzed carboalkoxylation reaction between -hydroxyalkenes 
and aryl or alkenyl halides which produce C2-substituted tetrahydrofurans with high 
diastereoselectivity.3 Even though this reaction was developed over 10 years ago, the 
enantioselective variant of this reaction has remained undeveloped until recently.  
 While many groups have demonstrated successful asymmetric carboamination 
reactions, the corollary developments for the asymmetric synthesis of cyclic ethers has 
been slower to develop. Nitrogen atoms hold a distinct advantage over oxygen atoms in 
that a protecting group can be used to modulate the electronics and sterics of the 
nitrogen atom while maintaining nucleophilicity. Because oxygen is divalent, it does not 
have this same capacity. Therefore, the development of an asymmetric 
carboalkoxylation reaction relies primarily on the chiral environment of the catalyst, and 
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not on substrate electronic manipulations. Efforts towards the development and use of a 
new chiral ligand for Pd-catalyzed carboalkoxylation reactions are described below.   
 
6.2 Asymmetric Synthesis of Tetrahydrofurans 
The reaction design for an asymmetric carboalkoxylation reaction took into 
account earlier developments for the enantioselective cyclization of ureas and 
sulfamides which demonstrated that subtle steric and electronic protecting group 
manipulations of the nitrogen atoms of the sulfamide strongly altered the 
enantioselectivity. While oxygen nucleophiles lack this opportunity for substrate control, 
the same catalyst conditions could induce desirable asymmetry since the reactions 
operate under the same Pd mechanism. Regrettably, the use of chiral phosphoramidites 
(R)-Siphos-PE and (S)-Siphos-PE failed to achieve synthetically useful enantiomeric 
ratios despite obtaining decent yields (Scheme 6.1). Without a protecting group handle 
to influence the substrates, the development of a new ligand was explored as a solution 
to developing an asymmetric carboalkoxylation reaction.  
 




Chiral phosphites with TADDOL backbones were considered as a possible 
modular scaffold for this purpose. The TADDOL backbone was selected as a potential 
scaffold because it bore similar electronics to chiral phosphoramidites which 
demonstrated decent yields but poor enantioselectivity. The TADDOL backbone is an 
attractive scaffold because it can easily be altered for tuning the ligand. For example, 
the ketal can be deprotected or alkylated in different ways, or different aryl rings can be 
incorporated by Grignard addition to the ester precursor. Secondly, different alcohols or 
amines can be incorporated during ligand synthesis. In this regard, synthesis of the 
ligands is performed by simply combining the TADDOL backbone with PCl3, and then 
adding the secondary component of the desired ligand. Finally, the ligands are stable, 
and they perform with the same capacity after two years storage in a dessicator. The 
development and optimization of the new chiral TADDOL ligand has been described 
and is summarized in Scheme 6.2.4  
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The ligand development unveiled important factors for inducing asymmetry. First, 
substitutions in the backbone either at the ketal ring or with the phenyl groups failed to 
improve the enantioselectivity, but phosphites derived from TADDOL, PCl3, and chiral 
cyclohexanol derivatives gave promising results. Initial experimentation with naturally 
occurring alcohols like menthol and isopinocampheol as consitutents of the ligand 
exhibited synthetically useful enantiomeric ratios (up to 81:19 er as shown in Scheme 
6.2). Further investigation of the substitution pattern demonstrated that increases in 
steric bulk of the chiral cyclohexanol improved the enantioselectivity. The model 
reaction was able to achieve 88:12 er by using a ligand bearing a chiral cyclohexanol 
with biphenyl substitution. 
 





After the ligand structure was optimized, the substrate scope was evaluated. A 
wide variety of electrophiles were competent for the reaction as shown in Scheme 6.3. 
These include electron-rich electrophiles as shown for product 6-5 and electron poor 
electrophiles as shown for 6-6. In addition, a Bn-protected indole was successfully 
incorporated in the synthesis of 6-7. 1,1-Disubstituted alkenes were tolerated by this 
reaction, but at this point the use of substrates bearing internal alkenes like 6-8 or 6-9 
have not produced desirable results.  
 





During the investigation, it was discovered that the steric bulk next to the oxygen 
nucleophile had a significant influence on enantioselectivity. As shown in Figure 6.1, 
the enantioselectivity advances with increasing steric bulk from hydrogen to phenyl from 
58:42 for 6-10 up to 92:8 for 6-13 when 4-bromobenzophenone is used as electrophile. 
 





The influence of steric bulk on enantioselectivity prompted an additional study 
where geminal substitution was positioned on different carbons of the alken-ol (Scheme 
6.4). Interestingly, no enantioselectivity was obtained for the synthesis of 6-15 where 
substitution occurs in the homoallyl position, but modest enantioselectivity was obtained 
for geminal methyl substitution in the allylic position as shown for the synthesis of 6-17. 
It may be possible that increased steric bulk in the allylic position could enhance 
enantioselectivity, although this has yet to be evaluated.  
 





The effect of electronics on the phenyl ring was also studied, but before this 
study was conducted, a new challenge had to be overcome. While studying the effect of 
aryl ring electronics on the enantioselectivity approximately one year after initial 
publication, results were irreproducible. The use of new anhydrous dioxanes as solvent 
failed to reproduce previously achieved enantioselectivities. It was suspected that the 
older dioxanes solvent was contaminated with water. To test this hypothesis, the new 
bottle of anhydrous dioxanes was used as solvent with 2 equiv of water. These 
conditions restored previously obtained levels of enantioselectivity. These conditions 
were utilized to conduct the following study. 
 





The influence of electronics on the bulky aryl ring was tested by first synthesizing 
a variety of p- substituted alken-ols. The reactivity of each alken-ol was tested with 4-
bromobenzophenone as shown in Table 6.1. In general, it seemed that electron-rich 
aryl rings improved enantioselectivity while electron-deficient aryl rings degraded the 
enantioselectivity, but a linear relationship could not be procured from this study.  
 
6.3 Conclusion 
This chapter describes the development of a new enantioselective synthesis of 
tetrahydrofurans via asymmetric Pd-catalyzed carboalkoxylation reactions. The 
development of new phosphite ligand A was crucial to achieving synthetically useful 
levels of enantioselectivity. While many electrophiles and many alken-ols were 
successfully utilized during the development of this reaction, several important details 
were unveiled that are essential to achieving high levels of enantioselectivity. 
Manipulations of the TADDOL backbone had relatively little influence on asymmetric 
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induction, but alterations to the chiral cyclohexanol portion of the ligand had a 
remarkable effect on enantioselectivity. Also, increased steric bulk next to the cyclizing 
alcohol improved the enantioselectivity. The studies herein will help guide future 
developments in the asymmetric construction of cyclic ethers.  
In terms of future directions, the limitations associated with 1,2-disubstituted 
alkenes is a significant challenge that could be overcome. In order to expand the 
substrate scope of this reaction, this challenge should be addressed. As such, new 
ligands and new reaction conditions will have to be devised as the Wolfe group has 
witnessed previously the dramatic difference in reaction conditions required for 
obtaining the high diastereoselectivity by the Pd-catalyzed carboalkoxylation reaction of 
1,2-disubstituted alkenes. 
 
A portion of the work described in this chapter was published in Angewandte Chemie 
and Angewandte Chemie International Edition.5 
 
6.4 Experimental Section 
 
General: Reactions were carried out under nitrogen in flame-dried glassware. 
Tris(dibenzylideneacetone)dipalladium was purchased from Strem Chemical Co. and 
used without further purification. Dichloromethane and toluene were purified using a 
GlassContour solvent system. Anhydrous dioxane was purchased from Acros Organics 
in a sure seal bottle and used as received. All other solvents and aryl halides were 
purchased from commercial sources and used as received. 1-(But-3-en-1-
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yl)cyclopentan-1-ol,3c and (+)-(1S,2R)-2-phenylcyclohexan-1-ol,6 4-methyl-2,2-
diphenylpent-4-en-1-ol,7 3,3-dimethylpent-4-en-1-ol8 and ligands9 were synthesized 
according to literature procedures. 4-Penten-1-ol was purchased from commercial 
sources and was used without further purification. Yields refer to isolated compounds 
that are estimated to be >95% pure as judged by 1H NMR or GC analysis unless stated 
otherwise. The yields reported in the supporting information describe the result of a 
single experiment, whereas yields reported in Tables 2 and 3 are average yields of two 
or more experiments. Thus, the yields reported in the supporting information may differ 
from those in the manuscript.  
 
Synthesis of Substrates: 
 
1,1-Diphenylpent-4-en-1-ol.[10] A flame dried round bottom flask equipped with a stir 
bar was cooled under a stream of nitrogen and charged with 4-pentenoyl chloride (5 
mmol, 0.55 mL) and diethyl ether (50 mL). The mixture was cooled to 0 °C in an ice 
bath for five min and then PhMgBr (20 mL, 20 mmol, 1M in THF) was added dropwise 
to the flask. The resulting mixture was warmed to rt and stirred for 12 h, then the flask 
was cooled to 0 °C in an ice bath and slowly quenched with saturated aqueous 
ammonium chloride (10 mL). The mixture was transferred to a separatory funnel, the 
layers were separated, and the aqueous layer was extracted with ethyl acetate (3 x 25 
mL. The organic layers were combined, dried over anhydrous sodium sulfate, filtered, 
and concentrated in vacuo. The crude product was then purified by flash 
chromatography on silica gel to afford the title compound (864 mg, 72%) as a colorless 
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oil. 1H NMR (500 MHz, CDCl3)  7.43 (d, J = 7.4 Hz, 4 H), 7.33 (t, J = 8.1 Hz, 4 H), 7.24 
(t, J = 6.6 Hz, 2 H), 6.85–6.78 (m, 2 H), 5.06–4.96 (m, 2 H), 2.44–2.38 (m, 2 H), 2.18 (s, 
1 H), 2.12–2.04 (m, 2 H). Spectroscopic data was consistent with that previously 
reported in the literature.[10] 
 
 
4-Methyl-1,1-diphenylpent-4-en-1-ol. A flame dried round bottom flask equipped with 
a stir bar was cooled under a stream of nitrogen and charged with PhMgBr (25 mL, 25 
mmol, 1M in THF). The solution was cooled to 0 °C in an ice bath for five min. In a 
separate flask ethyl 4-methylpent-4-enoate[11] (1.0 g, 7 mmol) was dissolved in 20 mL 
anhydrous THF, and the resulting solution was added dropwise to the flask containing 
the cooled PhMgBr solution. The reaction mixture was then warmed to rt, stirred for 12 
h, then was cooled to 0 °C in an ice bath and slowly quenched with saturated aqueous 
ammonium chloride (20 mL). The resulting mixture was transferred to a separatory 
funnel, the layers were separated, and the aqueous layer was extracted with diethyl 
ether (3x25 mL). The organic layers were combined, dried over anhydrous sodium 
sulfate, filtered, and concentrated in vacuo. The crude product was then purified by 
flash chromatography on silica gel to afford the title compound (1.54 g, 88%) as a 
colorless oil. 1H NMR (500 MHz, CDCl3)  7.43 (dd, J = 8.31, 0.98 Hz, 4 H), 7.34–7.31 
(m, 4H), 7.25–7.20 (m, 2 H), 4.73 (s, 1 H), 4.70 (s, 1 H), 2.48–2.42 (m, 2 H), 2.25 (s, br, 
1 H), 2.06–1.99 (m, 2 H), 1.74 (s, 3 H); 13C NMR (175 MHz, CDCl3)  147.1, 146.4, 
128.4, 127.0, 126.2, 110.1, 78.5, 40.0, 32.2, 23.0; IR (film) 3469, 2932, 1446 cm-1; MS 
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(EI) 252.1515 (252.1514 calcd for C18H20O, M +). 
 
 
(E)-1,1-Diphenylhex-4-en-1-ol. The title compound was prepared from PhMgBr (50 
mL, 50 mmol, 1M in THF) and (E)-ethyl hex-4-enoate[12] (2.28 g, 16.0 mmol) using a 
procedure analogous to that described above for the synthesis of 1e. This procedure 
afforded the title compound (1.23 g, 30%) as a colorless solid, mp 53–54 °C: 1H NMR 
(500 MHz, CDCl3)  7.40–7.43 (m, 4 H), 7.28–7.33 (m, 4 H), 7.20–7.24 (m, 2 H), 5.37–
5.51 (m, 2 H), 2.33–2.38 (m, 2 H), 2.23 (s, 1 H), 1.96–2.03 (m, 2 H), 1.63 (dd, J = 5.9, 
1.0 Hz, 3 H); 13C NMR (175 MHz, CDCl3)  147.2, 131.3, 128.3, 127.0, 126.2, 125.7, 
78.6, 41.7, 27.3, 18.1; IR (film) 3556, 2958, 1446 cm-1; MS (EI) 252.1510 (252.1514 
calcd for C18H20O, M +). 
 
 
3-(Cyclohex-1-en-1-yl)-1,1-diphenylpropan-1-ol. The title compound was prepared 
from PhMgBr (11 mL, 11 mmol, 1M in THF) and 3-(cyclohex-1-en-1-yl)-1-phenylpropan-
1-one[13] (1.2 g, 5.5 mmol) using a procedure analogous to that described above for the 
synthesis of 1e. This procedure afforded the title compound (600 mg, 37%) as a 
colorless oil. 1H NMR (500 MHz, CDCl3)  7.39–7.49 (m, 4 H), 7.28–7.34 (m, 4 H), 
7.18–7.24 (m, 2 H), 5.41 (s, 1 H), 2.38–2.45 (m, 2 H), 2.37 (s, 1 H), 1.88–2.03 (m, 6 H), 
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1.48–1.67 (m, 4 H); 13C NMR (175 MHz, CDCl3)  147.2, 138.2, 128.3, 126.9, 126.2, 
121.6, 78.7, 39.8, 32.5, 28.7, 25.4, 23.1, 22.7; IR (film) 3467, 2923, 1446 cm-1; MS (EI) 
292.1823 (292.1827 calcd for C21H24O, M +). 
 
General Procedure 1 for Synthesis of Diphenyl Substituted Alken-ols 
A flame dried 3-necked round bottom flask equipped with a stir bar and reflux 
condenser was cooled under a stream of nitrogen and charged with freshly ground 
magnesium (4 equiv) and anhydrous THF (1 mL THF/1 mmol Mg). Then, the aryl halide 
(3 equiv) was added as a solution in THF (0.2 mL / mmol aryl halide). The solution was 
cooled to 0 °C in an ice bath for five min. In a separate flask, ethyl pent-4-enoate (1 
equiv) was dissolved in anhydrous THF (1 mL THF/ 1 mmol ester), and the resulting 
solution was added dropwise to the flask containing the cooled Grignard solution. The 
reaction mixture was then refluxed for 12 h, then was cooled to 0 °C in an ice bath, and 
slowly quenched with saturated aqueous ammonium chloride (2 mL / 1 mmol ester). 
The resulting mixture was transferred to a separatory funnel, the layers were separated, 
and the aqueous layer was extracted with diethyl ether (3x25 mL). The organic layers 
were combined, dried over anhydrous sodium sulfate, filtered, and concentrated in 
vacuo. The crude product was then purified by flash chromatography on silica gel. 
 
 
1,1-di-p-tolylpent-4-en-1-ol. The title compound was prepared from p-tolylmagnesium 
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bromide (46 mL, 30 mmol, 0.65 M in THF) and ethyl pent-4-enoate (1.3 g, 10.0 mmol) 
using General Procedure 1. This procedure afforded the title compound (2.2 g, 83%) as 
a colorless oil. 1H NMR (400 MHz, CDCl3)  7.29–7.23 (m, 4H), 7.10 (d, J = 8.0 Hz, 4H), 
5.84 (ddt, J = 16.8, 10.2, 6.6 Hz, 1H), 4.98 (dq, J = 17.1, 1.7 Hz, 1H), 4.95–4.90 (m, 
1H), 2.36 – 2.27 (m, 9H), 2.05–1.99 (m, 2H). 
 
 
1,1-bis(4-methoxyphenyl)pent-4-en-1-ol. The title compound was prepared from (4-
methoxyphenyl)magnesium bromide (46 mL, 30 mmol, 0.65 M in THF) and ethyl pent-4-
enoate (1.3 g, 10.0 mmol) using General Procedure 1. This procedure afforded the title 
compound (1.8 g, 60%) as a colorless oil. 1H NMR (400 MHz, CDCl3)  7.33–7.28 (m, 
4H), 6.87–6.81 (m, 4H), 5.85 (ddt, J = 16.9, 10.2, 6.6 Hz, 1H), 5.00 (dq, J = 17.2, 1.7 




1,1-bis(4-fluorophenyl)pent-4-en-1-ol. The title compound was prepared from (4-
fluorophenyl)magnesium bromide (46 mL, 30 mmol, 0.65 M in THF) and ethyl pent-4-
enoate (1.3 g, 10.0 mmol) using General Procedure 1. This procedure afforded the title 
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compound (2.1 g, 77%) as an amorphous solid. 1H NMR (500 MHz, CDCl3)  7.38–7.33 
(m, 4H), 7.03–6.97 (m, 4H), 5.84 (ddt, J = 16.9, 10.1, 6.6 Hz, 1H), 5.04–4.94 (m, 2H), 
2.37–2.31 (m, 2H), 2.14 (s, 1H), 2.07–2.00 (m, 2H). 
 
General procedure 2 for asymmetric Pd-catalyzed carboalkoxylation reactions. A 
flame-dried Schlenk tube equipped with a stirbar was cooled under a stream of nitrogen 
and charged with Pd2(dba)3 (2 mol %), A (5 mol %), the alcohol substrate (1.0 equiv), 
and NaOtBu (1.50–2.0 equiv). The flask was purged with N2 then the aryl or alkenyl 
halide (1.40–2.0 equiv), and dioxane or toluene (0.10 M) was added. The resulting 
mixture was heated to 90 °C with stirring until the starting material had been consumed 
as judged by TLC analysis (ca. 12 h). The reaction mixture was then cooled to rt, 
saturated aqueous ammonium chloride (6 mL/mmol substrate) was added, and the 
mixture was transferred to a separatory funnel. The mixture was extracted with ethyl 
acetate (3 x 5 mL) then the combined organic layers were dried over anhydrous 
Na2SO4, filtered, and concentrated in vacuo. The crude product was purified by flash 




(6-11). The general procedure was employed for the coupling of 2,5-dimethylhex-5-en-
2-ol1 (26 mg, 0.20 mmol) and 4-bromobenzophenone (94 mg, 0.36 mmol) using a 
catalyst composed of Pd2(dba)3 (3.7 mg, 0.004 mmol) and A (7.5 mg, 0.010 mmol), a 
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reaction temperature of 90 °C and a reaction time of 12 h in 2mL of dioxane. This 
procedure afforded the title compound (51.0 mg, 77%) as a colorless oil: [α]23D +3.48 (c 
7.10, CH2Cl2); 1H NMR (500 MHz, CDCl3)  7.76–7.82 (m, 2 H), 7.73 (d, J = 8.1 Hz, 2 
H), 7.54–7.60 (m, 1 H), 7.47 (t, J = 10.0 Hz, 2 H), 7.35 (d, J = 8.1 Hz, 2 H), 2.85 (s, 2 H), 
1.95–2.03 (m, 1 H), 1.76–1.85 (m, 2 H), 1.56–1.66 (m, 1 H), 1.25 (d, J = 2.9 Hz, 6 H), 
1.14 (s, 3 H); 13C NMR (175 MHz, CDCl3)  196.8, 143.9, 138.1, 135.6, 132.3, 130.8, 
130.1, 129.9, 128.4, 83.3, 81.7, 48.5, 38.6, 36.7, 29.9, 29.4, 28.6; IR (film) 2966, 1654, 
1277 cm-1; MS (ESI+) 309.1847 (309.1849 calcd for C21H24O2, M + H+). The 
enantiopurity was determined to be 38:62 er by chiral HPLC analysis (Chiralcel ADH, 25 




yl)methyl]phenyl}(phenyl)methanone (6-13). The general procedure was employed 
for the coupling of 4-methyl-1,1-diphenylpent-4-en-1-ol (51 mg, 0.20 mmol) and 4-
bromobenzophenone (94 mg, 0.36 mmol) using a catalyst composed of Pd2(dba)3 (3.7 
mg, 0.004 mmol) and A (7.5 mg, 0.010 mmol), a reaction temperature of 90 °C and a 
reaction time of 12 h in 2mL of dioxane. This procedure afforded the title compound 
(74.8 mg, 86%) as a colorless solid, mp 89–91 °C: [α]23D +20.9 (c 6.30, CH2Cl2); 1H 
NMR (500 MHz, CDCl3)  7.79–7.86 (m, 2 H), 7.72 (d, J = 8.1 Hz, 2 H), 7.58–7.64 (m, 1 
H), 7.46–7.54 (m, 6 H), 7.26–7.40 (m, 6 H), 7.16–7.25 (m, 2 H), 3.03 (d, J = 13.2 Hz, 1 
H), 2.91 (d, J = 13.2 Hz, 1 H), 2.62–2.75 (m, 2 H), 2.09 (m, 1 H), 1.86 (m 1 H), 1.31 (s, 3 
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H); 13C NMR (175 MHz, CDCl3)  196.7, 148.2, 147.7, 143.8, 138.0, 135.6, 132.3, 
130.6, 130.1, 129.9, 128.4, 128.1, 128.1, 126.7, 126.5, 126.0, 125.8, 88.7, 84.6, 48.5, 
38.4, 37.4, 27.2; IR (film) 2966, 1654, 1277 cm-1; MS (ESI+) 433.2160 (433.2162 calcd 
for C31H28O2, M + H+). The enantiopurity was determined to be 95:5 er by chiral HPLC 
analysis (Chiralcel ADH, 25 cm x 4.6 mm, 2% IPA/Hexanes, 1.00 mL/min, λ 275 nm, 




(6-7). The general procedure was employed for the coupling of 4-methyl-1,1-
diphenylpent-4-en-1-ol (51 mg, 0.20 mmol) and 1-benzyl-5-bromo-1H-indole (103 mg, 
0.36 mmol) using a catalyst composed of Pd2(dba)3 (3.7 mg, 0.004 mmol) and A (7.5 
mg, 0.010 mmol), a reaction temperature of 90 °C and a reaction time of 12 h. This 
procedure afforded the title compound (80.5 mg, 88%) as a colorless solid, mp 127–128 
°C : [α]23D +22.6 (c 6.91, CH2Cl2); 1H NMR (500 MHz, CDCl3)  = 7.43–7.51 (m, 5 H), 
7.22–7.33 (m, 10 H), 7.10–7.20 (m, 5 H), 7.08 (d, J = 3.2 Hz, 1 H), 7.04 (dd, J = 8.4, 1.6 
Hz, 1 H), 6.46 (d, J = 3.2 Hz, 1 H), 5.29 (s, 2 H), 3.04 (d, J = 13.4 Hz, 1 H), 2.90 (d, J = 
13.4 Hz, 1 H), 2.62–2.66 (m, 2 H), 2.06–2.13 (m, 1 H), 1.67–1.75 (m, 1 H), 1.26 (s, 3 H); 
13C NMR (125 MHz, CDCl3)  148.5, 148.1, 137.8, 135.3, 129.8, 128.9, 128.7, 128.3, 
128.1, 128.0, 127.7, 127.0, 126.5, 126.4, 126.2, 126.0, 124.8, 122.5, 109.1, 101.5, 88.4, 
85.4, 50.2, 48.5, 38.8, 36.9, 27.1; IR (film) 2924, 1485, 1447 cm-1; MS (ESI+) 458.2478 
(458.2478 calcd for C33H31NO, M + H+). The enantiopurity was determined to be 96:4 er 
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by chiral HPLC analysis (Chiralcel ADH, 25 cm x 4.6 mm, 1% IPA/Hexanes, 1.00 




(6-5). The general procedure was employed for the coupling of 4-methyl-1,1-
diphenylpent-4-en-1-ol (51 mg, 0.20 mmol) and 4-(4-bromophenyl)morpholine (87 mg, 
0.36 mmol) using a catalyst composed of Pd2(dba)3 (3.7 mg, 0.004 mmol) and A (7.5 
mg, 0.010 mmol), a reaction temperature of 90 °C and a reaction time of 12 h in 2 mL of 
dioxane. This procedure afforded the title compound (68.0 mg, 82%) as a colorless 
solid, mp 143–145 °C : [α]23D +28.8 (c 6.70, CH2Cl2); 1H NMR (500 MHz, CDCl3)  7.47 
(dd, J = 12.8, 7.5 Hz, 4 H), 7.22–7.33 (m, 4 H), 7.13–7.19 (m, 2 H), 7.12 (d, J = 8.3 Hz, 
2 H), 6.79 (d, J = 8.3 Hz, 2 H), 3.87 (t, J = 4.7 Hz, 4 H), 3.09–3.14 (m, 4 H), 2.88 (d, J = 
13.5 Hz, 1 H), 2.74 (d, J = 13.5 Hz, 1 H), 2.59–2.68 (m, 2 H), 1.98–2.03 (m, 1 H), 1.69–
1.74 (m, 1 H), 1.23 (s, 3 H); 13C NMR (125 MHz, CDCl3)  149.7, 148.4, 148.0, 131.3, 
130.3, 128.1, 128.0, 126.5, 126.5, 126.1, 125.9, 115.4, 88.4, 85.1, 67.1, 49.7, 47.6, 
38.7, 37.0, 27.0; IR (film) 2966, 1515, 1446 cm-1; MS (ESI+) 414.2427 (414.2428 calcd 
for C28H31NO2, M + H+). The enantiopurity was determined to be 93:7 er by chiral HPLC 
analysis (Chiralcel ADH, 25 cm x 4.6 mm, 2% IPA/Hexanes, 1.00 mL/min, λ 210 nm, 





(+)-(S)-4-[(2-Methyl-5,5-diphenyltetrahydrofuran-2-yl)methyl]benzonitrile (6-6).  The 
general procedure was employed for the coupling of 4-methyl-1,1-diphenylpent-4-en-1-
ol (51 mg, 0.20 mmol) and 4-bromobenzonitrile (66 mg, 0.36 mmol) using a catalyst 
composed of Pd2(dba)3 (3.7 mg, 0.004 mmol) and A (7.5 mg, 0.010 mmol), a reaction 
temperature of 90 °C and a reaction time of 12 h in 2mL of dioxane. This procedure 
afforded the title compound (27.0 mg, 38%) as a colorless solid, mp 100–104 °C: [α]23D 
+23.9 (c 2.00, CH2Cl2); 1H NMR (500 MHz, CDCl3)  7.47 (d, J = 8.1 Hz, 2 H), 7.38–
7.42 (m, 4 H), 7.27–7.30 (m, 4 H), 7.22–7.25 (m, 2 H), 7.13–7.22 (m, 2 H), 2.90–2.95 (d, 
J = 13.5 Hz, 1 H), 2.79–2.85 (d, J = 13.5 Hz, 1 H), 2.55–2.67 (m, 2 H), 1.96–2.02 (m, 1 
H), 1.79–1.86 (m, 1 H), 1.23  (s, 3 H); 13C NMR (125 MHz, CDCl3)  148.1, 147.4, 
144.2, 131.7, 131.4, 128.2, 128.2, 126.8, 126.6, 126.0, 125.7, 119.4, 110.1, 88.8, 84.3, 
48.5, 38.2, 37.5, 27.3; IR (film) 2925, 2223, 1607 cm-1; MS (ESI+) 376.1670 (376.1670 
calcd for C25H23NO, M + Na+). The enantiopurity was determined to be 87:13 er by 
chiral HPLC analysis (Chiralcel ADH, 25 cm x 4.6 mm, 2% IPA/Hexanes, 1.00 mL/min, 




yl)methyl]phenyl}(phenyl)methanone (6-15). The general procedure was employed 
225 
 
for the coupling of 4-methyl-2,2-diphenylpent-4-en-1-ol[7] (51 mg, 0.20 mmol) and (4-
bromophenyl)(phenyl)methanone (94 mg, 0.36 mmol) using a catalyst composed of 
Pd2(dba)3 (3.7 mg, 0.004 mmol) and A (7.5 mg, 0.010 mmol), a reaction temperature of 
90 °C, and a reaction time of 12 h in 2mL of dioxane. This procedure afforded the title 
compound (73 mg, 84%) as a light yellow oil. [α]23D= +0.01 (c 5.9, CH2Cl2); 1H NMR 
(500 MHz, CDCl3)  7.57–7.62 (m, 1 H), 7.46–7.52 (m, 2 H), 7.26–7.36 (m, 11 H), 7.16–
7.22 (m, 2 H), 4.53 (d, J = 9.5 Hz, 1 H), 4.39 (d, J = 9.5 Hz, 1 H), 2.90 (d, J = 13.2 Hz, 1 
H), 2.81 (d, J = 12.7 Hz, 1 H), 2.73 (d, J = 13.2 Hz, 1 H), 2.61 (d, J = 12.7 Hz, 1 H), 1.12 
(s, 3 H); 13C NMR (125 MHz, CDCl3)  196.7, 146.5, 143.4, 138.0, 135.7, 132.4, 130.6, 
130.1, 130.0, 128.6, 128.5, 128.4, 127.3, 126.4, 126.4, 83.7, 75.5, 56.5, 50.3, 47.8, 
26.9; IR (film) 2926.7, 2247, 1654, 1276 cm-1; MS (ESI+) 433.2164 (433.2162 calcd for 
C31H28O2, M + H+). The enantiopurity was determined to be 51:49 er by chiral HPLC 
analysis (Chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 1.00 mL/min, λ 254 nm, 




yl)methyl)phenyl)(phenyl)methanone (6.21). The general procedure was employed 
for the coupling of 1,1-bis(4-fluorophenyl)pent-4-en-1-ol (55 mg, 0.20 mmol) and (4-
bromophenyl)(phenyl)methanone (94 mg, 0.36 mmol) using a catalyst composed of 
226 
 
Pd2(dba)3 (3.7 mg, 0.004 mmol) and A (7.5 mg, 0.010 mmol), a reaction temperature of 
90 °C, and a reaction time of 12 h in 2mL of dioxane and 7 μL of water. This procedure 
afforded the title compound (40 mg, 44%) as a colorless oil. 1H NMR (500 MHz, CDCl3) 
 7.79 (dd, J = 8.2, 1.4 Hz, 2H), 7.74 (d, J = 8.2 Hz, 2H), 7.61–7.56 (m, 1H), 7.49 (dd, J 
= 8.3, 7.1 Hz, 2H), 7.39–7.32 (m, 6H), 6.97 (td, J = 8.7, 2.7 Hz, 4H), 4.40 (p, J = 6.6 Hz, 
1H), 3.13 (dd, J = 13.6, 6.5 Hz, 1H), 2.91 (dd, J = 13.6, 6.3 Hz, 1H), 2.58 (dt, J = 12.4, 
7.0 Hz, 1H), 2.44 (ddd, J = 12.4, 8.0, 6.8 Hz, 1H), 1.99 (dq, J = 12.2, 7.1 Hz, 1H), 1.77 
(ddt, J = 12.6, 7.9, 6.7 Hz, 1H). The enantiopurity was determined to be 92:8 er by chiral 
HPLC analysis (Chiralcel ADH, 25 cm x 4.6 mm, 4% IPA/Hexanes, 1.00 mL/min, λ 210 




yl)methyl)phenyl)(phenyl)methanone (6-19). The general procedure was employed 
for the coupling of 1,1-bis(4-methoxyphenyl)pent-4-en-1-ol (60 mg, 0.20 mmol) and (4-
bromophenyl)(phenyl)methanone (94 mg, 0.36 mmol) using a catalyst composed of 
Pd2(dba)3 (3.7 mg, 0.004 mmol) and A (7.5 mg, 0.010 mmol), a reaction temperature of 
90 °C, and a reaction time of 12 h in 2mL of dioxane and 7 μL of water. This procedure 
afforded the title compound (58 mg, 61%) as a colorless oil. 1H NMR (400 MHz, CDCl3) 
 7.82–7.77 (m, 2H), 7.76–7.72 (m, 2H), 7.62–7.56 (m, 1H), 7.51–7.45 (m, 2H), 7.40–
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7.35 (m, 2H), 7.34–7.28 (m, 4H), 6.85–6.79 (m, 4H), 3.77 (d, J = 3.0 Hz, 6H), 3.15 (dd, J 
= 13.5, 6.4 Hz, 1H), 2.89 (dd, J = 13.6, 6.5 Hz, 1H), 2.57 (dt, J = 12.4, 7.0 Hz, 1H), 2.43 
(dt, J = 12.4, 7.3 Hz, 1H), 2.03–1.91 (m, 1H), 1.76 (dq, J = 13.4, 6.9 Hz, 1H).The 
enantiopurity was determined to be 92:8 er by chiral HPLC analysis (Chiralcel ADH, 25 
cm x 4.6 mm, 8% IPA/Hexanes, 1.00 mL/min, λ 254 nm, RT= 23.8 and 36.7 min). 
 
(S)-(4-((5,5-di-p-tolyltetrahydrofuran-2-yl)methyl)phenyl)(phenyl)methanone (6-20). 
The general procedure was employed for the coupling of 1,1-di-p-tolylpent-4-en-1-ol (60 
mg, 0.20 mmol) and (4-bromophenyl)(phenyl)methanone (94 mg, 0.36 mmol) using a 
catalyst composed of Pd2(dba)3 (3.7 mg, 0.004 mmol) and A (7.5 mg, 0.010 mmol), a 
reaction temperature of 90 °C, and a reaction time of 12 h in 2mL of dioxane and 7 μL of 
water. This procedure afforded the title compound (60 mg, 67%) as a colorless oil. 1H 
NMR (500 MHz, CDCl3)  7.82–7.78 (m, 2H), 7.76–7.73 (m, 2H), 7.61–7.57 (m, 1H), 
7.49 (dd, J = 8.3, 7.1 Hz, 2H), 7.38 (d, J = 8.1 Hz, 2H), 7.34–7.28 (m, 4H), 7.09 (dd, J = 
8.3, 2.4 Hz, 4H), 4.40 (p, J = 6.6 Hz, 1H), 3.16 (dd, J = 13.6, 6.5 Hz, 1H), 2.90 (dd, J = 
13.6, 6.4 Hz, 1H), 2.61 (dt, J = 12.2, 7.0 Hz, 1H), 2.47 (ddd, J = 12.3, 8.0, 6.7 Hz, 1H), 
2.31 (s, 3H), 2.30 (s, 3H), 1.98 (dq, J = 12.1, 7.0 Hz, 1H), 1.82–1.72 (m, 1H). The 
enantiopurity was determined to be 94:6 er by chiral HPLC analysis (Chiralcel ADH, 25 






yl)methyl)phenyl)(phenyl)methanone (6-22). The general procedure was employed 
for the coupling of 1,1-bis(4-(trifluoromethyl)phenyl)pent-4-en-1-ol (75 mg, 0.20 mmol), 
(4-bromophenyl)(phenyl)methanone (94 mg, 0.36 mmol) using a catalyst composed of 
Pd2(dba)3 (3.7 mg, 0.004 mmol) and A (7.5 mg, 0.010 mmol), a reaction temperature of 
90 °C, and a reaction time of 12 h in 2mL of dioxane and 7 μL of water. This procedure 
afforded the title compound (91 mg, 82%) as a light yellow oil. 1H NMR (500 MHz, 
CDCl3)  7.81–7.74 (m, 4H), 7.62–7.52 (m, 9H), 7.49 (t, J = 7.7 Hz, 2H), 7.37 (d, J = 8.1 
Hz, 2H), 4.43 (p, J = 6.6 Hz, 1H), 3.14 (dd, J = 13.7, 6.6 Hz, 1H), 2.93 (dd, J = 13.6, 6.2 
Hz, 1H), 2.67 (dt, J = 12.4, 7.1 Hz, 1H), 2.58–2.49 (m, 1H), 2.03 (dq, J = 13.7, 6.9 Hz, 
1H), 1.85–1.76 (m, 1H). The enantiopurity was determined to be 89:11 er by chiral 
HPLC analysis (Chiralcel ADH, 25 cm x 4.6 mm, 2% IPA/Hexanes, 1.00 mL/min, λ 254 
nm, RT= 17.2 and 24.0 min). 
 
(4-((3,3-dimethyltetrahydrofuran-2-yl)methyl)phenyl)(phenyl)methanone (6-17). 
The general procedure was employed for the coupling of 3,3-dimethylpent-4-en-1-ol (23 
mg, 0.20 mmol) and (4-bromophenyl)(phenyl)methanone (94 mg, 0.36 mmol) using a 
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catalyst composed of Pd2(dba)3 (3.7 mg, 0.004 mmol) and A (7.5 mg, 0.010 mmol), a 
reaction temperature of 90 °C, and a reaction time of 12 h in 2mL of dioxane and 7 μL of 
water. This procedure afforded the title compound (40 mg, 68%) as a colorless solid. 1H 
NMR (500 MHz, CDCl3)  7.81–7.77 (m, 2H), 7.77–7.74 (m, 2H), 7.58 (td, J = 7.3, 1.3 
Hz, 1H), 7.50–7.45 (m, 2H), 7.40–7.36 (m, 2H), 3.92 (q, J = 8.2 Hz, 1H), 3.80 (td, J = 
8.6, 4.6 Hz, 1H), 3.62 (dd, J = 9.0, 3.7 Hz, 1H), 2.82–2.69 (m, 2H), 1.86–1.73 (m, 2H), 
1.08 (s, 3H), 1.04 (s, 3H). The enantiopurity was determined to be 63:37 er by chiral 
HPLC analysis (Chiralcel ADH, 25 cm x 4.6 mm, 2% IPA/Hexanes, 1.00 mL/min, λ 254 
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